PS1 -002
d AOP Orphan Pharmaceuticals AG -Vienne (Austria); e Medical University of Vienna -Vienne (Austria) Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by deregulated hematopoietic cells proliferation and the presence of an acquired somatic mutation (JAK2V617F) in the JAK2 kinase. Hydroxyurea (HU) is the most widely used chemotherapeutic agent to treat PV but its possible longterm leukemogenic potential is a concern. Phase 2 studies of Interferon alfa (IFNa) have shown high rates of hematological but also molecular responses assessed by the quantification of mutant JAK2 allele burden (%JAK2V617F) in peripheral blood suggesting a targeted impact on tumor cells. We took advantage of the PROUD-PV international randomized controlled phase 3 trial (NCT01949805) comparing a novel, long-acting Ropeginterferon alfa-2b (AOP2014) with HU in PV patients (pts) to assess correlation between evolution of %JAK2V617F in blood and the impact of both drugs on malignant clones by functional assays testing malignant bone marrow (BM) hematopoietic progenitors in the French study population. Material and methods: %JAK2V617F was assessed on whole blood DNA using the JAK2 MutaQuant kit (Qiagen). BM progenitors clonogenic potential was studied by cultures with or without Erythropoietin (EPO) at baseline and after 12 months of therapy. The presence of colonies without EPO, namely Endogenous Erythroid Colonies (EEC) is a hallmark of PV. After 14 days colonies were enumerated, picked and genotyped.
Results: 257 pts were randomized including 13 in France. In this group % JAK2V617F at baseline in the AOP2014 (n = 5) and HU (n = 8) arms were 39% and 46%, respectively, reduced to 14% and 33% at 12 months. BM progenitors could be studied in 3 pts treated with AOP2014 and 7 with HU. AOP2014 induced an important reduction of EEC (median decrease 64%) between samples collected at baseline and after 12 months of therapy compared to HU (median decrease 25%). Clonal architecture studies showed that the % of JAK2V617F mutant colonies profoundly decreased in AOP2014-treated pts and not in HUtreated pts (table) Discussion/Conclusion: In this phase 3 trial comparing Ropeginterferon alfa2b versus HU, we found a different impact of both drugs on hematopoietic cells. Clonogenic assays suggest that IFNa is able to specifically target JAK2 mutant progenitors, an effect not seen with HU. Such targeted impact of AOP2014 suggests that sustained long-term molecular response may only be achieved with IFNa based treatment.
PS1 -003
Liposomal amphotericin B pharmacokinetics in a patient with invasive pulmonary aspergillosis treated by extracorporeal membrane oxygenation JB Foulquier 
Material and methods:
We report the case of a 33-year-old woman with a history of Hodgkin's lymphoma recently treated with intensive chemotherapy and admitted in our ICU for acute respiratory distress syndrome. Culture of bronchoalveolar liquid on day-1 found Aspergillus fumigatus, Streptococcus pneumonia and Moraxella catarrhalis. Voriconazole and piperacillin-tazobactam treatments were then started. Invasive pulmonary aspergillosis diagnosis was confirmed by radio-thoracic imagery and elevated galactomannan-antigen in broncho-alveolar liquid. A worsening in respiratory symptoms on day-34 led to a switch to L-Amb (4 mg/kg/day, 6 h infusion). Veno-venous ECMO was required while culture and antigen for Aspergillus fumigatus were still positive. A complete pharmacokinetic (PK) profile of L-Amb was performed at steady state on day-47 to guide therapy. Blood samples were collected before and 2, 4, 6, 8, 16 and 20 h after the onset of drug-infusion. Drug levels were determined using liquid chromatography paired with a photodiode array detector. Despite antifungal therapy, patient's clinical condition continued to worsen until death on day-55. Results: PK parameters, calculated using the PKSolver software, were similar to those reported in other studies conducted in patients without ECMO in critically ill conditions. Exposure to L-Amb was similar to that previously published in ICU patients: Cmin (i.e. 4.9 lg/mL in the present case) was close to the value reported in a very similar case (5.8 lg/mL). However, the Cmax was lower than that described in non-ECMO patients. This may be a result of the extended infusion duration which aimed at decreasing renal toxicity. Discussion/Conclusion: This is the first complete PK profile of L-Amb in a patient treated with ECMO. ECMO did not appear to have modified the pharmacokinetics of amphotericin B suggesting that no dose adjustment should be necessary in similar patients. Further studies are warranted to confirm this observation.
PS1 -004
Vasorelaxant effects of Eulophia macrobulbon and its main compound in rat mesenteric arteries S Wisutthathum Life's Imaging Platform -Lille (France); c U1011 Universit e de Lille -Lille (France) Introduction: Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice. We questioned the potential capacity of curcumin, contained in Curcuma longa extract (Biocurcuma TM ), to attenuate the risperidone-induced metabolic dysfunction. Material and methods: Two groups of mice were treated once a week, for 22 weeks, with intraperitoneal injection of risperidone (Risperdal) at a dose 12.5 mpk. Two other groups received intraperitoneal injection of the vehicle of Risperdal following the same schedule. Mice of one risperidone-treated groups and of one of vehicle-treated groups were fed a diet with 0.05% Biocurcuma TM (curcumin), while mice of the two other groups received the standard diet. Results: Curcumin limited the capacity of risperidone to reduce spontaneous motricity, but failed to impede risperidone-induced increase in food intake. Curcumin did not reduce the capacity of risperidone to induce weight gain, but decreased visceral adiposity and decreased the risperidone-induced hepatomegaly, but not steatosis. Furthermore, curcumin repressed the capacity of risperidone to induce the hepatic over expression of enzymes involved in lipid metabolism (LXRa, FAS, ACC1, LPL, PPARc, ACO, SREBP2) and decreased risperidoneinduced glucose intolerance and hypertriglyceridemia. Curcumin decreased risperidone-induced increases in serum markers of hepatotoxicity (ALAT, ASAT), as well as of one major hepatic pro-inflammatory transcription factor (NFjB: p105 mRNA and p65 protein). Discussion/Conclusion: These findings support that nutritional doses of curcumin contained in Curcuma longa extract are able to partially counteract the risperidone-induced metabolic dysfunction in mice, suggesting that curcumin ought to be tested to reduce the capacity of risperidone to induce the metabolic syndrome in human.
PS1 -006
Antipsychotics induced-camptocormia: a case-series M Y el eh e-Okouma a , A Pop b , P Gillet a , L Javot a a Centre R egional de Pharmacovigilance, CHRU de Nancy -Nancy (France); b Pôle G erontologie et Soins Palliatifs, CHRU de Nancy -Nancy (France) Introduction: Camptocormia is an involuntary flexion of the thoracolumbar spine, without fixed kyphosis, which increases during walking and standing up, and abates in the supine position. Few case reports of drug-induced camptocormia have been published. We present a case series of camptocormia induced by antipsychotics. Results: Camptocormia was observed in 4 patients (3F/1M, 67 year-old ) treated with antipsychotic (olanzapine n = 3, loxapine n = 1) for behavioural disturbances. A laterodeviation was also noticed in 2 patients. Falls related to camptocormia have been observed in 2 patients. All patients have history of neurodegenerative (n = 3) or vascular dementia (n = 1). The onset of the side-effect ranged from 2 to 96 days. A brain scanner was performed in 2 patients and showed no significant injuries. An increase of CPK values was noticed in one patient (254 UI/L). Discontinuation of the antipsychotic therapy (n = 3) and decrease dosage (n = 1) were performed. Total or partial improvement was observed in all cases. Discussion/Conclusion: According to French imputability method, these cases fulfil the criteria for possible cases of camptocormia induced by antipsychotics. There is no mention of this side effect in summary of products characteristics of LOXAPAC â or ZYPREXA â . Aetiologies of camptocormia are heterogeneous: primary and secondary myopathies, inflammation, dystonia, psychogenic or pharmacological side-effect. To the best of our knowledge, only 3 cases of antipsychotic-induced camptocormia have been published, all with olanzapine [1] [2] [3] . The mechanism involved is still unknown. However, two hypothesis are suggested to explain motor disorders related to antipsychotics medicines [2] : i) an inhibition of dopamine nigrostriatal tracts along with a relative increase of cholinergic activity ii) an imbalance between dopamine, noradrenaline and serotonin and regulation of the axial muscles. As severe and disabling entity leading frequently to falls, it appears mandatory to stop treatment as soon as the first manifestations of drug-induced camptocormia occur. References The arrival of opioid substitution treatments (OST) in the pharmacopoeia in the 1990s profoundly changed the management of patients suffering from opioid dependence. In France currently around 180,000 people are substituted by high-dose buprenorphine (HDB) or methadone. The objective of this work was to study their use, satisfaction and requests regarding OST. Material and methods: We interviewed patients during the OST dispensation at the pharmacy between December 2016 and March 2017, in two French departments, Is ere and Savoie. The questionnaire included questions about their profile, illness, use, satisfaction and request for information. Participation was voluntary and anonymous. Results: Forty seven patients were included, mostly men (72%). Mean age was 40 AE 10 years (min 26; max 62). 64% patients treated with HDB, 34% with methadone and 2% with HDB-naloxone. In half of the cases, the prescriber was the general practitioner (GP). The co-administered drugs were mainly psychotropic (60%): antipsychotic (19%), benzodiazepine (BZD) (15%), BZD-related (15%), antidepressant (11%). Concerning the use, 56% of the interviewed patients reported an overdose of OST and 30% the use of another route of administration than the oral route, mostly nasally (n = 9) or injectable (n = 4). Among the 16 patients actually treated with methadone, 8 were before with HDB but due to misuse, they changed. In 96% of cases, OST was well for the patient. Thanks to OST, 66% of patients found a benefit in the management of their addiction. 51% experienced adverse drug reaction. Among requests and remarks, need for medical and psychological follow-up was expressed by 8 patients, 3 wanted to stop OST and 3 denounced the ease of abuse of HDB. One patient expressed the need to be considered as any patient suffering medical disorders. Discussion/Conclusion: Characteristics of included patients are consistent with previous studies describing French patients with OST followed by GP. There is a misuse of these treatments with diversion of route of administration or increased dose [1] . Overall, the satisfaction with the OST was good, similarly with another study [2] which also revealed a stigmatization due to OST. The main request concerned management, including psychological. 
PS1 -009
Cirrhotic patients in ICU with gastro-intestinal bleeding managed according to recent guidelines display altered brain hemoglobin oxygen's saturation assessed by near infrared spectroscopy N Weiss, M Mallet, S Tripon, C Bouzbib, P Sultanik, M Rudler, D Thabut Hôpital Piti e-Salpêtri ere -Paris (France) Introduction: Near Infrared Spectroscopy (NIRS) is a non-invasive optical technique allowing a continuous measurement of brain's hemoglobin saturation in oxygen (rSO2). It is considered as a surrogate marker of cerebral insult, and recognized as a useful tool in cardiovascular surgery and neuromonitoring. A rSO2 <50% is associated with increased neurological impairment and post-operative mortality. In cirrhotic patients with gastrointestinal bleeding (GIB), hemoglobin (Hb) threshold for transfusion has been recently lowered to 7 g/dL. Some patients develop hepatic encephalopathy (HE) after GIB. In subarachnoid hemorrhage, a threshold of 7 g/dL of Hb could worsen neurological outcome. Objective: The aim of this study was to assess brain oxygenation using NIRS in cirrhotic patients with acute GIB admitted to ICU and managed according to recent guidelines, and to determine if brain injury was associated with Hb levels. Material and methods: Cirrhotic patients admitted in ICU for acute GIB were prospectively included. Bilateral continuous recording of rSO2 was started upon admission using a NIRS monitor (INVOS 5100c Cerebral Oximeter (Covidien©) with two sensors placed on the patient's forehead. Minimal rSO2 (mini rSO2), average rSO2 (avr rSO2) and AUC of rSO2 50% (AUC50% rSO2), an integrated parameter depending on the depth/duration of desaturation under 50%, were extracted. Results: 26 patients were included (median age: 60 years; 69% men). Etiology of cirrhosis was alcoholic 54%/ viral 19%/ NASH 23%/other 4%; Child Pugh A 15%/ B 20%/ C 65% and median MELD score 18. Median initial Hb was 7.9 g/ dL and nadir within 24 first hours was 7.8 g/dL. 14 patients (54%) had a nadir of Hb below 8 g/dL within the 24 first hours, and 15 (58%) patients were transfused. Median mini rSO2 was 37% right/37% left, avr rSO2 46% right/48% left and AUC50% rSO2 1138 right/698 left. 22 patients (85%) had mini rSO2 <50%. Mini rSO2 was significantly lower in patients having a nadir of Hb below 8 g/dL. Mini rSO2, avr rSO2 and AUC50% rSO2 were independently correlated to initial Hb (P < 0.01 for all), nadir of Hb within the 24 first hours (P < 0.005 for all), and MELD score (P < 0.05 for all). Discussion/Conclusion: 85% of cirrhotic patients admitted to ICU for acute GIB and managed according to recent guidelines displayed mini rSO2 below 50% within 24 h after admission. Low Hb levels within the 24 first hours were associated with brain desaturation. Further studies are mandatory to assess the influence of Hb thresholds on the development of HE. b INRA U1436, Ecole V et erinaire de Toulouse -Toulouse (France) Introduction: Since 2015, posaconazole, an antifungal drug, is available as a gastro-resistant tablet presenting a better oral bioavailability and less pharmacokinetic variability, than the oral suspension. Surprisingly, for the patients of the Hematology Department of Oncopole (Toulouse) treated at the dose of 300 mg/day with the tablet, the measured trough concentrations (median 0.81 mg/L; IQR [0.53-1.13 mg/L]) were twice as low as those previously published [1] [2] . One explored hypothesis concerns posaconazole stability in whole blood over 48 h at two temperatures in order to simulate transport conditions of blood samples from clinical services to the Laboratory. Material and methods: Two levels of blood samples were prepared by spiking drug-free human whole blood collected on heparinized tube with a stock solution of posaconazole, in order to reach plasma concentrations of 0.5 and 2 mg/L. After shaking blood samples for 30 min, spiked blood samples were placed at + 4°C and at room temperature for 4, 8, 24 and 48 h before centrifugation and plasma freezing. This duration was based on the delay between sampling at the Hematology Department and centrifugation at Laboratory for 30 blood samples on 2017. After thawing, posaconazole plasma concentrations were determined by a validated high-performance liquid chromatographyÀultraviolet detection method. Each condition was tested thrice and compared with blood samples centrifuged without delay. Results: Concentration changes were all below the allowed analytical variability (<15%), indicating no drug loss in blood whatever the experimental conditions. Discussion/Conclusion: Posaconazole loss in whole blood cannot explain the difference of concentrations between our values and those previously published, while populations are similar. We can also exclude an analytical variability because French pharmacology laboratories analyzing posaconazole, subscribe to a national quality assessment program. When one lab obtains abnormal results, the first measure consists in outsourcing the patients' samples to another accredited laboratory, to guaranty accurate results. Thus, question is still open. References 
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Quality control in vigilance database: a tool to guarantee data quality and patient safety in clinical trials J Fressard, M Nguon, E Blanc, P Robinson Direction de la Recherche Clinique et de l'Innovation, Hospices Civils de Lyon -Lyon (France) Introduction: Before October 2017, vigilance case-reports in clinical trials were entered into a database by the sponsor using the E2BR2 format in accordance with regulations. In order to verify this compliance, a quarterly quality control (QC) of twenty cases randomly-selected since 2013 was performed. The QC consisted of verifying the consistency of data entered into the vigilance database with source data sent by the investigator. The aim was to analyze the type and frequency of errors, and potential impact on patient safety. Material and methods: The randomly selected case reports used for QC from January 2013 to September 2017 were analyzed. Ten tabs (74 fields) for each case were checked in the vigilance database: case info, identification of the case, relevant history, results of test, narrative (considered not critical for patient safety), primary source, patient characteristics, reaction/event, product information, and relatedness (considered critical for patient safety). The number of fulltime pharmacists working in the vigilance unit over the years concerned was also collected. Results: Among 380 cases analyzed (28,120 fields), 319 fields were abnormally filled (1.1%): 70 in 2013, 71 in 2014, 44 in 2015, 97 in 2016, and 37 in 2017 until September. Anomalies were most frequently found in the reaction/event tab (n = 51, 16%), followed by the narrative tab (n = 50, 16%), the relevant history tab (n = 45, 14%), the patient characteristics tab (n = 44, 14%), the identification of the case tab (n = 38, 12%), the primary source tab (n = 36, 11%), the product information tab (n = 26, 8%), the relatedness tab (n = 21, 7%), the results of test tab (n = 7, 2%) and the case info tab (n = 1). There were 178 anomalies (56%) that were in tabs considered critical for patient safety. There were 2 full-time pharmacists in 2013 and 2014, 3 in 2015, 2 in 2016, and 3 in 2017. Discussion/Conclusion: The variation of anomalies per year may be in relation to the number of full-time pharmacists. However, overall anomalies were relatively rare, and even more so when considering those in tabs which could be critical for patient safety. Some tools are used in routine to minimize the risk such as standard operating procedures, 100% validation by a pharmacist and annual consistency control of cumulative data by study. Results: A 63-year-old Caucasian man was admitted in an intensive care unit for the management of voluntary drug intoxication with clobazam (maximum of 120 tablets). This intoxication was complicated by prolonged hospitalization (46 days) that required an orotracheal intubation (during 10 days). At day 1, a screening for drugs in the blood was performed using HPLC-UVDAD. Clobazam (8.3 mg/L, normal: 0.1-0.4 mg/L) and norclobazam (14.8 mg/L) were found. Contrary to clobazam detected at 0.2 mg/L, norclobazam was found at high concentration (20 mg/L) at day 7. The persistence of high concentration of norclobazam (14.3 mg/L at day 30) suggested a lack of elimination therefore an enzyme induction by phenobarbital was introduced and maintained during 10 days. The patient was discharged from the hospital at day 46. To explain the highly prolonged kinetics of norclobazam in this patient, we searched for mutations of CYP2C19 gene. We identified a homozygous mutated allele of CYP2C19*2 which is known to be associated a total loss of enzyme activity. Discussion/Conclusion: Norclobazam is the major active metabolite of clobazam with a longer half-life and much higher steady-state plasma concentrations as compared to the parent drug. The half-life elimination of clobazam is 18 h versus 40-50 h for norclobazam [1] . Moreover, there is a large inter-individual variability in the metabolism of clobazam which actually depends on the genotype of CYP2C19 [2] . In a French cohort, the frequency of CYP2C19*2/*2 was about 3% [3] . Norclobazam is not sufficiently hydroxylated in the liver resulting in a delay in its urinary excretion. The patient was finally left with a list of contra-indicated drugs because of their interactions with CYP2C19 and in particular antidepressant drugs. References Introduction: A case of Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) 2 months after a typhoid fever and meningococcal C vaccination in a 27-year-old woman has been recently reported to our Centre. APMPPE is a rare inflammatory chorioretinal disease that occurs in young adults, with a sex ratio of 1:1. It is clinically characterized by sudden visual loss, affecting both eyes in 80% of cases. The diagnosis is mainly based on ophthalmoscopy that reveals characteristic white-yellow placoid lesions of varying sizes. Outcome is mostly favorable with spontaneous healing over a few weeks and progressive good recovery of visual acuity in several months. Several causes of APMPPE have been suggested, including infections, sarcoidosis and drugs like vaccines. We aimed to review reports of APMPPE involving vaccines in the literature and the French Pharmacovigilance database (FPVD). Material and methods: We queried PubMed and Reactions Weekly online in October 2017. We searched for all reports of "Retinal pigment epitheliopathy" (MedDRA Preferred Term) in the FPVD and selected those involving vaccines. We collected characteristics of patients, nature of vaccines, time to onset and outcome of APMPPE. Results: We identified 7 cases of APMPPE involving vaccines in the literature and 3 in the FPVD (including our case), reported between 1978 and 2017. The median age of patients was 25.5 years old (11-31), and 60% occurred in men. Of the 10 cases, 2 involved several vaccines. Suspected vaccines were flu (n = 4), typhoid fever (n = 2), hepatitis B (n = 2), hepatitis A (n = 1), meningococcal C (n = 1), meningococcal A+C (n = 1), chickenpox (n = 1) and Japanese encephalitis (n = 1) vaccines. The median time to onset of APMPPE was 14 days (2 days to 2 months). For 7 patients, oral corticosteroids were initiated. Complete visual acuity restoration and regression of retinal lesions without recurrence were reported in 3 cases. In the 7 other cases, sight restoration and regression of lesions were only partial (persistence of a central scotoma in 3 cases), with time of follow-up varying from 1 month to 1 year. Discussion/Conclusion: Our case is the second reporting the occurrence of APMPPE following a typhoid vaccination and the first following meningococcal C vaccination; only one case has been reported after meningococcal A+C vaccination. Although current data do not allow establishing a definite association between vaccination and APMPPE, clinicians should be aware of this potential rare adverse effect. A recent pre-clinical study has shown that brain-penetrating statins can reduce the risks of relapse to cocaine and nicotine addiction in rats [1] . Based on this information, we hypothesized that simvastatin could have beneficial effect for smoking cessation in human. We therefore conducted a randomized, double-blind, placebo-controlled, proof-of-concept trial to assess the efficacy of simvastatin in smoking cessation. Material and methods: After informed consent, participants received behavioral cessation support and were randomly assigned to a 3-month treatment with simvastatin (40 mg/day) or placebo. The primary outcome was abstinence or smoking reduction at 3-month post-target quit date (TQD), as verified by measurement of exhaled carbon monoxide. Secondary outcomes were biochemically verified abstinence rate during weeks 9-12 post-TQD and prolonged abstinence or reduction at months 6 and 12 post-TQD. The values of the French Tobacco Craving Questionnaire-12 and safety were assessed at each visit during the 3-months of treatment. Results: Of 118 participants, 58 were randomized to simvastatin 40 mg/day and 60 to matched placebo. Simvastatin was not associated with higher 3-month abstinence or smoking reduction compared to placebo (14% of abstinent participants versus 22% respectively and 46% of participants who reduced their consumption by 50% or more versus 45% respectively; P = 0.30). Additionally, there was no significant difference in any of the secondary outcomes. Simvastatin was well tolerated. Over 3 and 9 months follow-up period, 78% simvastatin and 69% placebo participants were retained in the study. At 6 months and 12 months, smoking reduction remained significant from baseline in both groups. Discussion/Conclusion: Our results demonstrate that a 3-month simvastatin treatment (40 mg/day), added to individual behavioral cessation support, does not improve significantly smoking cessation compared to placebo in humans. On the other hand, the high rates of smoking reduction obtained in both groups highlight the benefit of frequent behavioral counseling in obtaining drastic and long lasting reductions in smoking. PS1 -016 99m-Tc dimercaptosuccinic acid renal scintigraphy time course allows assessment of interstitial fibrosis development during adenine rich diet in rats G Hache, M Bobot, P Garrigue, S Burtey, B Guillet UMRS_1076 / CERIMEDMarseille (France) Introduction: Chronic kidney disease (CKD) increases cardiovascular events risk and mortality. Fibrosis is the hallmark of CKD and the severity of CKD usually correlates with the magnitude of kidney cortical fibrosis. Evaluation of interstitial fibrosis is crucial in preclinical research focusing on CKD, however post mortem histological staining is currently the gold standard for assessing fibrosis in rodents' kidneys. Therefore, approaches that allow longitudinal assessment of kidney structure are required to refine studies involving rodents. Thus, we investigated dedicated small-animal SPECT/CT renal imaging to monitor renal damage in vivo during the induction of chronic kidney disease in rats. Material and methods: CKD was induced in Sprague-Dawley rats (n = 7), by feeding them a diet containing 0.25% adenine (ARD) during 4 weeks. Kidney function was assessed by serum creatinine and urea. (99m)Tcdimercaptosuccinic acid ((99m)Tc-DMSA) scintigraphy was performed once a week from day 0 to day 35. At the end of the protocol, histopathological evaluation of kidney damage and sirius red staining were performed. Results: Compared to control rats, we showed an increase in serum creatinine, serum urea from day 14 to day 35 in ARD rats, with a maximum at day 28 (creatinine: 98.9 AE 17.9 vs 49.1 AE 2.8 lM P < 0.001 -urea: 12.7 AE 3.0 vs 5.3 AE 1.0 mM; P < 0.001). ARD significantly decreased 99mTc-DMSA uptake in kidneys from day 14 to day 35, with a minimum at day 35 (0.195 AE 0.107 vs 0.248 AE 0.030% of injected dose /kidney; P = 0.013). Post mortem histopathological examination showed damage of tubular structures, and an increase in interstitial collagen I and III accumulation in renal cortex. Interestingly at day 35, 99mTc-DMSA uptake was negatively correlated to Sirius red staining. Discussion/Conclusion: 99mTc-DMSA scintigraphy was representative of cortical fibrosis in ARD rats. This imaging strategy enabled longitudinal monitoring of kidney fibrosis in rodents, and appears to be an efficient tool for evaluating therapeutic strategies against kidney fibrosis development. c Centre R egional de Pharmacovigilance de Bourgogne, CHU de Dijon -Dijon (France) Introduction: The use of intravenous immunoglobulin (IVIG) for the treatment of inflammatory and/or autoimmune disorders is increasing. Dermatologic adverse effects are labelled in the Summary of Product Characteristics (SmPC) of the IVIG but delayed eruptions and photosensitivity are not. Material and methods: We present 2 cases of delayed eruption induced by IVIG. Results: Case 1: A 76-year-old patient was treated with OCTAGAM â for chronic polyradiculoneuritis from 21st to 25th April 2017. Seventeen days after the last administration, a facial maculopapular eruption with edema and lesions on the neckline appeared. Over a period of 2 weeks, the skin lesions extended. The patient was hospitalized on 29th May, and the lesions regressed progressively with a topical therapy of corticosteroid. CLAIRYG â , another IVIG was administered from 18th to 22nd August 2017. On 29th August, he developed photodistributed erythematous skin lesions on the neck, the face, the arms and the palms, and dyshidrotic hand lesions. A blepharitis and a cheilitis were also observed. In early November 2017, he was again treated with CLAIRYG â . No lesions were found the last day of this treatment. On 20 December 2017, he reported papular eruption on the palms at home. Exploration showed reduced minimal erythema dose. Case 2: A 76-year-old patient was treated with CLAIRYG â for chronic demyelinating polyradiculoneuritis from 1st to 5th September 2017. He had already received CLAIRYG â in August 2017 and PRIVIGEN â in June 2017 with no side effects. Seven days after the last dose, a maculopapular eruption appeared, then an eczematous skin reaction most prominent on the hands and erythematous skin lesions on the face, the neckline and the scalp. The patient reported a sun exposure during the same period. He was hospitalized on 26th September, and the lesions regressed with a topical therapy of corticosteroid and cetirizine. In mid December, he was treated with PRIVIGEN â but the patient is lost to follow up. Discussion/Conclusion: We report 2 cases of delayed eruption and photosensitivity with IVIG. These side effects are not labelled in the SmPC of the IVIG. We found in the literature few cases of maculopapular eruptions, eczematous skin reactions until 3 weeks after the end of administration [1, 2] . As delayed reactions can be falsely ascribed to another drug, clinicians should be aware of delayed lesions with this class of drugs. Moreover, photosensitivity is not described in the literature. In many malaria-endemic sub-Saharan African countries, existing pharmacovigilance systems are not sufficiently operational to document the safety profile of antimalarial drugs reliably. This study describes the implantation of a community-based pharmacovigilance system in Côte d'Ivoire and its use to document the safety of ASAQ Winthrop â (artesunate-amodiaquine). Material and methods: Between February 2010 and October 2013 a prospective, longitudinal, descriptive, non-interventional study on the use of ASAQ in reallife conditions of use was conducted in seven community health centres of the Agboville district in Côte d'Ivoire. Twenty trained health centre employees and 70 trained community health workers were involved in data collection. All patients with suspected uncomplicated Plasmodium falciparum malaria seeking treatment at one of the participating health centres and treated with ASAQ could be enrolled. Two visits were planned, one for inclusion at the health centre and a second at home performed by a community health worker 3-10 days after the inclusion visit. Administration of ASAQ was unsupervised. Adverse events were documented at the home visit or during any unexpected visit to the health centre or to the hospital and coded and adjudicated by a local pharmacovigilance committee. Symptoms suggestive of hepatic failure, severe neutropenia, extrapyramidal disorders and retinopathy were considered a priori as adverse events of special interest. Results: 15,228 malaria episodes in 12,198 patients were evaluated. 2,545 adverse events were documented during 1,978 malaria episodes (13.0%). The most frequently observed events were asthenia (682 cases), vomiting (482 cases) and somnolence (174 cases). Most reported AEs were of mild or moderate intensity and resolved without corrective treatment. One hundred and five (105) adverse events reported during 100 episodes (0.7%) were considered as serious. Three serious cases of transient extrapyramidal disorders, identified as adverse event of special interest were reported in three patients. Discussion/Conclusion: The fixed dose combination ASAQ Winthrop â for the unsupervised treatment of uncomplicated P. falciparum malaria under real-life conditions of care in Côte d'Ivoire is well tolerated. The study emphasises the interest of involving properly trained community health workers to collect pharmacovigilance data in the field in order to document rare adverse events. Malaria, artesunate-amodiaquine, Côte d'Ivoire, pharmacovigilance.
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Comparative efficacy of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomized trials C Khouri Introduction: Recent guidelines from the European League against Rheumatism (EULAR) recommend oral calcium channel blockers (CCBs) as first-line therapy for Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc), and phosphodiesterase type 5 inhibitors (PDE-5i) in patients with severe RP and/or those who do not respond to CCBs. Intravenous prostacyclin (IV PGI2) analogues are indicated in some cases, and other treatments might also show some efficacy. Yet, there are few randomized, pairwise comparisons between all these treatments. We aimed at performing a systematic review with a network meta-analysis to assess the efficacy of treatments for SSc-related RP. Material and methods: This systematic review complies with the PRISMA statement guideline. The full protocol is available online (PROSPERO registry, CRD42017057518). Eligible studies were double-blind, randomized controlled trials (RCTs) assessing any pharmacological treatment for RP in patients with SSc. The outcomes were the frequency and duration of RP attacks, and its severity (assessed through the Raynaud's Condition Score or any other severity score). Data were abstracted and analyzed using the standardized mean difference (SMD). We performed a random-effects network meta-analysis using the graph theoretical method. Results: Fifty-six studies enrolling 3,757 patients (90.8% of whom had secondary RP) were included in quantitative analysis. IV PGI2 analogues, PDE-5i and CCBs were the only drug classes to significantly decrease both RP frequency and severity. The effect size was comparable between CCBs and PDE-5i for frequency [0.29 (0.05, 0.53) and 0.32 (0.07, 0.57), respectively], and about twice larger for IV PGI2 analogues [0.67 (0.34, 1.00)]. Differences were smaller on severity: SMD=0.32 (0.10, 0.54) for PDE-5i, 0.44 (0.20, 0.67) for CCBs, and 0.49 (0.19, 0.78) for IV PGI2 analogues. Only PDE-5i showed a significant effect on the duration of RP attacks, SMD=0.27 (0.03, 0.51). Results from one study were still pending at the date of this report (NCT01090492), and data from another study could not be obtained despite repeated requests (NCT00528242). Discussion/Conclusion: Network meta-analysis of RCTs showed the highest efficacy for IV PGI2 analogues. Among oral treatments, PDE-5i and CCBs had comparable efficacy, which is in line with the recently updated EULAR recommendations. However, the effect size is modest, and the lack of standardisation of outcome measures is a limitation. Pharmacovigilance and pharmacoepidemiology Department, Reims University Hospitals -Reims (France) Introduction: Serious adverse drug reactions (ADRs) are major concerns in terms of both individual outcomes and public health expense. Specific patients are often excluded from oncology trials. That is why observational studies are required to assess safety of antineoplastic in elderly and/or frail patients. Material and methods: To identify risk factors associated with serious ADR in oncology for frail or old patients, we performed a retrospective and comparative study between patients treated by antineoplastic aged 65 and over versus younger patients. Sociodemographic information, performance status, Charlson's index, suspected drugs, off-label use, concomitant medications and ADRs data were analyzed. Between January to December 2015, data were collected from spontaneous reporting in a 1.3 M inhabitants regional pharmacovigilance centre. Descriptive statistics and logistic regression using SAS 9.4 were undertaken. Results: We identified 167 patients (mean age 53.9 + /-23.5 years). Elderly accounted 57% of the patients and experienced less serious ADRs (P < 0.09). Among all the reported ADRs (n = 364), 30.4% referred to serious ones (n = 111). The majority of these serious ADRs were caused by targeted therapies (n = 16), pyrimidine analogue (n = 16) and nitrogen mustard (n = 15). In the logistic regression model assessing seriousness, the odds ratio (95% confidence interval) for age was 0.37 (0.15-0.91), for poor performance status (2) (3) (4) (5) Unit e de recherche clinique Paris centre -Paris (France) Introduction: Prednisone is a non-steroidal anti-inflammatory drug widely used in internal medicine and rheumatology, but dosing remains empirical. The active metabolite of prednisone is free prednisolone. The aim of this work was to build a population pharmacokinetic (PK) model of free prednisolone in patients with inflammatory/immunologic conditions. Material and methods: A total of 109 patients from the department of internal medicine of Cochin hospital provided 343 observations. Blood samples drawn for biological analyses were used for drug determination. Plasma prednisolone concentration was measured by liquid chromatography-mass spectrometry and the data was modelled using Monolix. Results: The pharmacokinetics was ascribed a one-compartment open model with 4 transit compartments standing for the absorption and metabolism process. Only size parameters influenced the pharmacokinetics. Free prednisolone CLU/F and VU/F, scaled allometrically on lean body weight, were respectively 30.6 AE 1.5 L/h and 112 AE 6 L for 50 kg LBW. CLU/F interindividual variability was 0.224 AE 0.032. The additive and proportional residual variabilities were respectively 4.4 lg/L and 0.196. Discussion/Conclusion: This study investigated the free prednisolone PK after prednisone administration for the first time in patients with inflammatory and or /immunologic conditions. The results points out some dosing issues, i.e., the possibility of under-or over-dosage in thin or overweight patients, respectively. In Côte d'Ivoire, the introduction of artemisinin-based combination therapy (ACTs) in the treatment of uncomplicated malaria in 2006 with the WHO requirement of a tolerance follow-up has been an opportunity for early start formal pharmacovigilance activities. Material and methods: The Department of Pharmacy, Drugs and Laboratories (DPML), in collaboration with the university, health programs, and development partners have developed a project for the establishment a national PV system. Regulatory texts have been adopted. Tools have been developed (National Policy Document, Training Manual, Notice Card, Awareness Leaflet, OMS software). A training program for health professionals on the good practice of PV has been implemented. A notification and information management circuit has been identified. Results: From 2008 to 2017, this program allowed training 1,500 health professionals in 74 districts with 150 focal points. 65 transfusion safety committees and a national counterfeit drugs committee were installed. The system of information allowed the collection of 2,240 notification forms (203 notifications per year) dominated by antimalarial (37%) with 8% of serious adverse events (SAEs). The management of Adverse Events Following Immunization (AEFI) is only effective during mass vaccination campaigns. It allowed correcting 6-7% of program error. For hemovigilance, the system is non-existent. From 2007 to 2017, 354 alerts (35 alerts per year) were issued. Only 7.5% of the alerts were generated locally. The management of these alerts resulted in the discontinuation of 227 products and 65 batches of drugs withdrawn from the market. Since 5 years, the control of fake drugs has allowed 13 seizures of more than 600 tons of prohibited pharmaceutical products, estimated at around 37 million euros. At international level, Côte d'Ivoire is a member of the WHO PV program, and participates in West Africa's Fake Drug Early Warning System. Discussion/Conclusion: The implementation of this important activity has many constraints. It will be effective only through the creation of a national pharmacovigilance center, equipped with adequate means for the good practice of PV, and a more active coordination of activities with health programs.
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Role of phosphodiesterases in controlling cGMP compartmentation in cultured vascular smooth muscle cells L Zhang, B Manoury, G Vandecasteele, R Fischmeister, V Leblais UMR-S 1180, INSERM, Univ Paris-Sud, Univ Paris-Saclay -Châtenay-Malabry (France) Introduction: Vascular cGMP is generated by the soluble guanylyl cyclase (sGC) activated by nitric oxide (NO) and the natriuretic peptide (NP) receptors, NPR-A and NPR-B. Degradation of cGMP by phosphodiesterases (PDE) is a key mechanism for mitigating the cGMP intracellular concentrations ([cGMP]i) and the subsequent cGMP-mediated responses. Here, we investigated the respective role of 3 PDE families, the calcium-activated PDE1, PDE5 and PDE9, in controlling [cGMP] i in cultured rat aortic smooth muscle cells (RASMC). Material and methods: We followed a pharmacological approach by using inhibitors for PDE1 (1 lM PF04471141, PF1), PDE5 (200 nM sildenafil) and PDE9 (5 lM PF04447943, PF9). Cyclic GMP-PDE activity was measured by a radioenzymatic assay in protein extracts from RASMC. Real-time [cGMP]i was recorded by fluorescence resonance energy transfer (FRET)-imaging using the cGi-500 sensor, in single living RASMC stimulated by a NO donor (DEA-NO; 1, 3 and 10 lM) or the A-type and C-type NP (ANP and CNP; 0.01 and 0.1 lM). Results: Biochemical assay revealed that PDE1, PDE5 and PDE9 represent the total cGMP-hydrolysing activity in RASMC. DEA-NO, ANP and CNP elicited a concentration-dependent increase in FRET signal, reflecting the rise in cGMP production by sGC, NPR-A and NPR-B, respectively. PF1 had no effect on the dynamics of the FRET responses induced by DEA-NO or ANP, but markedly increased the amplitude of the CNP (0.1 lM)-induced response (by 25%), without altering the kinetics of its recovery phase. Interestingly, in the presence of angiotensin II that is associated with an increase in intracellular calcium concentration, PF1 significantly delayed the recovery phase of the DEA-NO-mediated FRET response. Sildenafil significantly potentiated the maximum response to 10 lM DEA-NO (by 33%) and dramatically extended its recovery phase. Sildenafil also strongly elevated the peak of the FRET responses induced by 0.1 lM ANP or CNP, without altering their recovery phase. Finally, PF9 significantly modified the FRET response to DEA-NO, by increasing its maximum amplitude (by 2-fold at 3 lM DEA-NO) and delaying its recovery phase, without affecting the ANP-or CNP-elicited FRET signals. Discussion/Conclusion: Our data show that PDE1, PDE5 and PDE9 exert a distinct role in locally regulating the [cGMP]i in RASMC: the sGC/cGMP pool appears to be collectively regulated by PDE5, PDE9 and the calcium-stimulated PDE1, the NPR-A/cGMP pool by PDE5, and the NPR-B/cGMP pool by PDE5 and PDE9. Posaconazole is a triazole antifungal used to prevent invasive fungal infections (IFIs) in patients receiving chemotherapy or haematopoietic stem cell transplantation. Due to highly variable bioavailability of the oral suspension formulation, a delayed-release tablet was developed which showed improved bioavailability. A minimal target posaconazole plasma concentration of 0.7 mg/L is recommended for prophylaxis of IFIs. However, the relationship between plasma concentration of posaconazole and its efficacy against IFIs remains unclear. Material and methods: We analysed trough posaconazole concentrations and response against IFIs in 50 and 104 patients with haematologic malignancies receiving prophylactic posaconazole as the tablet or suspension formulation, respectively. Results: Mean plasma concentration of posaconazole was 1.91 AE 1.06 mg/L and 0.82 AE 0.57 mg/L in the tablet and the oral suspension group, respectively (P < 0.0001). The percentage of patients reaching the minimal target concentration of 0.7 mg/L was 92.0% and 47.1% in the tablet and oral suspension groups, respectively (P < 0.0001). Emergent aspergillosis occurred in 9 (8.7%) patients in the suspension group and in none of the patients taking the tablet formulation (P = 0.032). Among the 9 treatment failures, 3 patients taking the oral suspension reached the threshold concentration (≥0.7 mg/L) but nonetheless developed an infection. Discussion/Conclusion: Our results show a relationship between plasma concentrations of posaconazole and its prophylactic efficacy in patients with haematologic malignancies. Target posaconazole concentrations are reached more efficiently with the tablet than with the suspension formulation. The recommended prophylactic threshold of 0.7 mg/L for plasma concentrations of posaconazole may be too low.
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Evaluation of the effect of benzodiazepines on cognitive status in rats Y Kadil, H Filali, F Hakkou Pharmacology, Faculty of Medicine and Pharmacy of Casablanca -Casablanca (Morocco) Introduction: Benzodiazepines are widely used in the treatment of certain emotional disorders. They are the most commonly prescribed psychotropic medications in the treatment of anxiety and sleep disorders. They are effective, tolerated and have few side effects. However, they can lead to addiction and dependence, a syndrome associating, to varying degrees, an alteration of the state of consciousness with behavioral and memory disorder. Our objective is the evaluation of the effect of benzodiazepines on the cognitive status of rats. Material and methods: The study examines the impact of diazepam at a dose of 1 mg/kg on cognition in Wistar rats belonging to the Department of Pharmacology of the Faculty of Medicine and Pharmacy of Casablanca on period of 3 months using the object reconnaissance test.
Results:
The results showed a significant decrease in the percentage reconnaissance of the new object for the treated group during the 12-week period compared to the control group. Discussion/Conclusion: At this stage of our experiment, we can estimate that the initial objective, namely that of the set-up if there is an association between the administration of benzodiazepines and the cognitive decline in an animal model. We hope that future conditions will allow us to engage in a research process with the aim of highlighting the mechanisms that can induce cognitive decline and Alzheimer's disease. We conclude that chronic treatment of benzodiazepines is one of the leading causes of cognitive decline. Further study will be conducted in the same direction to determine the mechanism that induces these undesirable effects. Department of Clinical Pharmacology, CHU de Nantes -Nantes (France) Introduction: Terbinafine is a synthetic allylamine derivative, used as an antifungal drug. Its specific mechanism of action relies on the inhibition of squalene epoxidase. It is used in the treatment of onychomycosis or dermatophytes, and is usually well tolerated. A recent case of urinary retention in a patient treated with terbinafine was notified to our pharmacovigilance Centre. It led us to focus on the possible link between terbinafine and urinary retention. Material and methods: Scientific literature was reviewed and different pharmacovigilance databases were requested. Results: In the case reported to our pharmacovigilance Centre, urinary retention appeared in a 45-year-old male with onychomycosis the day following the initiation of the Terbinafine treatment, taken orally, concomitantly with diarrhea and nausea. The urinary retention resolved in a short amount of time after the drug was withdrawn. Three cases have also been reported in the French pharmacovigilance database. On the first report, urinary retention occurred in a 69 YO male a few minutes after the administration of Terbinafine, lasted a few hours, and reappeared after each administration. It improved shortly after drug withdrawal. In both other cases, the urinary disorder appeared at least ten days after the introduction of terbinafine, and improved after drug withdrawal. According to the FDA's data, 28 people have been reported with urinary retention during a terbinafine treatment. Among them, 85% were male, 57% were 60 YO or older and 57% had been taking the drug for less than 1 month. We also found in VigiLyze, besides the French cases, 5 other cases of urinary retention attributed to terbinafine. Lastly, the PSUR from September 2017 indicates that 25 cases of urinary retention have been reported with Lamisil â since it was marketed in 1990, for an estimated exposure of 8 million patients / year. Discussion/Conclusion: In the light of these data it seems to be possible for Terbinafine to rarely cause urinary retention in some patients. To our knowledge a wide variety of drugs has been shown to be responsible of urinary retention such as those with an anticholinergic activity, opioids and anaesthetics, alphaadrenoceptor agonists, but it is the first time urinary retention is being reported as a possible adverse effect of terbinafine. That adverse effect seems to affect more the men, with a fast regression after drug withdrawal. Although we have no explanation on the mechanism, physicians should be aware of that possible adverse effect with terbinafine.
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Reported vaccination side effects in Franche-Comte over a five-year period M Moltenis, D Pinston, S Davani, MB Valnet-Rabier Pharmacovigilance Regional Centre -CRPV Franche-Comt e -Besanc ßon (France) Introduction: In January 2018, the immunization schedule for children under 2 years of age was modified in France. Eight vaccines, previously only recommended, were added to the three vaccines which are already compulsory for children: diphtheria, tetanus and poliomyelitis. The purpose of this study was to evaluate the types of reported side effects induced by vaccination in a French region of 1,210,000 inhabitants. Material and methods: The request was conducted in the French National Pharmacovigilance database, in regards to all the adverse drug reaction (ADRs) reports with a vaccine as the suspect drug and registered by the Pharmacovigilance Regional Center (CRPV) of Besancon between 2012 and 2017. Results: 80 cases of vaccination side effects were extracted from 5,376 reported cases. The represented population consisted of 32.5% adults, 25% infants, 15% adolescents, 13.75% children and 13.75% elderly people. The sex ratio M/F was 0.77. There were 32 serious ADRs (40%), involving 21 hospitalizations, 9 otherwise "medically significant", 1 life-threatening and 1 incapacity. 78 cases involved inactivated vaccines; the most involved strains were influenza (18%) and pneumococcus (17%). Among the 12 cases concerning live attenuated vaccines, half were related to the M-M-R vaccine combination. 38% of the ADRs were general disorders and administration site conditions represented one-half of administration site reactions (pain, induration) and the other half were general system disorders (malaise, hyperthermia). 15% of ADRs were related to skin and subcutaneous tissue disorders, mainly urticaria and pruritus followed by rash, to which could be added a case of hypersensitivity. 11.8% of cases led to nervous system disorders, half of which were headaches and 11% were related to gastrointestinal disorders with mainly abdominal pain, vomiting and diarrhea. Of the 133 ADRs reported, 67% of the outcomes were reported as resolved. 11 cases out of 80 included the results of allergological analyses, 6 were positive with a hypersensitivity to aluminum confirmed in 4 cases. Discussion/Conclusion: Only 1.5% of the spontaneous reports recorded in Franche-Comte over a 5-year period concerned vaccination. Of the 40% of severe cases, none led to death and the majority of cases reported disorders at the administration site, hyperthermia or urticaria and were resolved. This study highlights the importance of performing allergological tests because half of them have established a real sensitization mainly related to the presence of aluminum. Sex/ratio was around one. The melanoma was the first indication. Most of the patients (47.2%) were asymptomatic although they were classified as grade 2 since they were prescribed a symptomatic or substitution treatment. Therefore, grade 2 patients represented 79.1% of the sample while only 7.3% were grade 1, 3.6% were grade 3, 1.8% were grade 4 and 1.8% were grade 5. No orbitopathy was reported. Hypothyroidism and thyrotoxicosis were equally reported. Antithyroid antibodies were positive in only 16% patients. The ultrasonography was informative in 19% patients. Levothyroxine was administered to the patient in most cases (57.3%) whereas synthesis antithyroid drugs were less frequently prescribed (20%) and only for a month. Five patients (4.5%) suffering from thyrotoxicosis were administered a symptomatic treatment based on beta-blockers. With a dedicated optimized management, most of the cases did not require immunotherapy discontinuation. Discussion/Conclusion: This is today the most comprehensive set of data currently published about ICI induced thyroiditis. Immune-mediated related thyroiditis are increasing due to a wider prescription of ICI therapy in various cancer conditions and systematic screening. Often asymptomatic, they lead to a local activation accompanied by hormonal deficiency in the long run. It is necessary to carry out an early and sustained multidisciplinary screening to allow immunotherapy continuation.
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Use of the French health insurance database for research in the field of mental health: review and perspectives A Revet [1] , no specific review focusing on their use for research in the field of mental health was available. The aim of this study was to review literature on the use of the Echantillon G en eraliste des B en eficiaires (EGB) and the Syst eme National d'Information Inter-R egime de l'Assurance Maladie (SNIIR-AM) for research in the field of mental health. Material and methods: The public MEDLINE and Web of Science databases were systematically searched, from 1st January 2003 (year of beginning SNIIR-AM) to 31st December 2017. The following keywords were used: " Echantillon g en eraliste des b en eficiaires (EGB)", "SNIIRAM (Syst eme national d'information inter-r egimes de l'Assurance maladie)", "French health insurance database", "French Social Security Insurance national database", "French national health care insurance system", "France national health insurance database", "representative sample of the French Social Security Insurance national database", "bases de l'Assurance maladie", "French health insurance record", "French claims database". "French reimbursement database", "French data warehouse". Articles in French or in English were eligible. Articles in connection, from near and farincluding, with different aspects of the field of mental health in France were selected. The systematic review was completed with publications extracted from the reference lists of identified papers. Results: A total of 1,393 articles were identified in the online search. After removing duplicates and unrelated articles, 73 articles were selected as eligible for further review. These 73 articles were characterized in terms of field of research, study design, study population and database used. Most of studies focused on psychotropic drugs with only few dealing with epidemiological issues (n = 7, 9.6%) and only 1 with health economics. Most of studies (n = 48, 65.7%) used SNIIR-AM. Only 5 studies (6.8%) focused on children. Discussion/Conclusion: Advantages and limitations of these two databases and the perspectives they open for research in the field of mental health, as well as issues related to the implementation of the Syst eme national des donn ees de sant e (SNDS) will be discussed. The pathophysiology of aortic stenosis (AS), the most common acquired valvulopathy, is not fully understood and there is to date no treatment to slow or stop the progression of the disease. To define new therapeutic strategies, reproducible and adequate animal models of AS remain essential and are lacking. A new mouse model has been proposed consisting of a single-nucleotide homozygous substitution mutation in the gene encoding EGFr, known as C57BL6 EGFrwa2/wa2. However, it has been recently shown that aortic regurgitation (AR) remained prevalent, and that AS was rare or absent. The aim of this study was to evaluate the effect of a High Fat Diet (HFD) and Vitamin D3 supplementation in this model. Material and methods: C57BL6 EGFrwa2/wa2 mice were fed with HFD and were subcutaneous injected with Vitamin D3 (16 UI/kg UI, 3 times a week, n = 16) during eighteen weeks. We used as control C57BL6 EGFrwa2/wa2 mice fed without HFD and vitamin D3 (n = 12). Echocardiography was performed 3 and 6 months later. Serum 25(OH)2D3, 1.25(OH)2D3, calcium, total cholesterol and phosphates were analyzed and histology/IHC were performed at 6 months to assess valvular fibrosis, calcification, lipid depositions and inflammation. Results: Echocardiographic analysis did not show any improvement of the model with HFD and vitamin D3 supplementation. We observed pure severe AS in only two animals in each group and predominant AR in remaining animals. The different variables studied by echocardiography which assess the severity of AS (peak jet velocity 2.45 AE 0.65 m/s; mean aortic gradient 18.72 + /-9.41 mmHg) and AR (vena contracta 0.51 + /-0.24 mm) were not significantly different between the two groups. Vitamin D3 supplementation and HFD did not affect inflammation and calcifications, although total cholesterol level was increased. Discussion/Conclusion: These results suggest that HFD and vitamin D3 supplementation had no effect on the C57BL6 EGFrwa2/wa2 mice model. This model essentially mimics AR and no AS. Further studies are needed to find a reliable animal model of AS.
PS1 -031
Audit concerning the medicinal care of elderly patients in a teaching hospital J Dinet Elderly people represent a significant number of hospitalized patients in most care units. Drug prescription for the elderly must follow specific rules according to the Haute Autorit e de Sant e (HAS) due to an increased iatrogenic risk. In the context of the certification carried out by the HAS in care facilities, the teaching hospital performed an audit to evaluate the quality of the clinical and medicinal care of the elderly. Material and methods: A 24-h audit was carried out in October 2016 concerning drug prescriptions of patients aged 65 or over, hospitalized for at least three days in medicine and surgery units. The questionnaire was about the analysis of clinical parameters in the medical record, such as age, weight, glomerular filtration rate (GFR), research of orthostatic hypotension, cognitive state and need to crush the pills. Furthermore, the quality of the prescription for frequently used pharmacological classes and/or classes at increased iatrogenic risk have also been assessed. Results: A total of 483 prescriptions were analyzed with an average patient age of 80. The prescriptions contained 12 lines on average and were computerized in 86% of cases (97% in medicine vs 21% in surgery). Patient's weight was computationally recorded in 94% of cases and was present in the paper file in 68% of cases. However, the weight coincides in both files in only 71% of cases. Cognitive state was recorded in 66% of cases, research of orthostatic hypotension in 21% and pharmaceutical analysis was never recorded (0%). The GFR estimate was found for 42% of patients, and when it was below 60 mL/min, a third of the treatment lines was appropriate. Concerning medications, 64% of patients received a psychotropic drug including a benzodiazepine (46%) and/or a neuroleptic (14%), 53% had a proton pump inhibitor, 29% had a statin, 17% had a vitamin K antagonist with an INR recorded in 83% of cases and only 3% of patients had a non-steroid anti inflammatory drug. Finally, it was found that patients hospitalized in surgery received significantly less psychotropic drugs than those hospitalized in geriatrics. Discussion/Conclusion: The results bring out the need to improve drug-prescribing practices, especially concerning the dosage adjustment and the recording and traceability of the clinical data in the medical record, to avoid any risk of error. This audit was also the opportunity to set up training tools highlighting areas of improvement for all prescribers of the hospital.
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Impact of a cortical microbleed on cognition and its pharmacological modulation by atorvastatin in female wild-type and transgenic mice In vivo Imaging Core Facility, Lille University Medical Center -Lille (France) Introduction: Epidemiological studies suggest that microbleeds (MB) are not clinically silent and could lead to cognitive decline in healthy subjects and in Alzheimer's disease (AD) patients as well [1] . By their pleiotropic effects, statins could prevent this cognitive decline. A higher prevalence of neurovascular diseases and AD [2] is observed among women. Furthermore, a sex-specific pharmacological response is possible. The aim of this study was to assess the impact of MB and the effect of atorvastatin on cognition in female mice during a 3 months follow-up using a murine model of collagenase-induced MB. Material and methods: Twelve-week-old female C57BL6 (WT) and J20 transgenic mice (APP) which express the human amyloid protein precursor (a model of AD) were operated by stereotaxic surgery. A cortical injection of collagenase was performed to induce a single MB. Some of the MB mice have received pellets of atorvastatin (AT). Six groups were established: WT sham, WT MB, WT MB+AT, APP sham, APP MB, APP MB+AT. Behavioral tests including open field, spontaneous alternation and touchscreen automated paired associates learning task were performed 6 weeks after surgery to respectively assess locomotor activity, working memory and visuospatial memory (VSM). A two-way ANOVA and a mixed linear model were performed to assess the statistical significance of any differences found. Results: The VSM was impaired in APP groups compared to WT groups regardless the existence of MB (-2.21%; P = 0.024). The VSM was better in MB groups compared to sham groups regardless the genotype (+4.34%; P = 0.0001). The use of atorvastatin improved VSM in WT MB (62.18 + /-0.87 vs 59.55 + /-0.58; P = 0.013) but not in APP MB. Among WT groups, working memory was not impaired by MB but was impaired by the use of atorvastatin (P = 0.039). MB or atorvastatin had no effect on locomotor activity. Discussion/Conclusion: In conclusion, female mice, regardless the genotype, seemed to offset the cognitive effect induced by MB. Atorvastatin had a heterogeneous impact on cognition, depending on genotype. A mechanistic characterization will follow, focused in particular on the role of estrogens. References Gaucher disease (GD) is a rare genetic disease. It is due to a lysosomal acid beta-glucosidase deficiency leading to an accumulation of glucoceramides in macrophage lysosomes. There are currently 2 specific treatments: i) enzymatic substitution reference treatment with imiglucerase or velaglucerase; ii) substrate reduction with eliglustat or miglustat (eliglustat being an analogue of ceramide whereas miglustat is a D-glucose analogue). Miglustat exerts a less specific and less potent inhibition than eliglustat. Material and methods: We report a case of diabetes in a patient treated with eliglustat reported to our regional pharmacovigilance center and review literature about glucose metabolism disorders in GD population. Results: This is a 51-year-old man with GD diagnosed 19 years ago and treated with imiglucerase. To improve his quality of life, treatment has been changed to eliglustat. He was treated since 13 months when he was hospitalized because of polyuria, polydipsia, weight loss and asthenia. GD was controlled but eliglustat was stopped. Type 2 diabetes was diagnosed and antidiabetics were started. A few months later, antidiabetic could be reduced but GD progressed, so imiglucerase was introduced again. Antibody anti-GAD and anti-IA2 were negative. No cases of diabetes were found with eliglustat in literature. In European pharmacovigilance database, we found 3 cases of diabetes associated with eliglustat whereas only 35 adverse drug reactions are registered with eliglustat. Furthermore, 2 cases of glucose metabolism disorders were also reported with miglustat: hyperglycemia and hypoglycaemia. Diabetes were also observed with imiglucerase (15 cases) and velaglucerase (3 cases). Discussion/Conclusion: Arguments supporting an adverse drug reaction include the partial regression of diabetes in our patient after stopping eliglustat. We also need to take into account the lack of perspective on safety profile of eliglustat. But GD can also have an impact on glucose metabolism. In fact, some experimental models showed that beta-glucosidase inhibition can have a benefit on hyperglycemia and insulin resistance. Moreover, in a recent review on glucose metabolism complications in GD patients, authors suggest a possible association between GD and insulin resistance [1] . More safety data are needed for eliglustat. Introduction: A systematic case-referent study was conducted upon request by the French health authorities to compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in reallife conditions. Material and methods: This study used the PGRx (Pharmacoepidemiological General Research eXtension)-ACS (acute coronary syndrome) registry. The study population was composed of (i) a cohort of patients with an index ACS, and (ii) reMI case-patients from the cohort or recruited externally to the cohort but in the same cardiology sites. Cohort patients not experiencing a reMI were defined as referents. Matched referents were selected for each case by individual matching. To avoid selection bias, patients were consecutively recruited after prospective/retrospective identification by centres blind to the study objectives. Cases and referents met similar eligibility criteria: gender; aged ≥18 years; living in France; index ACS during the study period, regardless of its rank. Multivariate conditional logistic regression assessed the OR (95% CI) for reMI associated with ticagrelor and prasugrel vs. clopidogrel, adjusted for aspirin use and cardiovascular risk factors. The exposure of interest was defined as antiplatelet use within 30 days of the index ACS. Leflunomide is an immunosuppressive agent commercialized as treatment for rheumatoid arthritis. Because of its immunosuppressive and possible antiviral properties, leflunomide has been evaluated in some case series of BK virus associated nephropathy (BKVAN) with favorable results, mostly in adult patients. Leflunomide targeted levels are usually between 50 and 100 mg/L in kidney transplant adults patients. Data in pediatric population are scarce. The aim of this study was to describe leflunomide concentration in kidney-transplant children. Material and methods: Therapeutic Drug Monitoring (TDM) of leflunomide is routinely performed dosing its active metabolite, teriflunomide, using a simple HPLC-UV method. Pediatric kidney transplant patients with at least one teriflunomide sample between 2010 and 2017 were retrospectively included. Viremia control was defined as undetectable BK viremia or a decrease of more than 1 log in the viral load from baseline after 2 months of treatment. Adverse events (hematological, digestive, metabolic disturbances, hypertension, hepatotoxicity) were recorded. Concentration of teriflunomide according to viremia control and tolerance were compared using t-test. Results: A total of seven patients, with a median age of 12.1 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , from three centers were included. Six were only kidney transplant and 1 was a lung-kidney transplant patient with cystic fibrosis. All patients reported high load BK viremia but none developed BKVAN. For 67% of the patients, complete BK viral clearance was observed during leflunomide treatment with drastic immunosuppressive therapy reduction. Mycophenolate was indeed discontinued in almost all patients. Of note leflunomide concentrations were significantly higher when viremia was controlled, but only 33% of the observed concentrations were greater than 40 mg/L. CF patient had lower concentrations with higher posology. No hepatotoxicity was observed in this study and no patient experienced graft rejection. Leflunomide was suspected to cause hemolytic anemia and one patient experienced biological pancreatitis with favorable outcome. Discussion/Conclusion: This study evidenced the wide interindividual variability of the exposure and supports the routine practice of TDM with a suggested target level of 30-40 mg/L in pediatric kidney transplanted patient, which need further consolidation. Introduction of new drugs was associated with new patterns of adverse drug reactions (ADR) including dermatological ones (DADRs). Although alopecia or hand-foot syndrome have been described since occurrence of the first cytotoxic drugs, other skin ADRs have appeared like cutaneous rashes, acneiform reactions. . . We performed a review of DADRs notifications of anticancer drugs using a large international pharmacovigilance database. Material and methods: We studied notifications of ADRs in the VigiBase â database from January 1st, 2000 to December 31st, 2016. We selected drugs according to the ATC code "antineoplastic and immunosuppressive" with an indication in cancer. The SOC term for DADRs was "skin and subcutaneous tissue disorders". Results: During the study period, among a total number of 12,269,318 notifications of DADRs for all drugs registered in VigiBase â , 1,370,887 were related to anticancer drug exposition (11.2%). Between 2000 and 2016, percentage of DADRs among anticancer drug ADRs increased from 5.9 to 9.8%. During this period, while the proportion of DADRs attributable to cytotoxic drugs remained constant, the increase was mainly related to "targeted" therapies notifications. In 2016, 1.84% of DADRs were related to an anticancer drug, mainly a "targeted" therapy (45.1%), including 11.0% anti-EGFR drugs: cetuximab, panitumumab, erlotinib, gefitinib. . .. The main DADRs were rash (18.4%), pruritus (11.7%) and alopecia (8.7%) with a special increase in cutaneous rash, acne, foot-hand syndrome, dry skin and skin exfoliation occurrence with "targeted" therapies. Discussion/Conclusion: Since 2000, the part of reported DADRs attributable to anticancer drugs significantly increased in VigiBase â . DADRs are related equally to cytotoxic and "targeted" therapies, mainly tyrosine kinase inhibitors.
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Work interruption in a short-term hospital service: a risk factor for medication error In 2016, a guide concerning the work interruptions (WI) was published by the Haute Autorit e de Sant e (HAS) as a tool for securing the medication circuit. Theses work interruptions have in recent years become a recurring habit for the health professionals and could be a contributing factor to iatrogenic risk. The objective of this observational quantitative prospective study was to assess the nurses' WI in a multi-purpose internal medicine unit in a teaching hospital; more so during critical task such as drug distribution (morning and evening shift) and pill organiser preparation (noon shift). Material and methods: Nurses were studied in September 2017 in a multi-purpose internal medicine unit. The observer followed the health professional for 2 h with an evaluation grid and collected the WI's characteristics: circumstances, concerned professional, reason, severity and length of each work interruption. Results: 244 WIs were accounted for during 17 observation periods (amounting to 34 h) with 7.2 interruptions per hour on average (ranging from 5.2 to 13). Most of the WIs were observed during pill organiser preparation (13 interruptions per hour), then during drugs distribution (6.4 per hour). The main source was physical interruption (84%) for complementary information request (42%), of non-emergency seriousness (70%), mainly of short duration (less than 1 min for 76% of cases) and mostly originating from a member of staff. In 24% of cases the WI originated from caregivers, and in 20% from another nurse. Only one third of cases needed quick response. Discussion/Conclusion: Nurses' WIs are common, notably during pill organiser preparation and drug distribution. A large amount of work interruption cannot be justified by an emergency situation. This study could lead to the development of correctives measures disseminated to the healthcare team. [1] . BP is an acquired autoimmune subepidermal blistering disease, which is preferentially observed in elderly patients. Its treatment can be tricky because of age, comorbidities and associated drugs. Material and methods: We report a case of necrotizing fasciitis (NF) induced by clobetasol and review literature. Results: A 79-year-old patient with medical history of severe psoriasis, diabetes, myocardial infarction, auricular fibrillation, hypertension and chronic renal failure, presented BP treated with topical corticosteroids: betamethasone and then clobetasol 30 g/day. 22 days after, he was hospitalized because of a septic shock with NF of the left upper limb requiring antibiotherapy (Group A streptococcus found) and emergency surgical load. The patient died the day after. In literature, we found 8 cases of NF in patients presenting BP treated with topical clobetasol [2] [3] [4] [5] . Patients were 52-86 years old and had all comorbidities. To note, topical clobetasol was used alone in only 2 cases [6] . In other cases, patients received associated immunosuppressants or systemic corticosteroids after clobetasol. 6 of the 8 patients died. In French pharmacovigilance database, one case of NF with clobetasol in a patient with infected psoriasis is described. Discussion/Conclusion: NF is a rare soft tissue infection with high mortality rate. Corticosteroids, even used topically, have immunosuppressive properties. Use of concomitant immunosuppressants, damaged skin, prolonged use and patients comorbidities can favour infectious complications such as NF. More studies are needed to better characterize and minimize the risk of NF under topical corticosteroids. References 
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Implication of the blood-brain barrier in the physiopathology of hepatic encephalopathy in cirrhosis S Mouri, N Weiss, H El Mourabit, C Bouzbib, A Schaefer, C Housset, D Thabut Hôpital Piti e-Salpêtri ere -Paris (France) Introduction: Hepatic encephalopathy (HE) is a complication of cirrhosis which independently influences prognosis. Pathophysiology of HE is still debated; hyperammonemia in conjunction with inflammation could play a central role. Improvements in cerebral imaging suggest also a vasogenic cerebral edema, suggesting alterations in blood-brain barrier (BBB) permeability. The aim of this work was to study the BBB permeability in rat HE models. Material and methods: The first model of cirrhosis used was Bile Duct Ligation (BDL). Three groups of operated rats were considered: BDL, BDL + hyperammonic diet ("BDL-NH3") and Sham. We added to each of these groups sodium benzoate (BNa; to activate the non-urea cycle pathway for ammonia removal) or rifaximin (RFX; antibiotic to suppress intestinal flora). HE was assessed using neurocompartmental testing (Open-field test). BBB permeability was assessed by IV injection of a fluorochrome (10 kDa). Fluorescence was estimated by fluorimetry after hemisphere squeezing. To challenge the role of inflammation, we compared BDL to carbon tetrachloride (CCL4)-induced cirrhosis (compared to control rats given mineral oil). The CCL4 rats were given intra-gastric CCL4 twice a week during 8 weeks.
Results: Ammonemia was significantly higher in the BDL-NH3 than in BDL rats, and higher in the BDL than in SHAM rats (P < 0.0001). Mean total distance traveled in 6 min was shorter in BDL-NH3 and BDL rats than in SHAM assessing that these animals displayed HE. Intra-cerebral fluorescence was significantly higher in the group BDL-NH3 than in BDL, and higher in BDL than in SHAM (P = 0.029) suggesting a passage of fluorochrome through the BBB. Supplementation in BNa decreased hyperammonemia in the BDL and BDL-NH3 rats (P = 0.032). Interestingly, BNa and RFX decreased intra-cerebral fluorescence in BDL and BDL-NH3 (P = 0.035 and P = 0.103, respectively). It suggests that hyperammonia have a central role in the pathophysiology of HE and that treatment by BNa or RFX could prevent alteration of BBB permeability in HE. When we challenged the BBB in CCL4 rats, we did not observe HE nor differences between intra-cerebral quantity of fluorescence (P = 0.15). These preliminary results suggest that HE could not appear without several factors, among them inflammation. Discussion/Conclusion: Our results in HE animal models suggest an increased BBB permeability by a mechanism dependant on hyperammonemia. Furthermore, pathophysiology of HE depends on several factors, and among them, inflammation could act synergistically. d M edecin g en eraliste -Pornichet (France) Introduction: Cyamemazine is a typical antipsychotic drug of the phenothiazine class. This drug is frequently prescribed in France in the treatment of psychosis and anxiety. Cyamemazine has a good safety profile. Cyamemazine-induced peripheral edema is not described in the summary of product characteristics (SPCs). Material and methods: We report a case of peripheral edema after the initiation of cyamemazine. Results: A 36-year-old woman with a medical history of psychosis was treated with lithium, diazepam, and zopiclone. Despite this treatment, anxiety persisted and cyamemazine was introduced in August 2017. A month and a half later, the patient developed edema of the lower limbs. Cardiac, renal and hepatic explorations were considered normal and clinicians suspected drug-induced edema. Cyamemazine, the last drug introduced was stopped and edema resolved within 3 days. Cyamemazine was switched to levomepromazine without recurrence of edema. Discussion/Conclusion: Peripheral edema is a known adverse drug reaction of some antipsychotic drugs, such as atypical antipsychotics and butyrophenone derivatives, but to our knowledge, this is the first publication which reports a cyamemazine-induced peripheral edema. We found in the French Pharmacovigilance Database 62 cases of peripheral edema where cyamemazine was suspected: in 16 cases, the final diagnosis was cyamemazine-induced edema, with a favorable outcome after the decrease or discontinuation of cyamemazine. According to the literature, the time to onset of edema after the initiation of antipsychotic varies from a few days to several months, and resolution is usually seen with the decrease or suspected-drug discontinuation. The etiology of peripheral edema induced by antipsychotics is still unknown but several mechanisms are suspected: i) peripheral vasodilatation mediated by inhibition of alpha 1-adrenergic receptors or inhibition of muscarinic (M1), histamine (H1) and serotonin (5HT2) receptors; ii) impaired regulation of fluids and electrolytes via dopaminergic blockade and iii) an immunoallergic reaction but this mechanism seems to be less plausible for us. Cyamemazine has anti-dopaminergic activity as well as antihistaminic, adrenolytic and anticholinergic properties and an affinity for 5HT2 serotonergic receptors. Physicians should be aware of the possible occurrence of peripheral edema induced by cyamemazine and this effect must be added in the SPCs.
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Adverse drug reactions of statins in a paediatric population: a descriptive analysis of individual case safety reports from VigiBase 
Material and methods:
We extracted reports in the paediatric population (<18 years) associated to statins (C10AA ATC class) as "suspected" drug until July 18, 2017. Reports involving infants (1-27 months), "anomaly congenital" for seriousness and "Congenital disorders" for ADRs were excluded. Characteristics of children (age groups, gender), type of ADRs (System Organ Class (SOC) and Preferred Term (PT) according to MedDRA classification), and ADRs seriousness were described. Results: A total of 311 reports was identified for 8 statins corresponding to 712 ADRs [atorvastatin (110 reports, 35.4%), simvastatin (80, 25.7%), lovastatin (47, 15.1%), pravastatin (36, 11.6%), rosuvastatin (34, 10.9%), fluvastatin (6, 1.9%), cerivastatin (4, 1.3%), pitavastatin (1, 0.3%); one report may have several statins]. Age mean was 11.5 years AE 5.0 with 182 (58.5%) adolescents (12-17 years) and 129 (41.5%) children (2-11 years). Girls accounted for 54.3% (169) of reports. Overall, 42.8% (133) of reports were "serious". The most frequently reported SOC classes were: "Musculoskeletal and connective tissue disorders" [76 (24.4%) reports including 36 (11.6%) "myalgia" and 11 (3.5%) "rhabdomyolysis"]; "General disorders and administration site conditions" [67 (21.5%) reports with 10 (3.2%) "asthenia", 7 (2.3%) "fatigue" and 6 (1.9%) "pain"] and "Injury, poisoning and procedural complications" [67 (21.5%) reports with 9 (2.9%) "off label use", 9 (2.9%) "accidental exposure to product by child", 9 (2.9%) "intentional overdose", 8 (2.6%) "accidental exposure to product" and 8 (2.6%) "intentional product misuse"]. Discussion/Conclusion: As far as we know, this study is the first one assessing statins safety in "real-life" paediatric populations. As expected, statin-related ADRs mainly concern musculoskeletal and general disorders. More interesting, a significant number of accidental exposure and intentional misuse was observed in this population. Trihexyphenidyl is an anticholinergic drug misused to procure hallucination, sedation, anxiolysis [1] . The aim of this cohort was to show and to describe, within a public health risk management policy, the risks of a longstanding but relatively unknown addiction: trihexyphenidyl addiction. Material and methods: On R eunion island, a cohort with systematic data collection has been set up by addictologists working in the CSAPA (Centres for addiction prevention and treatment), in the University Hospital, and in general practices who have active lists of patients misusing trihexyphenidyl. Data collection included socio-economic data and clinical data concerning addiction. Results: This cohort included 69 patients during November 2016. The average age of the patients was 36 years old, 97% were men, 93% had living accommodation but only 32% were employed. In this cohort drug administration was exclusively oral. The most common reasons for use were anxiolytic (46%), stimulation (26%) and sedation (10%), the main effects described were dyskinesia and behavioural disorders. Over half (61%) of the patients reported a co-addiction, mainly to benzodiazepines, cannabis, tobacco, alcohol and to buprenorphine. Discussion/Conclusion: There are very few cohorts describing trihexyphenidyl addiction [2, 3] . This cohort describing the clinical characteristics of 69 patients is the largest cohort studied for trihexyphenidyl addiction to our knowledge. Patients from the CSAPA were the youngest and most recently addicted, whereas general practice patients had been addicted for longer and were more socially integrated. This clinical description of trihexyphenidyl addiction therefore enables us to identify the patients who are the most at risk, in order to set up an adapted care protocol. References 
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Comparison between voriconazole trough concentration in children and adults I Mtar, M Ben Sassi, E Gaies, R Charfi, I Salouage, I Fazaa, N Jebabli, H El Jebari, A Klouz, R Daghfous, S Trabelsi Centre National de Pharmacovigilance -Tunis (Tunisia) Introduction: Voriconazole is an antifungal drug used in treatment of invasive fungal infections. It is a synthetic triazole with a large spectrum of activity. Its mechanism is to attack the fungal cell membrane. Its pharmacokinetic is characterised by very important inter-and intrapatient variability. The aim of our study is to compare children's voriconazole concentration to adult's concentration. Material and methods: We performed a retrospective study over a period of 5 years (January 2013 to December 2017) in the Department of clinical pharmacology. Samples were analyzed by high performance liquid chromatography. We considered the therapeutic range for the trough serum concentrations (C0) as 1.5-5 lg/mL. Results: We collected 1,032 samples from 332 patients (261 adults and 61 children) taking voriconazole for especially pulmonary aspergillosis. Median age was 32.85 years. Sex ratio (M/W) was 1.54. Average weight was 57.64 kg. Characteristics of our 2 populations were represented in Table 1 . Average dose was 8.17 mg/kg/day. Mean C0 was 2.95 lg/mL. Repartition of dose and concentration was noted in Table 2 . Universit e Clermont Auvergne, CHU Clermont-Ferrand, EA7280, CIRCEA, Service de Psychiatrie-addictologie, F-63001 -Clermont-Ferrand (France) Introduction: Some addictovigilance studies describe off-label use of morphine sulfate in non-chronic pain opioid-dependent patients for recreational purposes or as an alternative to conventional opioid substitution therapy (OST) [1] [2] [3] . The aim of this study is to provide comprehensive data on overdose and doctor shopping behaviour associated with this off-label use. Material and methods: Data were extracted from the comprehensive health insurance database (SNIIRAM) covering the entire French population. A retrospective cohort of non-chronic pain opioid-dependent patients, aged 15 and over, who benefited from a continuous morphine sulfate sequence of at least 3 months (interval ≤35 days between 2 dispensations) from April 1, 2012 and December 31, 2014 was extracted. Incidence of overdose and doctor shopping behaviour were compared by Cox regression method to those treated by OST: buprenorphine or methadone. Results: 1,075 non-chronic pain opioid-dependent patients were included (men: 76.6%, median age: 33 years). Overdose incidence was significantly higher in morphine sulfate cohort than OST patients, with Hazard Ratio (HR) of 3.6 (P < 0.01) versus buprenorphine and 1.9 (P = 0.03) versus methadone. Doctor shopping behaviour incidence was also significantly increased in morphine group compared to OST. HR in morphine sulfate cohort was 3.0 (P < 0.01) versus buprenorphine and 68.3 (P < 0.01) versus methadone. Discussion/Conclusion: This is the first study assessing risks associated with off-label morphine sulfate use at national level. The high incidence of overdose questions the relevance of morphine sulfate prescriptions as a secure OST. They suggest that these complex patients should be referred to addiction centres where they will be able to benefit from regular follow-up and dispensations rather than primary care. They also encourage the strengthening of risk-reduction measures, particularly the distribution of self-administered overdose rescue kits, containing naloxone, morphine antidote by its antagonistic activity. References Centre R egional de PharmacovigilanceAngers (France) Introduction: Direct Oral Anticoagulants (DOAs), dabigatran, apixaban, and rivaroxaban, are well known to induce hemorrhagic events. Until now, disorders of the central nervous system, apart from intracerebral hemorrhage, headache and vertigo, are not part of the adverse effects profile of this class of oral anticoagulants. The aim of this study was to describe hallucination reports with DOA in the French Pharmacovigilance Database (FPVD). Material and methods: We included all cases of hallucination recorded in the FPVD from 2008 to December 2017 in which a DOA was suspected. The cases were selected using the MedDRA high-level term "Perception disturbance". Results: During the study period, 9 ADR reports of hallucination where DOA was the only drug suspected were identified in the FPVD. Of these cases, 3 involved dabigatran and 6 involved rivaroxaban (there was no case with apixaban). Sex ratio was 1.25 and median age (IQ1-IQ3) was 79 (35-88) years. Five patients were treated for cardiac rhythm disease, 2 for thromboembolism prevention, 1 for hip replacement and 1 for unknown reason. Hallucinations were only visual in 3 cases, only auditory in 1 case, both visual and auditory in 1 case and unspecified in 4 cases. Median time from DOAs introduction to hallucination onset was 10 (1-90) days. DOA was withdrawn in 8 cases. Improvement was observed in 7 cases and in the remaining case the course was not described. For one patient, hallucinations did not reappear despite dabigatran reintroduction. Causality was rated as doubtful for 7 cases, plausible for one case and likely for one case. Another concomitant cause of visual hallucination was suspected in one case (Charles Bonnet syndrome). No patient had a previous history of hallucination. Discussion/Conclusion: Hallucinations induced by DOAs are not mentioned in the summary of product characteristic of these drugs and have never been described in literature. Despite its lipophilic nature (logP = 2.18), the passage of rivaroxaban across the blood-brain barrier would be low, estimated at less than 7% according to animal studies. This could be partly explained by the fact that rivaroxaban is a substrate of the P-glycoprotein, an ATP-dependent protein which pumps many foreign substances out of cell, limiting tissular (notably cerebral) diffusion. Although the mechanism involved in these DOAs-induced hallucinations is not known, their occurrence in a patient treated with rivaroxaban is probably multifactorial (gender, genetic polymorphism, drug interaction) but should be kept in mind. [1] . Its active metabolite, norQtp, has a strong affinity for the noradrenaline transporter. Material and methods: A 66-year-old woman, without medical history, is hospitalized in psychiatric department in the consequences of her attempted suicide by drug overdose. Venlafaxine is established because of the severity of the depressive episode. A few days later, she presents signs of obsessive disorders which impose to stop the antidepressant and direct to diagnosis of bipolar disorder of the humor. The practitioners choose then to establish a treatment by Qtp to an antidepressive dose as recommended in the bipolar depression [2] . She receives a first dose of 50 mg sustained release (SR) in the morning. The day is marked by a temporospatial disorientation, attention deficit disorder and cognitive difficulties. The next day a confusion state appears to a 100 mg SR posology. Are added to the first signs a non-recognition of the structure where she is hospitalized as well as difficulties to recognize her daughter. The third day the patient shows an increase of the confusion state to a 300 mg SR posology. The neurological examination, which was normal the previous days, reports a positive Romberg's sign and a nystagmus, signs of a vestibular syndrome. There is no extrapyramidal syndrome (EP). The fourth day, it is decided to realize a cerebral scanner and an electroencephalogram, which return both normal. Owing to the strong suspicion that the neurological manifestations of the patient are induced by the introduction of Qtp, this one is stopped. A progressive improvement in 3 days until return to the previous cognitive state without sequelae is observed. Results: The onset of a confusional state is not mentioned in the summary of products characteristics of Qtp. A request in the French Pharmacovigilance Database reports four cases. Two cases seem similar in our case. Discussion/Conclusion: In conclusion, we believe that it is essential to notify this adverse effect to the clinicians to avoid a therapeutic one-upmanship when the cutting off of the treatment is already sufficient to improve the health of the patient. References Results: 14 patients accepted to participate, 7 on tacrolimus, 7 on cyclosporine, with a similar estimated glomerular filtration rate (54 AE 13 and 51 AE 17 mL/ min respectively). Colchicine AUC0-48h was 56% higher among patients treated with cyclosporine compared to those treated with tacrolimus (57.5 AE 22.5 vs 36.9 AE 17.3 h.ng/ml respectively, P = 0.03 one sided test). Cmax and T1/2 did not significantly differ (6.5 AE 1.5 vs 4.9 AE 2.2 ng/ml and 16.6 AE 6.0 vs 18.7 AE 9.7 h respectively). Discussion/Conclusion: Conclusions: higher plasma concentrations of colchicine might be expected in renal allograft recipients treated with cyclosporine compared to tacrolimus. This result might be taken into account for choosing between both immunosuppressant drugs in patients suffering from gout. Clinical trial: NCT01160276. Introduction: E-cigarette (EC) is an electronic nicotine delivery system which offers an alternative for smoking withdrawal. Its use is increasingly widespread: number of users has significantly grown in the last few years. In parallel, democratization of this tool leads to the emergence of different misuses. Material and methods: In January 2018, we performed a literature review. We sought more information on users' forum and the internet. Results: Cannabis and derivatives are the most often misused substances with the EC: young people use cannabis oil or resin containing high concentration of d9-THC (KENNE et al, 2017, MEGHAN et al, 2015) . In France, we observe the emergence of a non-illegal alternative: cannabidiol (CBD). d9-THC and CBD show different affinities for CB1 and CB2 receptors. CBD (contrary of D9-THC) is an anxiolytic product which may induce depressive-like behaviors (LE BOISSELIER et al, 2017) . This can explain the use of CBD in e-liquids sold on internet, in EC stores or tobacco shops. Synthetic cannabinoids are also used in EC with heavy health injuries than marijuana (CASTELLANOS et al 2016).On users' forum, we can easily find various processes to prepare extemporaneous e-liquids mixtures including cannabis as well as Cocaine, crack and DMT. Discussion/Conclusion: Misuse of EC becomes very popular (Varlet et al 2016). Especially, since new models ("box mod") are available, the system allows control of heating temperature. Users can choose ideal temperature to vape the misused substance. Furthermore, PG and PEG 400 are often mixed with cannabis oil leading to harmful formaldehyde derivatives exposures at 230°C (Troutt et al, 2017). EC with a limitation in temperature regulation should restrict the consumption of those substances and aldehydes exposure. Furthermore, pulmonary route of some drugs administration is at higher risk of developing addiction (Hueza et al, 2016) so the inhalation of psychoactive substances contained in EC aerosols may become a challenge for addictovigilance centres and health authorities. ) is the latest marketed COX-2 selective inhibitor. In EU, it was first approved in UK in 2002; its marketing authorization was delayed in France until March 10th 2010. Etoricoxib is indicated in the symptomatic relief of osteoarthritis (30-60 mg once daily). An EU Risk Management Plan was submitted with a French extension consisting in a strengthened pharmacovigilance with a specific follow-up. Material and methods: We reviewed data provided by both French spontaneous reporting system via the network of National Pharmacovigilance centres and by the pharmaceutical company, from March 10th, 2010 to August 31st, 2016. We analysed all suspected adverse drug reactions (ADRs) concerning etoricoxib and notified either in the French pharmacovigilance or in the company's safety database. Results: We retrieved 352 ADRs concerning 310 patients, mainly female (69%). The mean age was 64 AE 14 years. One hundred and nineteen cases (34%) were serious. Two deaths were reported. Complete recovery was obtained in 87%. When available, indication was represented essentially by osteoarthritis (54%), all other indications were off-label. Dosages of 30 and 60 mg were used in 49% and 48%, respectively. Dosage was immediately maximal for 60 patients (19%). Despite major contraindications, 19 patients (6%) received etoricoxib. The most frequent system-organ classes involved were: cardiac disorders (14.8%), gastrointestinal disorders (13.9%), skin and subcutaneous tissue disorders (11.6%), vascular disorders (9.7%, including >65% vascular hypertensive disorders), nervous system disorders (9.1%), and general disorders (8.8%, including >60% of fluid retention or oedema peripheral). The analysis focused on the identified risks showed 20 thrombotic cardiovascular events (including 7 myocardial infarctions, 4 acute coronary syndromes, 4 strokes, 5 peripheral venous thrombosis AE pulmonary embolism), 83 renovascular events (27 edema, 32 hypertensive disorders, 9 congestive heart failures, 12 acute renal failures, 3 nephrotic syndromes), 11 gastrointestinal bleedings, 4 non-complicated ulcers, 2 perforated ulcers, and 59 hypersensitivity-related events and skin reactions (1 DRESS and 1 Lyell syndrome). Discussion/Conclusion: Despite the consistent adverse-event profile with the known effects of etoricoxib and other NSAIDs, an important misuse was observed, involving indication, warnings and precautions for use regarding cardiovascular risk, and contraindications.
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Evaluation of pre-analytical nonconformities in the laboratory of clinical pharmacology F Ben Salem, E Gaies, I Salouage, R Charfi, N Jebabli, M Ben Sassi, H El Jebari, A Klouz, R Daghfous, S Trabelsi Centre National de pharmacovigilance -Tunis (Tunisia) Introduction: Pre-analytical phase is an important step that conditions the quality of laboratory tests and the results obtained after analysis. Most errors occur during this phase according to the literature (between 60 and 85%). They could produce in test request, sampling, identification of patient or conservation. Our study aims to identify elements causing nonconformities in the monitoring of amikacin during the pre-analytical phase. Material and methods: This descriptive study was conducted between January 2009 and December 2016, and concerned all samples for amikacin monitoring. We have sought in all information sheets to collect nonconformities associated to patient's identity (name, gender, age, weight and service), diagnostic, drug's information (brand name, dose, route of administration) and blood sampling procedures. Results: We had a total of 1,985 blood samples for monitoring. We found 1,905 elements of nonconformities. They were related to the absence of information about patient's identity with the rate of 37% (name 0%, gender 0%, age 9%, weight 20%, and service 8%). Therapeutic indication was not mentioned in 35%. Nonconformities concerning drug's information were with a frequency of 21% (brand name 0%, dose 6%, route administration 15%). Blood sampling procedures were not respected in 7% (127 samples including 40 samples to monitor trough concentration and 60 samples to monitor peak concentration whose concentration were not valid, 20 samples whose time sampling were not mentioned and 7 samples were hemolyzed). Discussion/Conclusion: The control of the quality of laboratory tests involves the control of pre-analytical phase and factors causing nonconformities. Several actions should be undertaken to avoid nonconformities in order to improve the quality of care. Concerning the therapeutic drug monitoring, we must highlight the importance of sampling procedures which differ according to the molecule to be monitored. The no respect of these procedures can lead to a wrong dose adaptation. For thus, recommendations would be useful in order to harmonize the practices of medical and paramedical staff. d Centre r egional de Pharmacovigilance, CHU -Bordeaux (France) Introduction: Imatinib is a selective tyrosine kinase inhibitor and is used after stem cells transplantation (SCT) or chemotherapy in children for Acute Lymphoblastic Leukaemia (ALL) when Bcr-Abl transcript is still detectable. Potential side-effects regarding growth failure and bone metabolism have been described in chronic myelogenous leukaemia (CML) patients, but consequence of its exposition during childhood is little known for ALL paediatric patients. Material and methods: We reported the cases of two children treated for ALL with 300 mg/m 2 imatinib. The first one is a boy who started imatinib (EsPhALL protocol) at age of 2.4 years and got a SCT after 6 months of treatment. He stopped treatment when he was eleven. During treatment, imatinib plasma concentration was monitored and statural growth was tightly surveyed between 5 and 13.5 years. The second case is a girl who was diagnosed from ALL at twelve and started imatinib 6 months later. In the 2 cases, they received at least corticosteroids, vincristine, methotrexate for induction or continuation phase treatment. Both children were investigated for growth failure. Height was expressed as standard deviation score. Results: Under imatinib treatment, height of the boy slightly decreased from the À2DS to under À3DS curve between 5 and 11 years. When the treatment was stopped because of growth failure, there was a clear inflection in growth velocity and he is now at À2DS. At the opposite, growth velocity of the girl showed a break when she started imatinib. The glucagon/betaxolol test did not exhibit deficit of GH but IGF1 concentrations were below the range in the two cases. Observed imatinib concentrations were usual and not high. Discussion/Conclusion: As for CML paediatrics, ALL patients treated with imatinib are also at risk of growth failure. This side-effect could not be formally attributed to imatinib because of the variety of applied drugs but it seemed to involve IGF1 pathway that is consistent with previous publication on imatinib in CML. Nevertheless, there is still a hope as growth velocity was not definitely blocked and could increase with the stop of imatinib. c Centre r egional de pharmacovigilance de LyonHospices Civils de Lyon -Lyon (France) Introduction: Metoclopramide is an antiemetic agent with a neuroleptic structure and can cause neurologic disorders. Following safety issues in children, its indication in children was restricted to antimitotic-induced emesis by the French medicine agency and pediatric formulations were withdrawn from the market. However, we have witnessed ongoing off-label use of metoclopramide as well as adverse drug reactions (ADR) occurring in this specific population. The aim of this study is to determine the characteristics of ADR occurring in children after the indication restriction. Material and methods: All ADR involving metoclopramide in children (0-18 years old) and reported to the French Network of Pharmacovigilance Centres between February 2012 and January 2017 were selected. For each case, age, gender, type of ADR, seriousness of the ADR and indication of treatment were analyzed. A brief comparison of the number of ADR that occurred before and after the indication restriction was also performed. Results: A total of 67 reports involving metoclopramide in children less than 18 years old was recorded between February 2012 and January 2017 (F: 45, M: 22, mean age: 12). Serious ADR accounted for 49 cases including 28 patients who required an emergency consultation and 21 who required a hospitalization. A medication error was the cause of the ADR in 17 cases. The indication of treatment was unknown for 25 cases and metoclopramide was prescribed for other indications than antimitotic-induced emesis in 25 cases. These indications included emesis in a context of gastroenteritis (15 cases), food poisoning (4), virosis (3) or pregnancy (3). The most frequently reported ADR were nervous system disorders (58) including extrapyramidal disorders (48) (such as dystonia, dyskinesia, hypertonia) and visual disorders (4). Psychiatric disorders (4) such as confusional state or sleeping disorders and skin disorders (6) were also the main reported ADR. Compared to the analogous period before the restriction of indication (2007 to 2012), the number of ADR reports related to metoclopramide in children during the study period was almost diminished of half. Discussion/Conclusion: Despite risk minimization measures taken by the French medicine agency, metoclopramide is still used among in children in unapproved indications. The number of reports has significantly decreased but serious neurologic ADR still occurs in this population. A new information campaign targeting prescribers should be performed in order to limit off-label use of metoclopramide.
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Descriptive analysis of the methods of administration of injectable cytotoxic drugs in hospitals I Jebrane, I Rahmoune, H Filali, F Hakkou laboratoire de pharmacologie et toxicologie cliniques, CHU Ibn Rochd -Casablanca (Morocco) Introduction: Medication administration errors remain a burden for all health professionals and all disciplines. [1] The main purpose of our study is to analyze and evaluate the administration of injectable cytotoxic drugs prepared in hospitals. Material and methods: This is a prospective descriptive transversal study spread over 4 months (April-July 2015) in 120 patients, based on the analysis of the reconstitution and administration of anticancer drugs, performed at the level of 4 units of oncology of which 3 belong to the public sector (CHU Ibn Rochd of Casablanca) and one belonging to the private sector. Results: Cytotoxic drugs, prepared in hospital in a personal way, were administered to patients in a common room of the day hospital in 79.2% of cases or in the hospital unit in 21.8% of cases. The preparations were administered by a polyvalent nurse (94.2%) or by a doctor (5.8%). The control of hospital preparations before administration to patients was carried out in 8.33% of cases. As for the modalities of administration, 31.49% of the reconstituted injectable cytotoxic drugs were administered according to the recommended good administration practices. The different nonconformities noted are: uninsured photoprotection (49.2%), the duration of administration not respected (39%), the wrong route of administration (3.5%), the chronology (15%). and concomitant administration with other non-compatible drugs (17.3%). Discussion/Conclusion: The manipulation of cytotoxic drugs constitutes a real public health issue in terms of the quality of the drugs administered and the environmental and professional risks incurred by the manipulators. Indeed, the circuit of use of cytotoxic drugs in health facilities, ranging from prescription to administration, requires the establishment of rules of good practice regarding their handling. Hôpital Piti e-Salpêtri ereClichy (France) Introduction: There is no gold-standard for the diagnosis of hepatic encephalopathy (HE) and especially in case of minimal HE (MHE) where the value of paraclinical examinations is debated. MR-spectroscopy has been proposed as a valuable diagnostic tool for the diagnosis of HE by showing increased glutamate/glutamine peak and decreased myoinositol and choline peaks. However, access to MRI is difficult and no real life experience has been reported. We studied the interest of a multimodal approach combining clinical, neuropsychological, biological and MR-spectroscopy in the diagnosis of MHE. Material and methods: We conducted a retrospective study in a single tertiary university hospital in Paris, France, where all out-patients referred to a specific hepato-neurology consultation dedicated to the diagnostic of MHE underwent a clinical examination, psychometric tests (Critical Flicker Frequency-CFF, Psychometric Hepatic Encephalopathy Score-PHES), ammonemia and cerebral MRI with spectroscopy (MRS). Patients were classified as having MHE or not by consensus between two experts. Results: We included 56 patients between February 2013 and April 2016. Median age was 57 years [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] . Forty-four (79%) had a cirrhosis (etiology: alcohol 35%, NASH 9%, viral 23%, alcoholic and non-alcoholic steatohepatitis 26%, other 7%) with a median MELD of 10 [7-12]. Twelve (21%) had non-cirrhotic portal hypertension (Budd-Chiari 33%, extra-hepatic portal hypertension 33%, idiopathic portal hypertension 16%, portal agenesia 9% and nodular regenerative hyperplasia 9%). According to the experts, 57% had an MHE, whereas 43% had not. Among the clinical informations, only the presence of a portosystemic shunt (TIPS or surgical) was associated with MHE. A venous ammonemia >50 lM, MRI T1 hyperintensity of the basal ganglia and an MRS HE profile suggestive of HE were all statistically associated with the diagnosis of MHE (P < 0.0001). The best diagnostic performance was achieved by combining MRS with either MRI T1 hyperintensity (AUC=0.93) or ammonemia (AUC=0.91). Discussion/Conclusion: A multimodal approach combining clinical data, ammonemia and cerebral MRI with MRS seems to have good accuracy for the diagnosis of MHE. Further prospective studies are mandatory.
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Observational study of the management of patients with chronic pain: OKAPI study Biostatistics Unit (DRCI), University HospitalClermont-Ferrand (France) Introduction: Chronic pain affects 25% of the general population and 7-10% suffer from neuropathic pain (NP). NP involves the N-methyl-D-aspartate (NMDA) receptor, and blocking this receptor with ketamine, could improve chronic pain. Ketamine is a non-competitive NMDA antagonist and has an action on the phencyclidine site. It modifies the frequency and duration of the opening of the channel, which modulates the intracellular calcium influx and limits the long-term potentiation and neuronal sensitization of the neurons concerned. Nowadays, ketamine is frequently used for the management of chronic pain (neuropathic pain, fibromyalgia) when refractory to other treatments. The main objective of this prospective, multi-center and observational study is to evaluate the safety, use, benefits and risks of repeated use of ketamine over a one-year period for patients suffering from chronic and persistent pain. Material and methods: This study (NCT03319238) is conducted in thirty pain clinics. The risks are evaluated by collecting the adverse effects; the benefits by pain assessment and emotional status using the Numerical Rating Scale (NRS) and questionnaires: Neuropathic Pain in 4 questions (DN4) and Hospital Anxiety and Depression scale (HADs). Patients are followed on one year period. Results: 585 patients (mean age 50.6 AE 11.4 years) with chronic pain have been included (76% women), 39% with NP (DN4: 5.4 AE 2.9), 46% with fibromyalgia, 8% with algoneurodystrophy and 4% with other types of pain. A number of patients are anxious (50%, evaluation on HAD anxiety score) and are depressed (37%, evaluation on HAD depression score). Patients are being followed for a few months. Discussion/Conclusion: This study will highlight the current practices of ketamine administration in chronic pain in pain clinics. Patient follow-up is still ongoing and will allow to evaluate the effects of ketamine on pain, depression and the benefit-risk balance. It will also identify the concomitant drug use and evaluate the impact of ketamine on quality of life. CHU de Grenoble, G eriatrie -Grenoble (France) Introduction: Adverse drug reactions (ADR) are a major health issue, especially in the elderly, due to frailty and polymorbidity requiring polypharmacy. The risk of ADR and ADR-related hospitalizations increases with age. One to 2 thirds of these ADR are predictable and preventable. The aim of this study was to identify characteristics of preventable and non-preventable ADR in the elderly. Material and methods: We performed a retrospective analysis of serious ADR that occurred in the elderly over 75 years and were spontaneously reported to the Grenoble pharmacovigilance center from 2005 to 2015. The preventability of each report of ADR was assessed by the French ADR preventability scale [1] . We compared preventable and not preventable ADR based on age, sex, number of suspected drugs, seriousness, type of ADR and drugs. Results: Overall, 966 notifications of serious ADR were analyzed. Patients were 82.1 AE 5.2 years old and 56.5% were women. Among these ADR, 27.7% (n = 268) were preventable and 319 errors occurred, mostly during prescription (68.7%) and drug dispensation (29.9%). Patients suffering from preventable ADR were significantly older than those with no preventable ADR (P = 0.008).Vascular disorders (ie. hemorrhages and hematomas), renal disorders (ie. acute kidney injury) and disorders of hemostasis were significantly more frequent in case of preventable ADR. Preventable ADR were significantly more related to antithrombotics, drugs acting on the renin-angiotensin system (RAS), analgesics, antigout and anti-inflammatory. A drug-drug interaction was much more frequent in preventable ADR (21.6%) than in not preventable ADR (1.9%). Discussion/Conclusion: This is a retrospective analysis, so our data were limited. Pharmacovigilance suffers from under reporting and so, lack of exhaustiveness. Some limits are inherent to the preventability scale. A quarter of ADR were preventable in the elderly, consistently with previous studies. Precautions have to focus on prescription and medical monitoring of antithrombotic agents and drugs acting on the RAS. Collaboration between pharmacovigilance, clinical pharmacist and practitioner could easily help to reduce occurrence of preventable ADR. Reference Results: Over this 6-year period, among a total of 28,698 and 229,481 spontaneous reports respectively registered in the Vietnamese and France databases, 136 (0.47%) and 576 (0.25%) were drug-induced SJS/TEN. The male/female ratio of SJS/TEN patients was significantly different between 2 countries (Vietnam=0.58, France=0.41, P = 0.001). SJS/TEN mainly occurred in adult patients (18-65 years) in both nations but Vietnamese SJS/TEN patients were younger than French ones, with a mean age of 42.48 (AE22.95) and 48.59 (AE25.38) respectively (P = 0.011). Concerning the "suspected" drugs, we mainly found cotrimoxazole (n = 69, 1.3%), lamotrigine (n = 59, 1.11%), allopurinol (56, 1.06%) in the French database and carbamazepine (n = 25, 18.38%), paracetamol (n = 20, 14.71%), allopurinol (n = 15, 11.03%) in the Vietnamese database. Antiepileptics (N03A) were the ATC class mainly reported in SJS/TEN in Vietnam (n = 33, 16.1%) and France (n = 132, 2.49%). Among beta-lactam antibiotics, the cephalosporins and carbapenems group (J01D) was the most reported in Vietnam (n = 24, 11.71%) and the penicillin group (J01C) was mostly reported in France (n = 82, 1.55%). Discussion/Conclusion: These data show some important differences for the characteristics of cases of drug-induced SJS/TEN between France and Vietnam. The "suspected" drugs seem similar in the 2 countries, except for antibiotics. Outside the diseases pattern, geographic location, lists of marketed drugs, the differences could be explained by the genetic variation (HLA-B), the knowledge and attitude of healthcare workers about ADR reporting and the overuse of antibiotics in Vietnam. Quetiapine is an atypical antipsychotic indicated in schizophrenia and bipolar disorders. A well-known hematological adverse effect is neutropenia and agranulocytosis. We are reporting the case of a patient who presented with two severe thrombocytopenia episodes, each immediately preceded by the use of quetiapine (Xeroquel â ). Results: Mrs M. is a 70-year-old patient, with a history of post transfusion hepatitis, auricular fibrillation, aortic and mitral valvuloplasties, maturity onset diabetes and serious chronic depression. One day, at 17h30, she was started on quetiapine LP 50 mg and the last platelet count was normal. The day after this first intake, her platelet count was 7 G/L (reference range: 150-450 G/L). Thrombocytopenia was associated with predominant purpura in the lower limbs. She was immediately hospitalized. Quetiapine was stopped and her other treatments were continued without any modification. A systemic corticotherapy was started. Two further platelet counts were obtained, 1 day and 3 days after discontinuing quetiapine, showing higher platelet levels at 20 G/L and 108 G/L respectively. A peripheral thrombocytopenia was diagnosed on the myelogram. That same day, quetiapine was reintroduced with a control platelet count on the following day, showing a significant decrease to 6 G/L, then 4 G/L. Quetiapine was again discontinued and intravenous immunoglobulins were started in addition to corticotherapy. One day after quetiapine discontinuation, the platelet count improved and the 5th day, the platelet count had increased to normal value (164 G/L). At the end of the hospitalization, the platelet count was 249 G/ L. Subsequently, quetiapine was reintroduced by mistake with a third thrombocytopenia episode resolving after discontinuation of quetiapine which was definitively stopped. Discussion/Conclusion: Quetiapine-induced thrombocytopenia is an uncommon adverse drug reaction. Few cases have been reported in the literature and none with such a fast onset delay as in our case report. The clinical presentation: very fast onset delay, severe drop in platelet count and rapid improvement after quetiapine discontinuation are typically representative of an immune thrombocytopenia mechanism. According to the chronological criteria and the two positive rechallenges, the causality assessment is probable and quetiapine is now contraindicated in this patient. Quetiapine induced thrombocytopenia can be serious, patients must be monitored with a complete blood cell count. Results: This case concerns a 60-year-old woman, admitted in psychiatric specialized center and treated by paliperidone injections once a month since June 2017. She presented on September 4th, 2017 an episode of diarrhea and vomiting without any neurological disorders. On the 6th, she collapsed and presented convulsive seizures with loss of consciousness. The emergency assistance found her with Glasgow score at 3, nonreactive pupil, blood pressure at 10/7, cardiac rhythm at 78, and hypothermia at 35°C. She was transferred to intensive care: blood tests showed hyponatremia (112 mM), hyperglycemia (10.2 mM) and low osmolarity (241.6 mM). The cerebral-CT revealed a major diffuse cerebral edema with bilateral cortical and frontal-parietal ischemia, cerebellar and bilaterally temporal engagement. The patient had no history of massive water ingestion, and toxicology screening was negative except for benzodiazepines. A medical examination during the night revealed a cerebral death state with abolition of all brain stem reflexes and no spontaneous ventilation. The patient died on September 7th, 2017. Discussion/Conclusion: Hyponatremia due to antipsychotic use is a potentially fatal complication; it could be related to an AE as to a symptom of underlying psychiatric disease. Most of the cases are related to a syndrome of inappropriate antidiuretic hormone (SIADH). Although the mechanism is unclear, some hypotheses could explain an increase of antidiuretic hormone (ADH) release: activity on dopaminergic receptors, baroreceptor reflex mechanisms or central serotoninergic receptors stimulation. The summary of product characteristics does not mention hyponatremia as an AE of paliperidone injections, but SIADH is described. We found in literature, other cases of delayed hyponatremia, as ours, appearing in patients treated by monthly doses of paliperidone. Several cases of hyponatremia related to paliperidone were registered in VigiBase â (WHO database) and only one other leading to death. Providers should be aware of this complication with paliperidone to monitor and prevent the first signs of hyponatremia.
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The drugs that mostly frequently induce gynecomastia: a case/non-case study of a pharmacovigilance database c Centre R egional de Pharmacovigilance -Grenoble (France); d Centre R egional de PharmacovigilanceToulouse (France) Introduction: Gynecomastia, although asymptomatic and non-serious, can have a negative impact on self-confidence and the body image. Drug-induced gynecomastias can account for up to 25% of all adult gynecomastias. At present, about forty molecules have been identified as being involved in the development of this pathology. The objective of the present study was to establish a comprehensive overview of drug-induced gynecomastia on the basis of spontaneously reported adverse drug reactions (ADRs) in the French national pharmacovigilance database (FPVD). Material and methods: We performed a case/non-case study of drug-induced gynecomastia. Cases corresponded to the reports of gynecomastia in men recorded in the FPVD between 1 January 2008 and 31 December 2015. The non cases corresponded to all other spontaneously reported ADRs (excluding gynecomastia) recorded in the FPVD during the same period. Data were expressed as the reporting odds ratio (ROR) and the 95% confidence interval. Results: Of the 255,354 ADRs recorded in the FPVD during the study period, 107,127 ADRs were analyzed, after excluding women in particular, including 106,800 non cases and 327 (0.31%) cases of gynecomastia. The average age of patients experienced gynecomastia was 58.1 AE 19 years old with extremes ranging from 7 to 90 years old and a median of 61 years old. RORs were statistically significant for 54 international non-proprietary names, mentioned 429 times in cases of gynecomastia. Only one drug was involved in 59% of cases. The most frequently implicated drug classes were anti-retroviral drugs (23.5%), diuretics (15.5%), proton pump inhibitors (11.9%), HMG-CoA reductase inhibitors (9.1%), neuroleptics and related (6.5%), calcium channel blockers (6.3%) and 5-alpha reductase inhibitors (4%). Discussion/Conclusion: A comprehensive study of a national pharmacovigilance database enabled us to identify the drug classes that most frequently induced gynecomastia, even if this kind of study have some bias linked with spontaneous reporting, such as under-reporting or selective reporting. For most drugs involved in gynecomastia, a physiopathological mechanism is known or suspected, leading to hormonal imbalance in favor of estrogens. Otherwise, we noticed there was a lack of harmonization in the summary of product characteristics between original and generic medicines. Even though most of the identified drugs were already known to induce gynecomastia, the present work should raise physicians' awareness of the drugs responsible for developing this pathology. . This software is used to record, code and transmit serious adverse events to the competent authorities in the required format and regulatory delays. It also permits the generation of line-listing and summary tabulation in order to elaborate development safety update report. The choice has been to change of software company (EveReport â -EveDrug). The aim of the study is to describe the methodology applied for the data migration and the different problems encountered by the 6 hospitals. Material and methods: 4 databases per sponsor were concerned by the migration: medicinal products, medical device, experimental procedures and biovigilance adverse events databases. The first stage consisted of exporting the data toward test databases in order to compare them between the 2 softwares. The data compared proceeded from adverse events issued from a random sample, suspected unexpected adverse reactions and software configuration. After comparison, non-compliances were transmitted to EveDrug in order to reach consistency between the 2 databases. Then the new software company imported data during a week-end so that the sponsor could use the new software on Monday. Non compliances after transition to production databases were also recorded and classified as critical or not for the activity of vigilance. Results: 15,153 adverse events have been concerned by the migration which have been realised successively during 4 week-end for the 6 sponsors. It took approximately 1 month of work for the sponsors, including 38 questions and answers to the editor, comparison of data, planning of the logistic of the migration, amelioration requests. Major problems identified were: recuperation incomplete of the data (attached documents), clinical trial design not exactly preserved (randomization arms), login and password unpreserved, imperfect printings of report (CIOMS), incorrect import function from XEVMPD thesaurus, loss of specific functionalities (default spreadsheet, locked cases, changeable receipt date, check for duplicate, language of MedDRA dictionary). Discussion/Conclusion: The migration constitutes a critical stage because of risk of information loss and unusable functionalities. Sponsors have legal responsibilities to ensure security of patients involved in clinical trials and the migration of safety data had to be successful. Cocaine is an illegal alkaloid stimulant mostly used as a recreational drug. It is commonly snorted, inhaled or used as a solution injected into a vein. Recently an increase in cocaine consumption was observed in France and then serious complications and mortality. Toxicity on central nervous system, heart, is extensively documented. Material and methods: We report here a rare case of acute hepatitis in a regular user of inhaled cocaine. Results: A 31-year-old man, regular user of inhaled cocaine and former heroin snorted addict in methadone maintenance, is hospitalized for radiographic pulmonary infiltrates with history of dyspnea and diffuse pain. Two days later, afebrile abdominal pain increases concomitant with asthenia. The blood test reveals cytolysis and severe hepatocellular insufficiency (AST: 39 N, ALT: 40.6 N, Alk P: 1.3N, GGT: 1.4N, bilirubin: N, protime: 42%, factor V: 30%, CPK: N). Liver histology shows centrilobular without macrovesicular steatosis, inflammatory infiltrates or fibrosis. Serologies do not show viral infection, legionella and pneumococcal urinary antigen tests are negative as well as autoantibodies. Additional explorations also find a cardiac decompensation revealing dilated cardiomyopathy, multiple arterial and venous thromboses. The patient's condition deteriorates with refractory cardiogenic shock and he died. Discussion/Conclusion: In the literature, cocaine-induced acute hepatitis are rare and usually occur hours or few days after an overdose [1] . Initially serum aminotransferase are elevated with minimal increase in alkaline phosphatase. The prothrombin time becomes rapidly abnormal and the serum bilirubin begins to increase 2-3 days later. Immunoallergic features and autoantibodies are usually absent. Liver histology shows centrilobular necrosis and fatty changes [2] . Cardiomyopathy is reported with cocaine. Cocaine also promotes endothelial damage and platelet aggregation [3] . Clinicians should keep in mind that cocaine can induce noninfectious acute hepatitis which can lead to death. References Previous studies highlighted a significant association between fibrates and venous thromboembolism (VTE) events in diabetic patients. Literature is divergent regarding the general population. Material and methods: We had two approaches to assess the link between fibrates and VTE events: 1) a case control-study using the Caen University Hospital medical information database (programme de m edicalisation des syst emes d'information) between January 2008 and December 2012. Cases were defined as patients presenting a dyslipidemia and hospitalized for VTE without evident provoking factor. Cases were matched, in an up to 4:1 ratio, to controls defined as patients presenting dyslipidemia and hospitalized for any other reason (except for active malignancy). A multivariate conditional logistic regression analysis was performed; 2) a comparative case/non-case study in the World Health Organization pharmacovigilance database VigiBase â , where notifications for VTE with fibrate intakes were selected as cases. A disproportionality analysis was performed.
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Results: In the case-control study: 163 cases and 514 controls were recruited. Fibrates were significantly associated with a higher risk of VTE events, in both univariate (odd ratio (OR) 3.50, 95% Confidence Interval (CI) 2.07-5.90, P < 0.0001) and multivariate analysis (OR 3.67, CI 1.82-7.37, P = 0.0003).In the case/non-case study: 946 cases of VTE included fibrate intakes. The reporting odd ratio for VTE was significantly higher for fibrates (1.14, CI 1.07-1.22). Discussion/Conclusion: Fibrates are strongly associated with a higher incidence of VTE events in our study. This combined study with both retrospective and real life data provides relevant information where former classic researches were discordant. Terpenes derivatives are components of several drugs most of which are available over the counter. However, their neurological toxicity is probably underestimated. Material and methods: We report a case of seizure occurred after terpenes derivatives application in a context of self-medication in a patient treated with an intravenous antibiotherapy for a bronchopulmonary infection. Results: A 24-year-old woman has a history of cystic fibrosis with chronic treatment unchanged recently. On October 19th, 2017, meropenem (6 g/day) and tobramycin (400 mg/day) are introduced for a bronchopulmonary infection. The next day, she is hospitalized after a generalized tonic-clonic seizure with loss of consciousness (about 10 min), hypersialorrhea, tongue bit, urine loss and without prodromes. Neurological examination and cerebral scanner do not suggest lesion explaining the symptomatology. Biological tests were normal. The patient specifies after this episode to have applied terpenes derivatives (VICKS VAPORUB â ) 5-6 times a day (overdose) since few days. There was no recurrence thereafter. It should be noted that the patient had already received meropenem without incident. Discussion/Conclusion: Camphor, terebenthine, menthol, thymol and eucalyptus are components of VICKS VAPORUB â . These liposoluble molecules would induce a cellular respiration inhibition conducting to a neuronal hyperexcitability and lowering seizure threshold [1] . Moreover, in this case report, seizures were probably favored by meropenem concomitant treatment. Epileptic disorders are indeed a rare but well-known adverse effect of b-lactams, they have an epileptogenic potential as a result of inhibition of the GABAergic system and neurotoxicity [2] . In conclusion, the concomitant intake of terpenic derivatives and meropenem have very probably favored the occurrence of this seizure, no other triggering factor having been highlighted, hence the importance of being careful with self-medication drugs. References Material and methods: We describe here a case reported to the Regional Pharmacovigilance Centre of Montpellier: a woman who presented a life-threatening interstitial pneumonia with cytarabine which worsened in BOOP with decitabine. Results: A 42-year-old woman was diagnosed with acute myeloid leukemia (AML) by the end of March 2017. On April 1st, she initiated chemotherapy treatment with idarubicin (until April 5th) and cytarabine (until May 6th). Three weeks after starting chemotherapy (April 22nd), the patient presented a serious pneumonia. Chest radiography showed ground glass opacities and, interstitial pneumonia was diagnosed. On May 12th, chest scan showed a regression of pulmonary lesions and on July 6th, the lesions had disappeared. Second line chemotherapy with decitabine was initiated from July 6th through to August 13th. On July 21st, chest scan showed a recurrence and worsening of pneumonia. Pulmonary biopsy was performed and BOOP was diagnosed. On November 9th, chest scan showed a significant improvement of pulmonary lesions. Because of this side effect, no third line could be initiated. The patient died on December 2nd. Discussion/Conclusion: Cytarabine and decitabine are associated with pulmonary toxicity but BOOP is not a known side effect. They are pyrimidine analogues and have a structural analogy. Indeed, for this patient, a recurrence and worsening of pneumonia can be considered as a positive rechallenge. In practice, decitabine is often used after cytarabine treatment. Hence, clinicians should be aware that if a patient presents cytarabine side effects, and especially BOOP, the risk-benefit balance of decitabine must be carefully evaluated. This study explored the use of non-cancer drugs in lymphoma survivors during the early trajectory (0-2 years) of cancer survivorship and determined the factors that influenced this consumption. Material and methods: Between January and March 2014, a cross-sectional survey was conducted to assess drug consumption in adult lymphoma survivors at the Toulouse University Hospital. This study was based on a questionnaire consisting of ten open questions related to medical prescription and/or self-medication occurring within the last 3 months. Results: A total of 83/103 lymphoma survivors returned the questionnaire. This study showed that 91.6% of patients were drug consumers (about twice more than the general French population with a comparable age) with an average of 4.79 AE 2.79 drugs per patients. 75.9% reported to have at least one continuous therapy, 74.7% reported to have at least one occasional therapy and 51.8% reported to have self-medication. 21.7% of patients were treated with ≥5 drugs. Overall drug consumption mainly concerned analgesics (62.6% of patients), cardiotropic agents (39.8%) and psychotropics (32.5%). The presence of comorbidity, urban residence and female gender were associated with overall drug consumption. Finally, only seven survivors (8.4%) reported no use of any medication. Discussion/Conclusion: This study shows that, at least during the early trajectory of cancer survivorship, lymphoma patients are heavily treated with non-cancer drug therapy. This drug consumption profile may have serious implications in terms of safety, overall benefit and health economics.
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The course of psychotropic drug use in lymphomas: a pharmacoepidemiological study in the French Health insurance database Introduction: Psychological disorders are frequent in patients suffering from lymphomas. In this context, the incidence rate of psychotropic drug use is three times higher than in the general population at the initial phase patients' trajectory. Moreover, an excessive duration of treatment for a significant fraction of these patients has been described. However, patterns of a potential inappropriate chronic use of these drugs after initial treatment have not been explored. The aims of this study were to describe psychotropic drug use during distinct phase of lymphoma patient trajectory (before diagnosis, active treatment phase and survivorship) and to assess factors associated with prolonged use of these drugs during survivorship. Material and methods: We conducted a pharmacoepidemiological cohort study with data extracted from the Echantillon G en eraliste des B en eficiaires between 2009 and 2014. Results: This study shows high prevalence of psychotropic drug use during lymphoma care pathway with a prevalence of use close to 50% whatever the phase of the disease with prolonged inappropriate use for one survivor in five. After adjustment, factors significantly associated with prolonged use of anxiolytics and hypnotics during survivorship were older age, antecedent of psychotropic drug use, the presence of co-morbid conditions and deprivation. Discussion/Conclusion: This pharmacoepidemiological study depicts an overconsumption of psychotropic drugs in comparison to the French general population during the active treatment phase but also during the pre-cancer phase with persistence during survivorship. In this context, early detection and effective therapy of anxio-depressive disorders are still a critical issue in lymphomas.
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Post-marketing surveillance of celecoxib safety: a 12-year follow-up study in France Results: We retrieved 511 ADRs concerning 511 patients, mainly female (66%). The mean age was 62 AE 17 years. Three hundred and twenty-eight cases (64%) were serious. Twenty-four deaths were reported. Complete recovery was obtained in 81%. When available, indication was respected in 66 patients (34%), represented mainly by OA (58%), AS (25%), and RA (17%). Dosages of 200 and 400 mg were used in 48% and 36%, respectively. Dosage was immediately maximal for 72 patients (14%). Despite major contraindications, 28 patients (5.5%) received celecoxib. The most frequent system-organ classes involved were: skin and subcutaneous tissue disorders (29.7%), gastrointestinal disorders (12.5%), immune system disorders (9.8%), cardiac disorders (8.0%), and renal and urinary disorders (7.4%). The analysis focused on the identified risks showed 47 thrombotic cardiovascular events (including 16 myocardial infarctions, 4 acute coronary syndromes, 21 strokes, 6 peripheral venous thrombosis AE pulmonary embolism), 57 renovascular events (8 edema, 4 hypertensive disorders, 8 congestive heart failures, 35 acute renal failures, 2 nephrotic syndromes), 26 gastrointestinal bleedings, 2 non-complicated ulcers, 3 perforated ulcers, and 193 hypersensitivity-related events and skin reactions (53% serious). Discussion/Conclusion: Despite the consistent adverse-event profile with the known effects of celecoxib and other NSAIDs, an important misuse was observed, involving indication, warnings and precautions for use regarding cardiovascular risk, and contraindications. These findings should call for reminders of the rules for proper use of coxibs and other NSAIDs.
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Therapeutic drug monitoring as a tool for assessment of drug interaction between lamotrigine and other antiepileptic drugs M Ben Sassi, E Gaies, I Salouage, R Charfi, N Jebabli, H El Jebari, A Klouz, R Daghfous, S Trabelsi Centre National de Pharmacovigilance -Tunis (Tunisia) Introduction: Lamotrigine (LTG), one of the newer antiepileptic drugs, showing efficiency against partial seizures, tonic-clonic seizures, and absence. LTG can be used in monotherapy or in association with other antiepileptic drugs (AEDs). Therapeutic monitoring of LTG is necessary especially in potential drug interactions. The aim of our study was to identify interactions with concomitant AEDs. Material and methods: It is a retrospective study (January 2012 to December 2017) conducted in the National Centre of Pharmacovigilance. Samples were analyzed by an automated turbidimetric immunoassay. AEDs therapeutic range (TR) for trough concentration (C0) are 3-14 lg/mL for LTG, 50-100 lg/mL for valproic acid (VA), 4-8 for carbamazepine (CBZ) and 15-30 lg/mL for phenobarbital (Pb). In a first time, we have compared LTG C0 when LTG was administrated alone and when it is associated to other AEDs. In a second time, LTG C0 was compared according to the concentrations (C0) of the associated AEDS. Comparison between different groups was made using ANOVA test. Results: We have included 654 samples collected from 409 patients treated by LTG (508 samples in monotherapy and 146 samples in polytherapy). Sex ratio (M/W) was 1.16. Median age was 13.49 years old. LTG median dose was 3.33 mg/kg/day. Median concentration was 4.1 lg/mL. Among our samples, 32.62% were under the TR, 65.24% were within TR and 4.69% were above the TR. Results of LTG C0 according to its association with other AEDs were described in Table 1 . Then, LTG C0 was compared according to C0 of the associated AEDS. Results show a significant increase in LTG C0 when concentration of VA acid exceeds 50 lg/mL (9.24 lg/mL vs 5.13, P < 0.0001). Dose of LTG in the two groups was the same. Statistic analysis was not done for groups receiving CBZ and Pb in association to LTG because of the lowest number of samples.
Discussion/Conclusion: Our results demonstrate a significant increase in LTG C0 when it is associated to VA with an increase of the rate of LTG C0 above the TR. The inhibition of LTG metabolism is related to the VA C0 as it was showed in our results. In addition, LTG C0 was decreased when it was associated to CBZ and Pb. Because of the inducer effect, the rate of LTG C0 under the TR was increased.
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Exacerbation of a hypocalcemia associated with short term use of omeprazole I Aouinti, O Charfi, G Lakhoua, S Ben-Hammamia, H Zayani, N Alaya, S El-Aidli, R Daghfous, A Zaiem, S Kastalli Centre National de Pharmacovigilance -Tunis (Tunisia) Introduction: Omeprazole is one of the most widely used drugs in the world. It is generally well tolerated. Hypomagnesaemia and hypocalcaemia are rarely associated with omeprazole, some cases are reported in literature since 2006 [1] [2] [3] . This side effect occurred in about all cases after chronic use of omeprazole; in one case, it occurred after short-term intravenous use [1] . We report herein a case of hypocalcaemia exacerbated after 3 days of omeprazole treatment.
Results: A 46-year-old woman underwent thyroidectomy. The patient presented a hypoparathyroidism after the surgery and was supplemented with calcium. Calcium level was 2.09 mM in June 2017. In August 2017, she was treated for respiratory infection with clarithromycin and omeprazole (as a gastroprotective treatment). The 3rd day of treatment (August 8th), the patient presented cramps. Laboratory tests showed a calcium level at 1.55 mM. The patient stopped the 2 drugs. Doses of calcium supplementation were increased with addition of alfacalcidol. Calcium level has risen to 2.08 mM on August 19th. One month later, the patient was treated again with omeprazole and clarithromycin. The 3rd day of treatment, cramps reoccurred and calcium level was at 1.78 mM. So, she stopped the treatment with calcium level rise to 2 mM, at the control laboratory test. Discussion/Conclusion: Omeprazole responsibility was suspected in this case mainly because the recurrence of hypocalcaemia after reintroduction of this drug and the literature data. In fact, in 2006 was published the first paper associating omeprazole to hypomagnesaemia and hypocalcaemia. Since that date, some other cases of proton pump inhibitors (PPI) mainly omeprazole induced hypomagnesaemia associated with hypocalcaemia were reported. This entity was called PPIinduced hypomagnesemic hypoparathyroidism since hypomagnesaemia and hypocalcaemia were not accompanied by an appropriate increase in parathyroid hormone concentration [2] . In our case, the magnesium level was not assessed. The mechanism of these electrolyte disturbances remains still unclear and several hypotheses are proposed. The femoral block with single injection of bupivacaine (bupi) provides analgesia after arthroscopic knee surgery. Femoral block may be complicated by toxic side effects (cardiac, neurologic) due to a systemic passage of bupi. The aim of this study is to assess the safety of bupi administered for femoral block (neurostimulation) by a pharmacokinetic study in patients hospitalized for knee arthroscopy. Material and methods: A double-blind and retrospective study including 20 patients for knee arthroscopy was conducted. The femoral block was induced by the administration of isocratic bupi 0.125% (0.3 mg/kg) in perineural. Full pharmacokinetic profile of bupi (11 samples for each patient) was done (T0, T5, T10, T15, T30, T60, T90, T120, T180, T240min and T24hours). Blood samples were removed from the outer jugular vein. Monitoring of bupi was performed by liquid chromatography (HPLC). Results: The mean age was 34.2 years, the sex ratio M/W was 1.5. The mean of injection volume of bupi was 27.4 mL. The mean of anesthesia duration was 63.28 min. Analysis of different concentrations showed relatively high plasma levels of bupi in all patients between T30 and T90 min but sufficiently below the toxic threshold (1.2 lg/mL). No toxic effects were observed.
Pharmacokinetic parameters
Mean AE SD We herein report a 25-year-old Caucasian woman, with no medical history and no medication except for oral estrogen-progestin contraception (levonorgestrel-ethinylestradiol), who presented with cervical lymphadenopathy, fever and arthralgia without weight loss, night sweats or skin involvement. An exhaustive infectious disease screening was negative and lymph node biopsy revealed histiocytic necrotizing lymphadenitis suggesting KFD. Autoimmune screening tests evidenced high titers of anti-histone antibodies suggesting DILE induced by estrogen-progestin medication. The patient received a short course of non-steroidal anti-inflammatory treatment for painful lymphadenitis and arthralgia. Oral levonorgestrel-ethinylestradiol contraceptive medication was stopped and KFD and DILE completely recovered with a long-term disappearance of anti-histone antibodies. Discussion/Conclusion: We report the first case of KFD associated-DILE following oral levonorgestrel-ethinylestradiol medication. Even though levonorgestrelethinylestradiol induced lupus is well known, the association with KFD has never been reported and the physiopathology remained unknown.
PS1 -076
Leukocytoclastic vasculitis induced by lercanidipine F Zgolli, I Aouinti, G Lakhoua, O Charfi, S Ben-Hammamia, S El-Aidli, R Daghfous, A Zaiem, S Kastalli Tunisian National Centre of PharmacovigilanceTunis (Tunisia) Introduction: Leukocytoclastic vasculitis (LCV) caused by drugs is approximately 10-24% of cases. The most frequently implicated agents are propylthiouracil, penicillins, allopurinol and sulfonamides [1] . Calcium channel blockers are less involved in this skin impairment. In fact LCV was only reported with two molecules of this therapeutic class: amlodipine and diltiazem. Material and methods: We report herein an exceptional case of LCV induced by lercanidipine. It was notified in the Tunisian National Centre of Pharmacovigilance in 2017. It was scored according to the French method of imputability.
Results: An 87-year-old woman with past medical history of arrythmia was treated with lercanidipine, flecainide amiodarone and bisoprolol. Seven months after starting lercanidipine (10 mg/day), she developed a polymorphic and pruritic cutaneous eruption limited in extremities. Skin examination showed an erythematous maculopapular eruption associated with necrotic and purpuric lesions. The rest of the physical examination was normal. Laboratory findings showed an accelerated erythrocyte sedimentation rate and a high level of C-Reactive Protein (82 mg/L). Histological examination of skin biopsy revealed LCV, with characteristic perivascular neutrophilic infiltrates and leukocytoclasis. Lercanidipine was stopped, the other drugs were continued and a symptomatic treatment was initiated. A favourable outcome was observed with disappearance of the pruritus and cutaneous lesions, 15 days after the drug cessation. Discussion/Conclusion: The responsibility of lercanidipine was retained because of the compatible chronology, mainly the favourable outcome after the medication withdrawal and the evocative skin biopsy. The intrinsic score of this case, according to the updated French method of imputability, was I3. According to our knowledge, this case is the first LCV with lercanidipine. We report an unusual case of a cognitive decline appeared one week after beginning a therapy with VPA. It was evaluated according to the French Method of imputability [1] .
Results: A 61-year-old man with past medical history of post-traumatic epilepsy since 2005 was treated with phenobarbital. Twelve years later, he developed an algodystrophy. Phenobarbital was stopped and the patient switched to VPA therapy (1.5 g/day). Otherwise there was no primary evidence of neuropsychological dysfunction and the patient had never received VPA before. One week after the onset of VPA, he gradually developed amnesia, spatial and temporal disorientation, agitation and behaviour disorder. He presented diurnal and nocturnal enuresis, sleep disturbance with drowsiness. The neurological exam was normal and VPA was stopped. A favourable outcome was spontaneously observed in one week. Discussion/Conclusion: The responsibility of VPA in inducing this cognitive impairment was valued as possible I2 because of compatible delay (one week after VPA onset) and mainly the suggestive evolution (seven days after VPA withdrawal). Most common neuropsychiatric adverse effects of VPA include tremor, irritability, ataxia and sedation. Impairment in cognitive abilities, including memory, attention, and the speed of mental information processing, is less reported with VPA and generally appeared several years after its use. It is usually reversible from few weeks to months after the drug withdrawal. Its mechanism is not fully elucidated so far. It seems to be related to either a central toxicity or an indirect effect through the hyperammonemia that can be induced by VPA [2] . References Introduction: Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) is of particular interest to manage the inter-individual pharmacokinetic variability of these drugs. Indeed, the measurement of plasma concentrations is helpful to improve drug efficacy or to prevent toxicity or drug-drug interactions. The aim of this work was to develop and fully validate an ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for the quantification of eight TKI in human plasma (imatinib, dasatinib, nilotinib, sunitinib, ruxolitinib, erlotinib, ibrutinib, dihydrodiol-ibrutinib). Material and methods: Sample purification was achieved using protein precipitation with a mixture of acetonitrile/zinc sulphate in water. Chromatography was performed in a 6.5 min run time using gradient elution on a C18 reversed phase column with a mobile phase consisting of 0.1% formic acid and ammonium acetate 10 mM in water (A) or acetonitrile (B). Detection was performed with triple quadrupole mass spectrometry in positive-ionization mode. The method was validated according to the European Medicines Agency guidelines. Results: Calibration ranges were validated from 0.5-100 ng/mL for dasatinib, ibrutinib, dihydrodiol-ibrutinib, sunitinib, from 5-1000 ng/mL for ruxolitinib and from 25-5000 ng/mL for imatinib, nilotinib, erlotinib. In these concentrations ranges, within-day and between-day precisions as well as overall bias were within AE15%. Relative matrix effect was corrected by the internal standard (imatinib-2H8). The drugs were stable in whole blood for 8 h at room temperature (RT) except ibrutinib (4 h at 4°C) and for 12 h at room temperature in plasma, except ibrutinib (4 h at RT). No drug loss was observed after 3 months of storage at À80°C in plasma. A carry-over higher than 20% was observed for nilotinib then a blank sample has to be inserted after high concentration level samples to prevent any bias. The method was successfully applied to the analysis of incurred patients' samples in the context of routine TDM. Discussion/Conclusion: A UPLC-MS/MS method was developed and allowed measurement of eight TKI in plasma using a sensitive, easy and fast experimental procedure with good analytical performances. This assay is reliable to further investigate the pharmacokinetic/pharmacodynamic relationship of widely prescribed targeted therapies in onco-hematology. It also provides clinicians a useful pharmacological tool to individualize and to optimize patient's treatment responses.
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Strategy to reduce cholesterol -a review of two approaches: target and fixed-dosage F Gueyffier, R Babu, P Faure, C Fort, J Gafsi Universit e Lyon1 -Lyon (France) Introduction: Current guidelines on statin use differ in their approach: US guidelines promote the use of a fixed statin dosage depending on the cardiovascular (CV) risk whereas EU ones promote dosage adaptation to achieve target levels of cholesterol. Our aim was to compare advantages and disadvantages of each strategy. Material and methods: A review and analysis of current literature was performed to determine the advantages and disadvantages of both strategies. Additionally, a meta-analysis was performed to compare CV mortality, stroke and myocardial infarction sub-groups within each strategy. Finally, a cost estimate was also done. Our work did not show differences in costs for both strategies, but fixed dosage strategy displayed a greater benefit in term of CV risk reduction. There are limitations to the meta-analysis that was performed: i) a small number of studies included, ii) an inequality of weight of the sub-groups and iii) a non-exhaustive search. Furthermore, for myocardial infarction, studies following target strategy used lower than standard dosage compared to fixed dosage strategy studies using standard dosage but still presented a higher clinical benefit, difficult to explain. Even if the trend advocates for the promotion of the fixed-dose strategy, further investigation with a more robust methodology is required to validate this hypothesis. Hydroxyzine is an old H1-antihistamine which has been recently accused to cause QT prolongation. Very little data is available about this side effect in the literature and it is only fundamental data [1] . We decided to explore the hydroxyzine risk of QT prolongation in real-life conditions. Material and methods: Primarily, we conducted a prospective study to evaluate the impact of hydroxyzine on hospitalized patients QT, and we analyzed data of patients concerned by this side effect. Then we performed a descriptive study of QT prolongation reports with hydroxyzine in the French PharmacoVigilance database. Lastly, we did a comparative study of QT prolongation with H1-antihistamines in VIGIBASE â . Results: We included 37 patients in the cohort of the prospective study. Among them 7 patients presented a QT prolongation. They all had other risk factors of QT prolongation such as renal insufficiency or use of other drug known to prolong QT. We found 42 cases of QT prolongation imputed to hydroxyzine in the French Pharmacovigilance data base. In all cases, there were other risk factors of QT prolongation. Fourteen H1-antihistamines out of the 24 investigated were associated with a significant ROR value. For 7 of them, QT prolongation was indicated in the side effects section of the SMPC (Summary of Product Characteristics) and 4 were listed in CREDIBLEMEDS â list. Discussion/Conclusion: The prospective study demonstrated that hydroxyzine common use in patient with risk factors of QT prolongation greatly increases the risk of QT prolongation. This was confirmed by data found in the French PharmacoVigilance database. In our comparative study in VIGIBASE â , QT prolongation was associated with most H1-antihistamines while this risk was only described in the literature for some of them. These studies have strong arguments supporting the noxious effect of hydroxyzine and more widely of all H1-antihistamines on QT and shows that QT prolongation might be a class effect of H1-antihistamines. Hydroxyzine prescription should be used with caution in patients with QT prolongation risk factors. We intend to communicate further information to prescribers to ensure the best possible care of patients treated with hydroxyzine. Reference The recommended dose is 200 mg (IV or PO) every 8 h for 48 h, followed by 200 mg once daily for maintenance dose applied 12-24 h after the last loading dose. The median trough plasma concentrations of isavuconazole (i.e. value determined just before drug readministration) at steady state (>7 days of treatment) in patients who received the drug in the SECURE and VITAL trials, were 3-4 mg/L. Recently, 5 patients from Toulouse and Poitiers hospitals presented unexpected high concentrations few days after the last loading dose, questioning about the responsible factors. For some patients, these high levels were concomitant with side effects. Material and methods: Plasma concentrations were determined using a validated chromatographic technique. Based on the population pharmacokinetic model published by Desai [1] , firstly we simulated the expected pharmacokinetic profiles of isavuconazole for the recommended loading and maintenance doses. Secondly, by associating these simulations to the patient's measured concentrations, we could estimate the most likely kinetic profile and corresponding pharmacokinetic parameters. A pharmacogenetic exploration of CYP3A4/5, representing the main elimination routes, was systematically performed using a real-time PCR. Results: For all patients, peripheral distribution volume and elimination clearance were different of the median values (197.6 L and 2.36 L/h) reported by Desai: 115.4, 204.9, 73.6, 160.6, 71.7 L and 0.63, 1.06, 0.46, 1.38, 1.47 L/h, respectively. All of them presented the CYP3A5*3 polymorphism while 2 patients presented the CYP3A4*22 one. Discussion/Conclusion: For some patients, unexpected high levels of isavuconazole could be explained by the CYP3A4*22 polymorphism while for others, the cause is still unidentified. Based on these unexpected high concentrations, we proposed two recommendations: (i) to collect a blood sample just before the first maintenance dose to estimate precociously the most likely patient's kinetic profile; based on this profile, a dose adjustment is proposed, (ii) to explore CYP3A4/5 polymorphisms for patients presenting unexpected kinetic profiles. Unbound fraction (fu) is the pharmacologically active form of a drug and could be an alternative of interest to therapeutic drug monitoring (TDM) for HIV patients experiencing virological failure, despite efficient total concentrations (Ct). Between-subject variability (BSV) of fu could explain differences in efficacy/toxicity response with optimal Ct. Ultrafiltration (UF) is often used to evaluate fu, but only sparse data on analytical procedure are available, without any comparison with the gold-standard, equilibrium dialysis (ED). Therefore, fu comparison between studies is laborious. We aimed to establish a protocol to evaluate fu of dolutegravir (DTG), darunavir (DRV) and atazanavir (ATV) by ED and UF on HIV patients' samples. Material and methods: Through spiked plasma with the 3 antiretrovirals (ARV), time to reach binding equilibrium, non-specific binding (NSB), binding saturation and stability, influence of hemolysis and interaction with ARV on fu were evaluated by ED. Using a design of experiment process, different combinations of UF conditions (temperature/centrifugation) were compared with ED at 37°C. Then, fu of 110 patients was evaluated on both methods, in order to compare them and to assess fu BSV. A LC-MS validated method was used to measure ARV concentrations. Plasma proteins were measured to explain fu BSV. Statistics were based on ANOVA and results were expressed as median and interquartile range [25%;75%]. Results: Equilibrium was reached after 4 h at 37°C on ED for each drug. Binding of the 3 ARV were stable 5 days at +4°C or after 2 thaw cycles and NSB were <10%. Protein binding was saturated above 10 mg/L (P < 0.01). Only DTG binding equilibrium was influenced by hemolysis (P < 0.01) or interaction with other ARV (P < 0.01). Excepting for ATV, specific combination of temperature, time and centrifugal speed of UF allowed similar results compared to ED. Hospitalier Universitaire Grenoble Alpes -Grenoble (France) Introduction: Skin ulcers negatively affect the individual's quality of life and represent a substantial economic burden to healthcare systems. The impact of drugs on skin ulcers has been poorly investigated. The aim of this study was to identify pharmacological classes suspected to induce skin ulcers, through a pharmacovigilance disproportionality analysis of the World Health Organization pharmacovigilance database VigiBase â . Material and methods: We conducted a disproportionality analysis of data from VigiBase â , using VigiLyze â , following a two-stage procedure in order to minimize false positive discover rate. First, we retrieved all individual case safety reports (ICSRs) for the preferred terms (PT) 'decubitus ulcer', 'pyoderma gangrenosum', 'diabetic ulcer', 'varicose ulceration' and 'ischaemic skin ulcer'. We extracted all drugs for which the lower boundary of the 95% credibility interval of the Information Component (indicator value for disproportionate reporting, calculated as the log2 of the observed/expected ratios) was superior to 0. Drugs were grouped into pharmacological classes; only those classes with signal reported in at least two different types of ulcers were selected. Secondly, we performed the disproportionality analysis for each selected pharmacological class within the broader 'skin ulcer' PT. The cut-off for signal detection was defined as a PRR lower boundary 95% confidence interval greater or equal to 1, and number of cases greater or equal to 3. Results: From the 15,984,150 ICSRs available at the time of the extraction, we identified 15,568 reports of 'skin ulcer'. Ten pharmacological classes of drugs had a significant disproportionality signal for 'skin ulcer'. Increased signal reporting was found for angiogenesis inhibitors (PRR = 4. . Discussion/Conclusion: To the best of our knowledge, this study is the first to report a possible association between skin ulcers and ten pharmacological classes, including bisphosphonates, anti-CD20 monoclonal antibodies, coxibs and calcineurin inhibitors. Further studies should be conducted to confirm these findings. Few studies have shown a significant association between pediatric off-label drug use and adverse drug reactions (ADRs). Evaluate prospectively the relationship between adverse drug reactions and unlicensed or off-label drug use in hospitalized children. Provide more information on prescribing practice, the nature and consequences of unlicensed or off-label drug use in pediatric inpatients. Material and methods: Multi-center prospective study using automatic data extraction and a computer algorithm for determining pediatric drug labelling (i.e. off-label or unlicensed use). Detection of ADRs is carried out by health care professionals and research groups using a trigger tool and patients' electronic health records. The causality between suspected ADRs and medication is evaluated using the Naranjo and the French methods of imputability. Results: 477 confirmed ADRs in 5,917 patients for a 3-year period. Hypokalemia and withdrawal syndrome were the most frequent ADRs. Captopril and ursofalk was the most prevalent unlicensed administered product (Temporary Use Authorization). The most frequent off-label use concerned both fungizone and cyamemazine. Final result will be available and presented in the congress. Discussion/Conclusion: This first large multi-centre prospective study in France using electronic data base will help to identify risk factors for ADRs, set-up preventive actions for pediatric inpatients' care, guide future research and increase the awareness of physicians in ADR detection and declaration. ALFT "with identified non-DILI cause" (viral, autoimmune hepatitis) and ALFT with well-identified DILI cause, cases with drug exposed ALFT and undetermined ALFT. Drug exposure within 30 days prior to index date (initial symptoms of liver disease) is investigated for all cases, whatever the cause of ALFT. The risk of drug-exposed ALFT, expressed as rate per million treatmentyears (tt-yrs), will be calculated using reimbursement data of EGB (permanent random sample of the national healthcare insurance system database). This incidence rate will be compared to that of ALFT "with identified non-DILI cause" in order to identify drugs increasing the risk of ALF. Results: To date, 119 of 148 cases ALFT cases have been adjudicated by a hepatologist group in the 17 liver transplant participating centres. Among them: 53 cases (44.5% of ALFT) have been classified as ALFT with non-DILI cause (autoimmune hepatitis n = 17 (14.3%); vascular liver injury n = 10 (8.4%); hepatitis B n = 8 (6.7%); other viruses n = 4 (3.4%); alcoholic ALF n = 6 (5.0%); mushroom intoxication n = 4 (3.4%); other causes n = 4 (3.4%) and 50 cases (42% of ALFT) related to paracetamol including 30 cases (25%) with voluntary overdosage and 21 cases (17.6%) of accidental paracetamol-DILI; 10 cases (8.4%) exposed to drugs 30 days prior to liver injury including 4 DILI with probable causality: amoxicillin (1 case), antituberculous (1 case), antiepileptics (1 case) chemotherapy (1 case) and 6 cases with possible other DILI (several concomitant drugs) and 5 cases (4.2%) not exposed to drugs 30 days prior to liver injury. Discussion/Conclusion: In France, over the years 2015-2016, the role of paracetamol in ALFT is further increasing, with a significant proportion of accidental counterpart. Other drugs account for 8.4% of ALFT. Non identified causes are significantly reduced. The results for the whole 143 patients will be available for April 2018. Patients were mainly male (77% in 2008 to 73% in 2016), with a median age of 36.5 years for men and 35.0 for women. The first hospital admission was via emergencies unit with a rate increasing from 44% to 50% over the period. The average number of hospitalizations per patient ranged from 1.30 to 2.17, with a decrease since 2015 in parallel with an increase of the number of hospitalized patients, sign of a renewal of patients treated at the hospital for cocaine use. An increase of 64% of the F14.0 code was observed during the study period (vs. 73% for the F12.0 = cannabis and 41% for the F11.0 = opiates). The calculated standardized incidence (age, sex, area, and years) found very high values in Guyane, Guadeloupe and Martinique. In metropolitan France, the highest incidences were in Occitanie and PACA Regions. However, this retrospective analysis did not provide additional information on hospitalization events, patient's consumption patterns or toxicological analyses. In addition, the coding of ICD-10 is not always accurate or specific to identify all cases. Discussion/Conclusion: The analysis of this database corroborates the data collected by the FAN concerning the worrying increase of the damage related to the use of cocaine in France. Hôpital Piti e-Salpêtri ere -Paris (France) Introduction: The protein S-100 beta (PS-100) is a small dimeric cytosolic protein synthetized in astrocytes and Schwann cells. High serum levels of PS-100 are associated with brain lesions and altered blood-brain barrier permeability in traumatic brain injury, ischemic stroke, cerebral tumors and subarachnoid hemorrhage. Early brain damage has been detected in patients with cirrhosis. We hypothesized that those insults could be detected by the PS-100 serum levels (normal values <0.10 lg/L). Hence, the aim of the present study was to assess PS-100 levels in cirrhotic patients, and compare them to PS-100 levels in non-cirrhotic patients followed up in the same department for initial workup of elevated liver enzymes (controls). Material and methods: We prospectively included a population of cirrhotic patients admitted for complication of cirrhosis in ICU and controls. Baseline data were recorded and levels of ammonemia and PS-100 determined at admission. Overt HE was diagnosed as a West-Haven score ranging between 2 and 4. Results: Between October 2013 and October 2014, 124 cirrhotic patients (mean age: 63 years, male gender: 73%, etiology of cirrhosis: alcoholic 51%, viral 25%, other 24%, Child-Pugh 11 [8] [9] [10] [11] [12] , MELD score 21 [14-26]) and 79 non-cirrhotic patients (mean age: 63 years, male 59%, etiology of elevated liver enzymes: alcoholic 5%, viral 44%, NASH 38%, other 13%, mean Fibroscan: 5.3 kPa, mean FibroTest: 0.15) were included. Among cirrhotic patients, 40 patients (33%) displayed HE at admission and 50 (41%) had an infection. Mean PS-100 level were 0.15 AE 0.01 for cirrhotic patients and 0.07 AE 0.01 for non-cirrhotic patients (P < 0.0001). In cirrhotic patients, PS-100 was correlated to AST (P = 0.0027), bilirubin (P = 0.0001), Child-Pugh score (P = 0.001) and MELD (P = 0.0004) and inversely correlated to albumin (P = 0.04), sodium (P = 0.01), PTT (P = 0.001), and FV (P = 0.011). PS-100 levels were not correlated to the presence of overt HE nor to infection. In multivariate analysis, levels of PS-100 were independently associated with MELD score (P = 0.0006), whereas overt HE was associated to hyperammonemia (P = 0.002) and the presence of infection (P = 0.008) but not to PS-100 levels. Discussion/Conclusion: Patients with cirrhosis in ICU display neurological insult or blood-brain barrier dysfunction even in the absence of overt HE. Brain damage is more frequent in patients with advanced liver disease.
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The influenza vaccination coverage among hospital workers: difference in behaviour between medical staff and other health-care workers. G Bertoliatti, J Louis, E Delbende, J Doucet, L Bessaraoui, AA Zulfiqar, N Kadri, J Leporrier, G Luc, C Marchand F ed eration de m edecine interne g eriatrie th erapeutique, CHU hôpitaux de Rouen -Rouen (France) Introduction: Last year, France faced a major influenza outbreak resulting in many emergency hospitalizations. In our 114-bed care unit, we treated 71 patients with both known (21 nosocomial) or suspected influenza. The mortality reached 12%. Caregivers (CG), highly exposed, are vectors of transmission. However, the influenza vaccination coverage (IVC) of CG is unsatisfactory. The aim of this study was to evaluate the IVC in medical and non-medical staff in a care unit having taken in charge lots of patients suspected of influenza to implement measures to better cope with a future flu outbreak. Material and methods: From January to February 2017, an anonymous quiz was distributed to caregivers assigned to the 114 beds of one internal medicine and three short-stays geriatrics departments. This quiz included characteristics of the respondent, his medical history, his vaccination status and his views about vaccination. The questionnaire also focused on information received from the hospital and proposals for improving immunization coverage. Results: 129 people responded to this survey (62% of CG): 84% of the physicians and 57% of the paramedical staff. The median age group was from 30 to 40. 97 responses were from paramedical staff. 47 people were vaccinated against influenza: 65% of the medical staff and 28% of paramedical staff. Adverse events reported were limited. Nearly 75% of people considered themselves to be wellinformed. The motivations of the vaccinated people were mainly professional (to protect the patient) (39) and then personal: to protect relatives (14) and themselves (13). Arguments for non-vaccination were divided into two categories: forgetfulness (9) or personal conviction (safety concerns. . .) (50) and differed significantly between physicians (forgetfulness) and non-medical staff (personal conviction). Discussion/Conclusion: Compared to the literature, the IVC of this population seems relatively good. It is not excluded, however, that those who have not answered the questionnaire, are essentially unvaccinated people. Our results show a significant difference between physicians and paramedical staff concerning the IVC and reasons for non-vaccination. It is essential to strengthen information campaigns on the benefits of vaccination, particularly regarding the risk of transmitting flu to frail patients. Our study shows that non-vaccination often results from non-rational arguments, especially in paramedical personnel. This must be taken into account to adapt the messages delivered. While there is clear consensus on the benefit of initiating statins in elderly with cardiovascular disease, the benefit of starting these treatments in patients without such history remains debated. The aim of this study was to evaluate, in real life, the effect of initiating statins in the elderly, according to cardiovascular risk. Material and methods: This cohort study was performed using data of the random representative sample of the French healthcare system database for the 2008-2014 period. Patients were eligible for the study if they were aged 75 years and above during the study inclusion period (2009) (2010) (2011) (2012) . Every trimester during this period, new users of statin were dynamically included in the cohort. New users of statin were defined as a first identified statin dispensing without statin dispensing in the previous year. To each statin new-user, one statin non-user was matched on age, gender, numbers of different drugs dispensed and medical consultations, and history of cardiovascular diseases or use of cardiovascular drugs. Patients were classified as high (history of previous coronary heart disease), moderate (diabetes or use of cardiovascular medications), or low cardiovascular risk (none of the above). Effect of cumulative use of statins on occurrence of acute coronary syndrome or all-cause death was analyzed by using multivariable time-dependent Cox models stratified on cardiovascular risk at inclusion. Results: 3642 new statin users matched 1:1 with statin non-users, for a total of 7284 patients were included in the study, 4.8% of whom were at high cardiovascular risk, 84.9% at moderate risk, and 10.3% at low risk. Over the study followup (median: 4.7 years), the cumulative use of statins was associated with a lower risk of outcomes in the high-risk group (adjusted hazard ratio (HR) 0.75 per year of use; 95% confidence interval (95% CI) 0.63-0.90), in the moderate-risk group (HR 0.93 per year of use; 95% CI 0.89-0.96), but not in the low-risk group (HR 1.01 per year of use; 95% CI 0.86-1.18). Discussion/Conclusion: This study confirms the benefit of initiating statins in elderly treated for secondary cardiovascular prevention or at identified cardiovascular risk. However, in primary prevention, outcomes were similar regardless of statin use for older adults with no identified cardiovascular risk factors.
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Complying to the new Jard e law: getting help from an "old" friend. Results: This new legal framework is affecting multiple qualitative aspects of our activity. The major changes regarding vigilance affect the reporting of serious adverse events (SAE), now only mandatory for category 1 trials (interventional research studies involving an intervention on patients not justified by their routine treatment). For category 2 and 3 trials (interventional research studies that include only minimal risks and constraints or non-interventional research studies in which all the practiced procedures and the products are used routinely), all SAE not attributable to the experimental procedure must be notified to the relevant vigilance department (pharmacovigilance, materiovigilance, biovigilance . . .). The reporting system used in some "old" studies prefigures the new regulatory system of SAE surveillance in type 2 and 3 categories trials. The BACLO-PHONE trial [2] started in January 2016 under the previous regulations. In this study on off-label prescriptions of baclofen in alcohol withdrawal, all AE are received and assessed by the pharmacovigilance center, graded as non-serious or serious and recorded in the French National Database. The center reports AE periodically and SAE without delay to our unit, where we proceed to an additional assessment in order to detect potential SUSAR or new safety information, and record them. No SUSAR or new safety data was detected to this date. Discussion/Conclusion: The specific system for AE reporting in the BACLO-PHONE trial has laid grounds for AE reporting procedures in upcoming category 2 and 3 trials as it provides us with a methodological template suitable to these trials with minor adjustments. References The androgenic anabolic steroids (AAS) are the subject of much misuse and abuse by athletes, sports persons, and body builders in attempt to increase muscle mass and body-weight. The AAS are present in over-the-counter dietary supplements and are bought illegally on the internet. Material and methods: We report two Caucasian male body builders (aged 28 and 34 years) with acute hepatitis cholestatic requiring hospitalization following ingestion of dietary supplement containing 17a-alkylated AAS. Results: In the first case, 2 months after administration of dehydrochloromethyltestosterone (Turinabol TM ) 60 mg per day and in combination with phytotherapy (Desmodium TM ), patient presents pruritus, major cutaneous and conjunctival icterus, discolored stools, dark urine accompanied by micturition burning. Laboratory test results revealed severe cholestasis with: hyperbilirubinemia (620 lM), PAL increased (251 IU/L), light cytolysis (TGO 48 IU/L, TGP 50 IU/L), insufficiency renal (DFG 66 mL/min/1.73 m 2 , creatinine 119 lM). In the second case, patient had taken AAS including methandienone (Dianabol TM ) 40 mg per day and methyltestosterone (Induject TM ) 176 mg weekly. 20 days after ingestion of the dietary supplements, he presents pruritus, cutaneous and conjunctival icterus and laboratory test results revealed severe acute liver disease with hyperbilirubinemia (394 lM), PAL increased (319 IU/L), cytolysis (TGO 65 IU/L, TGP 93 IU/L). He previously takes AAS (stanozolol and clenbuterol) 2 months before the onset of these effects. In both cases, liver biopsy found toxic hepatitis cholestatic. AAS withdrawal and hepatic dialysis allowed complete resolution. Discussion/Conclusion: Since few years AAS have been abused. Exceedingly high doses are often consumed over long periods, in particular by body builders. Dehydrochloromethyltestosterone, methandienone, methyltestosterone are 17a-alkylated AAS, which are known to induce liver toxic. The mechanism responsible for hepatotoxicity induced by 17a-alkylated AAS remains poorly understood. However, oxidative stress leading to increased ROS (reactive oxygen species) production could play a role in the hepatotoxicity of 17a-alkylated AAS [1] . These cases show the problem of the misuse and lack of regulation for AAS. Reference 
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Comparison of the adverse effects of direct oral anticoagulants and vitamin K antagonists: from a study conducted at the Regional Pharmacovigilance Center of Reims L Melinat, B Azzouz, E Herlem, T Trenque, S Dukic Centre R egional de Pharmacovigilance et de Pharmaco epid emiologie -Reims (France) Introduction: Anticoagulants treatments are at the forefront of drugs causing iatrogenic accidents leading to hospitalization. These accidents are mainly related to the hemorrhagic risk. The new family of oral anticoagulants, the direct oral anticoagulants (DOACs) is studied closely. Many international studies prove the same efficiency for this family compared to the family of vitamin K antagonists (VKAs). The aim of this study is to compare the serious or non-serious adverse effects of VKAs and DOACs. Material and methods: The study carried out is a descriptive retrospective study. We studied the adverse effects collected by the Regional Pharmacovigilance Center of Reims from 2013 to 2015. The query was made using the following keywords: "dabigatran", "apixaban" and "rivaroxaban" for DOACs; "fluindione", "acenocoumarol" and "warfarin" for VKAs. We have compared these data with the number of anticoagulants boxes sold in the Champagne-Ardenne area. Results: 479 cases of hemorrhage were reported (107 with DOACs vs. 372 with VKAs). However, compared to the number of boxes sold the DOACs hemorrhage represents 62% against 38% for the VKAs. Among the most hemorrhages observed with DOACs, we found gastrointestinal hemorrhages (72% for DOACs vs. 28% for VKAs) and cerebral hemorrhages (70% for DOACs vs. 30% for VKAs). Discussion/Conclusion: On the contrary to what is found in international studies, it appears that in our region DOACs are responsible for more adverse effects than VKAs for the years 2013, 2014 and 2015. However, it may be necessary to modulate our remarks. Indeed, it should be noted that very few adverse effects reported in the database and especially for older drugs as VKAs. In addition, DOACs are new drugs compared to VKAs and health professionals are more willing to report the adverse effects of new molecules.
PS2 -015
Successful rechallenge of rituximab after immediate reaction C Ladhari, I Hamza, S El Aidli, N Alaya, R Daghfous, S Kastalli, A Zaiem Centre national de pharmacovigilance de Tunis -Tunis (Tunisia) Introduction: Rituximab, an anti-CD20 monoclonal antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma and has also other indications including autoimmune diseases; rheumatoid arthritis and microscopic polyangiitis [1, 2] . The majority of patients experience mild to moderate infusion-related reactions (IRRs) during the first infusion of rituximab [1] . Modalities of reintroducing the drug remain a challenge for the clinician. Material and methods: We report a case of IRRs during the first infusion of rituximab with successful rechallenge after dilution of the drug and slow infusion. Results: A 38-year-old male was admitted to nephrology department for his first rituximab (MabThera â 500 mg) infusion for membranous glomerulonephritis. He had no allergic reactions in medical history. He received premedication with methylprednisolone, paracetamol and hydroxyzine before rituximab's infusion. Thirty minutes after beginning of undiluted rituximab's infusion (5 mL/30 min), the patient developed an urticaria, warm feeling and dyspnea. The infusion was stopped and immediate symptomatic management was given. The symptoms were resolved within 3 h. Because the drug had not been diluted and the infusion was probably quick, we rechallenge rituximab through 1/10 dilution with low rate of infusion over 12 h. The patient had well tolerated the infusion. Discussion/Conclusion: This reaction was defined as Grade 2 according to the NCI Common Terminology Criteria for Adverse Events [4] . Most of the IRRs are due to massive nonimmune cytokine release that occur during the intravenous administration of the agent [3] and include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, anaphylactoid events, and death within 30-120 min of infusion [5] . Quick management of these reactions is required to avoid severe complications. Occurrence of IRRs during the first administration of rituximab is possible and does not require the definitive withdrawal of this effective drug. Clinicians should respect the precautions for use of Rituximab to minimize the risk of occurrence of such event References 
PS2 -016
Social media screening in pharmacovigilance activities: a new approach N Schiller, A El Hachemi D epartement de pharmacovigilance, LYSARC -Pierre-B enite (France) Introduction: Partly due to underreporting of reporting adverse drug reaction as well as public health crisis, the pharmacovigilance regulation trends to empower the patient. That is why social media and big data may become a powerful tool to detect safety signals. The aim of this study is to describe the regulation, how to extract data from social media and to exploit them. Material and methods: Regulatory texts (e.g. ICH guidelines, GVPs), Eudralex, the CIOMS and EMA websites were screened. Scientific literature retrieved on PubMed and Google Scholar was also screened. Results: To be able to extract safety data from social media, a process consisting of 4 successive steps has been set up: (i) Data extraction based on a keyword's (drug name) research: with raw data collection. This collection is based on the natural language processing; (ii) Translation: using a standardized MedDRA dictionary. A correspondence is established by an algorithm between the vernacular language of the Internet and the MedDRA preferred term; (iii) Filtration of data that may contain an adverse event by removing most irrelevant information. The lexicon-based method is the most used; (iv) Identification: all posts designating an adverse event is identified as "proto-AE" that is to say as "posts with resemblance to adverse events". A statistical analysis on extracted drug-adverse drug reaction pairs is performed to identify potentially harmful drugs. These results are also compared with regulatory databases to check the relevance of the information. From the regulatory landscape, marketing authorization holders have the responsibility to collect, document, signal and follow all adverse events find on the Internet or social media according to the applicable regulation. They will rely on GVPs module IV and IX, on chapter II.b of CIOMS V, on ICH E2D and on FDA Guidance for Industry. To consider these data as valid, it is necessary to have at least one adverse event, a suspicious drug, information on the declarant and information on the patient. Discussion/Conclusion: We note that the popularity of social media has opened the dialogue on adverse drug reaction. User posts contain information on treatment outcome making social media a unique and robust source of new information related to health. It allows earlier and faster signal detection. However social media should not be used as a tool of primary signal warning or detection because identify an adverse drug reaction requires investigation. [2] . Even though France is one of the countries where the use of any drug during pregnancy is the highest, the frequency of off-label drug use remains unknown. The aim of this study was to describe the off-label medication use in a cohort of French pregnant women. Material and methods: All women who had given birth to a viable baby in one of the maternity wards in Haute-Vienne were included in the N eHaVi study cohort after giving their informed consent. Data on the outcome of pregnancies and drug or toxic exposure during pregnancy were collected. Drugs were classified according to the labelling of the summary of product characteristics (SmPC) as follows: on-label, off-label safe, off-label at risk and off-label contra-indicated. Results: During their pregnancy, the 397 women included in the study used a mean of 8.9 AE 5.3 drugs . Overall, 66.7% of drugs used were off-label: 38.3% off-label safe, 21.5% off-label at risk and 6.9% off-label contra-indicated (essentially non-steroid anti-inflammatory drugs). In 400 viable babies, five malformations were encountered (1.25%, 95% CI: 0.16-2.34). After pharmacovigilance analysis, none of the malformations could be explained by the administered drugs. Discussion/Conclusion: The magnitude of off-label prescription during pregnancy in France is high. Women and health professionals should be more aware of the potential danger of drug use during pregnancy. Various measures to limit the off-label medication use during pregnancy ("Temporary Recommendations for Use", pictograms on the packaging) have been adopted by the French Medicine Agency (ANSM). Moreover, drug adverse effects during pregnancy should be evaluated through an improved notification in pharmacovigilance and appropriate pharmacoepidemiological studies in order to enable faster changes in the labelling of SmPCs. References b Clinical Pharmacology Department INSERM CIC1406, Grenoble University Hospital -Grenoble (France) Introduction: Inhibitors of the sodium-glucose co-transporter-2 (SGLT-2) are a novel class of glucose lowering agents showing promising results. However, the recent CANVAS trial showed an increased risk of amputation in patients treated with canagliflozin. As a result, the US Food and Drug Administration (FDA) now requires a boxed warning to be added to the canagliflozin drug label, while the European Medicines Agency (EMA) includes a warning in the prescribing information for all SGLT-2 inhibitors. Whether this risk concerns only canagliflozin or all SGLT-2 inhibitors is unclear. Material and methods: We performed a disproportionality analysis using the WHO global database of individual case safety reports (VigiBase â ) to address this issue. We extracted all ICSRs associated with the following preferred terms: foot amputation, leg amputation, limb amputation, metatarsal excision and toe amputation (grouped into "lower-limb amputation"). Disproportionality analysis was performed using the proportional reporting ratio (PRR). To take into account the baseline risk of amputation related to diabetes, we performed the disproportionality analysis among blood glucose lowering drugs. The cut-off for signal detection was defined as a PRR lower boundary 95% confidence interval greater or equal to 1 and number of cases (n) greater or equal to 3. Results: Among the 8,289,765 reports available since January 2013, we identified 79 reports of lower-limb amputations associated with SGLT-2 inhibitors. Among all blood glucose lowering drugs, the proportional reporting ratio (PRR) was increased only for SGLT-2 inhibitors [5.54 (4.23, 7.27)]. While we observed an expected signal for canagliflozin [7.09 (5.25, 9.57)], the PRR was also high for empagliflozin [4.96 (2.89, 8.50)] and, for toe amputations only, for dapagliflozin [2.62 (1.33, 5.14)]. Discussion/Conclusion: In conclusion, our results reveal a positive disproportionality signal for canagliflozin, and also for empagliflozin, and, for toe amputations only, for dapagliflozin. The mechanisms underlying the risk of amputation remain largely unknown. However, there is no obvious pharmacological reason that would explain differences between the different SGLT-2 inhibitors. Further prospective data are therefore needed to better characterize the risk of amputations with the different SGLT-2 inhibitors.
PS2 -019
Pharmacokinetic adaptations of antibiotic posology: sampling errors in patients with continuous infusion of vancomycin in an university hospital B Franck, H Ben Romdhane, S Laarif, J Debord, C Monchaud, JB Woillard, S Couderc Laboratoire de Pharmacologie et de Toxicologie, CHU Dupuytren -Limoges (France) Introduction: The pharmacokinetic (PK) adaptations of posology of vancomycin require precise and exact information: loading dose or not, administration hours, posology, patient weight, blood creatinine concentration, indication of antibiotic. When vancomycin is administrated with continuous infusion, sample for vancomycin blood concentration measurement must be realized from the opposite arm of the infusion. If it is not the case, the vancomycin concentrations could be overestimated and lead to inappropriate PK adaptations. The goal was to estimate the prevalence of that kind of sampling errors in the Limoges university hospital. Material and methods: The extractions of data were from laboratory software GLIMS and PK software PKJUST (department of pharmacology and toxicology, Limoges university hospital, France); study period: 7 years (from July 2010 to June 2017). Every vancomycin blood concentration measurement (GLIMS) in patients with at least one vancomycin (continuous infusion) PK adaptation of posology with PKJUST, have been kept. All the aberrant concentrations (>50 mg/L) have been isolated. Results: 3717 adaptations of posology with PKJUST (vancomycin with continuous infusion) have been extracted. It concerned 1458 patients: 913 male, 545 female, mean age 52.1 years old (median 61.4, min 4 days old, max 107.6 years old). 221 concentrations (163 patients) over 50 mg/L have been identified (5.9% of the adaptations, 11.2% of the patients) including 32 over 100 mg/L, 12 over 200 mg/L and 3 over 500 mg/L. Discussion/Conclusion: A high proportion of aberrant concentrations, due to sample in the infusion, have been isolated. These errors lead to a new sample (opposite arm), a new analysis (increase in cost) and an increment of the delay for a PK adaptation result. If aberrant blood concentrations of vancomycin are easy to isolate, normal value after sample in the infusion, can be used for a PK adaptation and can lead to underexposure of the patient, with a risk of failure of the antibiotic. It happened in our department this year and the consequences were two days with underexposure. These data will be used to raise awareness of the clinical professionals.
PS2 -020
Adverse Drug Reactions associated with protease inhibitors in children: a comparison of Atazanavir versus Darunavir using data from VigiBase [1] . However, as already observed in adults, there is an increased use of Darunavir (DRV) based antiretroviral regimens compared to Atazanavir in current clinical practice. Compared to some older protease inhibitors (PIs), DRV has a high genetic barrier to resistance development [2] . Regarding its safety profile, it is safer than ATV regarding hepatobiliary injuries and similar to those of boosted ATV for lipids [3] [4] [5] . The aim of this study was to compare frequency and seriousness of Adverse Drug Reactions (ADRs) associated with Atazanavir and Darunavir in children. Material and methods: We used the available pharmacovigilance data from VigiBase â (the WHO global database of individual case safety reports -ICSRs). We considered all ADRs related to the whole system organ class (SOC), as defined in the MedDRA dictionary. Data are presented as a reporting odds ratio (ROR) with a 95% confidence interval [95% CI]. Results: 212 individual case safety reports (ICSRs) associated with ATV and 82 with DRV were included. Mean age was 1 (range 0-17) year, 51% (151/294) were female (7.8% unknown). Among these cases, 82.5% (160/194) vs. 88.6% (71/80) were serious for ATV and DRV respectively (P = 0.19), with a frequency missing of 20. Of 453 ADRs reported with ATV and 171 with DRV, the main SOCs reported were cardiac disorders, congenital, familial and genetic disorders, hepatobiliary disorders and skin and subcutaneous tissue disorders. We found that for the hepatobiliary disorders SOC there were forty-six (10.1%) vs. 1 (0.6%) ADRs reported for ATV vs. DRV, respectively (ROR 19.2 [2.6-140.5]). Qualitative analysis of the type of hepatobiliary injury is in process. Within all the others SOCs, there were no statistically difference between ATV and DRV. Discussion/Conclusion: Children treated with ATV were more likely to present Hepatobiliary disorders compared to those treated with DRV. This result is in agreement with the one observed in adult patients and the high prevalence of hepatobiliary injuries with ATV.
PS2 -021
Drug iatrogenic disease and recourse to the adult psychiatric emergencies E Terro, C Boulay, N Massy Pharmacovigilance, CHU de Rouen -Rouen (France) Introduction: Although well known in general population, the incidence of the adverse drug effects (ADR) is not so extensively investigated in psychiatric emergencies units (PEU). An Israeli study founded 7.5% of psychiatric hospitalizations due to ADR [1] . The aim of our study was to estimate the incidence of ADR leading to emergencies consultations or occurring during patient's management in psychiatric facilities. Material and methods: We included 600 adult patients managed from January 1st, 2017 in a local psychiatric hospital and collected data from the medical record. We distinguished "patients without ADR", "patients with ADR" with two groups "consulting for ADR" (ADRC) and "ADR during the hospitalization" (ADRH). For all ADR we specified typology, gravity and evolution, treatments involved and preventability. Results: The incidence of ADR in the whole studied population was 15.66% IC95% [12.8-18.6], with 5.83% IC95% [4.15-8 .10] of consultations due to ADR and 9.83% IC95% [7.62-12.57] of ADR occurring during hospitalization. The more frequently observed ADR were sedation (30% of ADR), dysarthria, dyskinesia, hypotension, dependence, withdrawal syndrome and electrolyte disturbances. The main suspected drugs were loxapine, cyamemazine, diazepam, oxazepam, lormetazepam, bromazepam, zolpidem, sertraline and lithium. 43.3% of the all ADR were serious and mostly observed in the ADRC. ADR were preventable and one third had favourable outcome. The mean number of drugs per patient was not significantly different between "non-serious" and serious" ADR, 4.14 IC95% [3.57-4 .71] vs. 5.04 IC95% [4.24-5.84] respectively. "Patients with ADR" had a longer stay than "patients without ADR" (P = 0.001). Patients in ADRC group had more often medical and surgical histories (P = 0.06), psychiatric follow-up (P = 0.001) and had less frequently enforced hospitalizations compared with patients in ADRH group. Discussion/Conclusion: In our study, the incidence of ADR leading to consultation and hospitalization in an emergency psychiatric facility was higher than that observed in the general population. One third of the ADR was due to excessive or unintentional sedation. Although they had positive outcome, they increased the length of hospital stays. These results enlightened the length of ADR problems in PEU and allowed discussions on preventive strategies. Reference 
PS2 -022
Hormonal therapy-induced meningioma A F eral, L Adda, B Batteux, V Gras, K Masmoudi Centre R egional de Pharmacovigilance de Picardie -Amiens (France) Introduction: Meningioma is a benign tumor of the central nervous system developed from arachnoid cells. Meningiomas are 2-3 times more common in women. Ionizing radiation is the main environmental risk factor, especially in patients who have been treated in childhood for leukemia or medulloblastoma. Exogenous hormones could also play a role. The presence of progesterone receptors is found in most meningiomas (in 80% of cases).
Material and methods:
We research all meningioma cases in women treated with hormonal therapy notified to the Pharmacovigilance Center of AmiensPicardie. Results: We report 5 women cases, between 2012 and 2017, affected by meningioma with hormonal therapy. One of them was treated by ionizing radiation in childhood for leukemia. All of them were treated with a systemic progestin treatment (etonogestrel, cyproterone acetate, progesterone, nomegestrol or medrogestone) including 3 patients with an estrogen treatment associated (topical application or skin patch), for oral contraception or hormone replacement therapy. The tumor occurred at an average of 10 AE 7.07 years [extremes: 2; 20]. The hormonal therapy was stopped in 4 patients and the tumor regressed in one of them. There was one surgical excision showing the presence of progesterone receptor by immunohistochemistry with an anti-progesterone nuclear receptor antibody. All women benefited from cerebral MRIs monitoring. Three patients have not yet recovered and one of them presents an irreversible anosmia. Discussion/Conclusion: The development of meningioma occurs several years after prolonged progesterone hormonal therapy, facilitated by the presence of progesterone receptors. The hormonal dependency of meningiomas is not always suspected. Regression of meningiomatosis may be observed after discontinuation of progestin treatment. It seems to be necessary to communicate more about this risk to health professionals and patients. In the context of deaths due to prescribed and illicit opioids overdose, the development of naloxone formulations easier to administer for nonmedical users, such as intranasal delivery systems, are of major concern. In France, Nalscue â a take-home intranasal naloxone was available under a temporary utilisation of use since July 2016. Material and methods: All patients followed at the addiction care center who received at least one prescription of intranasal naloxone were included. Study was conducted between July 2016 and December 2017. Information about socio-demographic characteristics, opioids maintenance therapy, and consumption of illicit substances, were collected. An initial descriptive analysis of patients was performed. Results: A prescription of take-home intranasal naloxone was proposed to 39 patients. Nineteen patients had a dispensation by the hospital pharmacist (48%). One patient had two dispensations because he gave the product to a friend. A training for awareness of opioid overdose recognition and response was performed by the physician, the pharmacist and nurses to all the patients and/or his/her family. Four women and 15 men were included, with a median age of 39.0 years [IQ25-75: 36-45], 26.3% have regular resources (n = 5), 84% a stable housing (n = 16) and 42% a professional activity (n = 8). All patients were under methadone maintenance therapy. Patients were assessed at risk for opioids overdosage because of their concomitant consumptions as follow: heroine (17 patients), buprenorphine (8 patients), morphine sulfate (5 patients), and other opiates (2 patients, codeine, and tramadol). One patient has a medical history of opiates overdose. The prescription indication was the overuse of opiates (n = 8; other not documented). At that time no use of the dispensed intranasal naloxone for overdose rescues was noted. Discussion/Conclusion: This intranasal naloxone just obtained marketing authorization in France. A widespread implementation is necessary to reduce opioid overdose mortality. To increase access, new formulations of naloxone will be soon available in France.
PS2 -024
Tacrolimus individual dose adjustment using population pharmacokinetics model F Ben Salem, E Gaies, M Ben Sassi, R Charfi, N Jebabli, I Salouage, H El Jebari, A Klouz, R Daghfous, S Trabelsi Centre National de Pharmacovigilance -Tunis (Tunisia) Introduction: Tacrolimus (TAC) is an immunosuppressant, largely used in renal transplantation. It has large inter and intra-individual pharmacokinetics (PK) variability and a narrow therapeutic index. Its therapeutic drug monitoring can be made using trough concentration (C0) or area under the curve (AUC) which is the best indicator of drug exposure. In Tunisian renal transplant patients, a PK model for tacrolimus was developed and Bayesian estimators were established as tools for determination of AUC0-12 h using only three time points and for individual dose adjustment (DA). Aim: To evaluate the reliability and the usefulness of Tunisian TAC PK model and its Bayesian estimators for dose adjustment in Tunisian renal transplant patients. Material and methods: It is a retrospective study (Jan 2010-Mar 2017) including 42 renal transplant recipients. AUC0-12 h was calculated using 3 time points (T0, T1 and T3 h). AUCs were classified according to therapeutic interval (TI). After the first kinetic and when AUC0-12 h was not in TI, a DA was proposed. From the 2nd kinetic, AUCs were classified according to TI and to our recommendations for DA (Recommendation followed by the physician (RF), recommendation partially followed (RPF) and recommendation not followed (RNF). Results: We had 127 AUC0-12 h. Sex ratio M/W was 1.8. Median age was 34 years old. Results of the 1st DA are summarized in table 1. Before the 2nd DA which concerned 24 patients, 5 AUC were TI. We had 13 RF, 3 RPF and 8 RNF. After second DA, we had 17 AUC in TI. Concerning the 3rd and 4th DA, we had only 8 patients, 5 of them were in TI, 1 was TI. After the 4th DA, we had 5 RF, 1 RPF and 1 RNF. Six patients were in TI, 1 was <TI and 1 >TI. Introduction: Vomiting and constipation are common Adverse Drug Reactions (ADRs) to tramadol and codeine. There are few data investigating putative differences in these two ADRs between the two drugs and results about adverse events in clinical trials or meta-analysis are conflicting. The aim of the present study was to compare vomiting and constipation reported with tramadol and codeine as ADRs in a pharmacovigilance database. Material and methods: We performed a disproportionality analysis in VigiBase â , the World Health Organization Global Individual Case Safety Report (ICSR) database including all ICSRs registered until the 6th October 2017, to measure the risk of reporting "vomiting" or "constipation" (MedDRA Preferred Term) compared with all other ICSRs [as a reporting odds ratio (aROR 95% CI) adjusted on age and sex] for with tramadol (N02AX) or codeine (N02AA) ("suspected" or "concomitant"). Only reports with age (≥ 18 years) and sex known were included. Descriptive statistics (Wilcoxon and Chi-squared tests) were performed to compare tramadol and codeine. Results: Among the 156,863 ICSRs with tramadol or codeine, there were more reports with tramadol (87.5%) than with codeine with 22,708 reports of vomiting and 3027 constipations. Mean age was 55.6 AE 17.4 years with tramadol and 54.9 AE 17.8 with codeine (P < 0.001). There were more female in the tramadol group (63.8%) than in the codeine one (61.3%, P < 0.001). Vomiting was more frequently associated with tramadol than with codeine [aROR = 3.50 (3.28-3.73)] and constipation more frequently found with codeine than with tramadol [aROR = 1.44 (1.31-1.59]. Discussion/Conclusion: This is the first study to compare these two frequent ADRs between the two most used opioid analgesics in the context of real world. It clearly found that vomiting is more frequently reported with tramadol and constipation more often found with codeine. These results can be explained by pharmacodynamic differences between the two drugs: tramadol and codeine stimulate mu opioid receptors whereas tramadol also indirectly activates 5HT receptors through 5HT reuptake inhibition. The more important prevalence of vomiting with tramadol can be explained by stimulation of both mu and 5HT3 receptors in area postrema and hypothalamus and the ability of tramadol to induce less constipation can be related to activation of enteric 5HT3 and 5HT4 receptors. This study can help to the choice between the two step 2 opioid analgesics according to the clinical characteristics of the patients. Results: We retrieved 8041 ICSRs corresponding to 22,270 AEs. 75% of ICSRs were serious and 12% led to death. We identified 301 ICSRs for vemurafenib+co-bimetinib in bitherapy; 2287 for dabrafenib+trametinib in bitherapy; 4060 for vemurafenib; 66 for cobimetinib; 819 for dabrafenib, and 508 for trametinib. Patients' median age was 59 years; 56% were male. AEs common to the 4 drugs were: general signs and symptoms Not Elsewhere Classified (NEC); rashes, eruptions and exanthems NEC; asthenic conditions; nausea and vomiting symptoms; diarrhoea; febrile disorders; arthralgia; skin neoplasms malignant and unspecified; neoplasms malignant site unspecified NEC; metastases to specified sites; death and sudden death. Focusing on reported AEs with a frequency >1%, photosensitivity and photodermatosis conditions (n = 29); renal failure and impairment (n = 24) and alopecias (n = 11) were reported only with the bitherapy vemurafenib+cobimetinib whereas feelings and sensations NEC (n = 227), visual disorders NEC (n = 83) and headaches NEC (n = 82) were reported only with the bitherapy dabrafenib+trametinib. Appetite disorders (n = 202), erythemas (n = 210), pruritus NEC (n = 158) and bullous conditions (n = 133) were reported more frequently with vemurafenib. Musculoskeletal and connective tissue pain and discomfort (n = 191); pain and discomfort NEC (n = 81) were more often reported with dabrafenib. Skeletal and cardiac muscle analyses (n = 25); acnes (n = 16); hepatocellular damage and hepatitis NEC (n = 13) and oedema NEC (n = 12) were reported more often with cobimetinib. Discussion/Conclusion: Beyond the common base of AEs to these targeted therapies, AEs profiles differed between bitherapies and between molecules in real-life settings. These differences should be taken into account for the prevention and surveillance of AEs. Service de pharmacologie clinique, CHU de Nantes -Nantes (France) Introduction: Lithium is the lead treatment for bipolar disorder. Its mechanism of action is still not fully known, but it at least acts through modification of neuronal functioning. Lithium has a narrow therapeutic range and needs to be closely monitored. This monitoring is usually done by measuring its plasmatic concentration. Unfortunately, this plasmatic concentration is not always correlated to the observable clinical response. Indeed, situations with patients presenting clinical signs of overdosing whereas their lithium plasmatic concentration is under the therapeutic range are regularly reported in clinical pharmacology. In those situations, a measure of the intracellular lithium concentration can be made, and it is most of the times high. This intracellular lithium dosing is based on the assumption that the entry of lithium inside the erythrocyte is quite similar to the entry in the nervous cells where it acts; in consequence, this intracellular lithium dosage is probably more accurate. Material and methods: To assess this hypothesis, we conducted a literature review in PubMed without any limit of time using the terms "lithium" AND "red blood cells". This search was supplemented by some references of interest cited in the first articles found. Results: After an extended research, we found only 18 articles regarding the comparison between intracellular and plasmatic concentrations of lithium. Except for one from 2003, they all date from 1973 to 1993. The results are quite contradictory; there are as many studies that found the intracellular measure more accurate as studies that found it less accurate than plasmatic measure. Two points of agreement seem to emerge from these studies: (i) plasmatic and intracellular lithium concentrations follow the same tendencies, but the plasmatic concentration varies more quickly; (ii) the ratio between those two concentrations might probably be the more predictive measure of a good clinical response to the treatment. Discussion/Conclusion: Those articles date back to the times were lithium therapy was at its beginning and are therefore not optimal. Thus, they are probably outdated. Furthermore, they disagree both on the methods and on the results, making it impossible to conclude on the accuracy of those two lithium concentration measures. There is an obvious need for a new study on this issue, which we are going to implement.
PS2 -026
PS2 -027
PS2 -028
Validation of a simple and rapid HPLC-DAD method for the routine therapeutic drug monitoring of ceftolozane in critically ill patients e Department of Anesthesiology and Critical Care, Amiens University Hospital -Amiens (France) Introduction: Ceftolozane, combined with tazobactam as inhibitor of betalactamase, is a new cephalosporin antimicrobial with potent activity against multiresistant gram-negative bacteria. Ceftolozane-Tazobactam is currently indicated for the treatment of complicated urinary tract infections and intra-abdominal infections, especially in critically ill patients. This study aimed to develop and validate a simple and rapid method for determining plasma ceftolozane concentration. Material and methods: The analysis required deproteinisation with acetonitrile of a 300-lL sample of plasma previously acidified with 180-lL of 15% perchloric acid. Supernatant (25 lL) was then analyzed using HPLC coupled with diode array detector set at 245 nm, with a mobile phase of acetonitrile (A)-sodium dihydrogen phosphate buffer (B) (pH 2.6) on a reverse-phase column Kinetex Biphenyl, 150 mm x 4.6 mm, 5 lm of particle size according to an elution gradient from 10/90 to 70/30 (A/B). Results: The calibration curve was linear from 2.5 to 200 lg/mL with a mean regression coefficient (r 2 ) of 0.9995. The intra-day and inter-day coefficients of variation ranged from 0.5% to 1.9% and 2.6% to 4.8%, respectively. The intraday and inter-day biased ranged from 4.7% to 6.6% and 4.4% to 5.3%, respectively. Plasma samples were found to be stable at À20°C for at least one month and similar concentration results were found when samples were obtained from dry tube, lithium heparin and EDTA tubes. This assay method was then used for determining plasma ceftolozane concentration in patients treated with ceftolozane and showed results consistent with data obtained in clinical studies. Discussion/Conclusion: This method offers simplicity and applicability to perform daily therapeutic drug monitoring of ceftolozane when pharmacokinetic/ pharmacodynamic parameters are at risk of high variability.
PS2 -029
Level of pharmacological knowledge of street drug sellers M Kamagat e, KS N'zou e, MS Yobo-Bi, OH Bosso-Kodjo, CO Diallo UFR-SM, Universit e Alassane Ouattara -Bouak e (Côte d'Ivoire) Introduction: Street drugs are a major public health problem in Africa. Objective: To assess the pharmacological knowledge of street drug sellers. Material and methods: This was a descriptive cross-sectional study carried out with street drug sellers in the city of Bouak e between June and July 2016. Their level of knowledge about efficacy and safety of Amoxicillin 500 mg capsule and diclofenac 50 mg tablet was assessed. Results: Sellers were predominantly female adults (93%, n = 14), with a fixed point of sale. They sold other goods in 47% of cases. Fatigue (40%) was the main indication of diclofenac according to sellers followed by diffuse soreness (25.7%). The indications of amoxicillin were nonstandard in 76.2% of cases. Its dosage and target were compliant in 6.7% and 93.3% of cases respectively. "Belly sores" (71.4%) were the main indication of amoxicillin on the illicit market. On the other hand, the indications, dosage and target of diclofenac 50 mg tablet were nonstandard in 82.9%, 93.3% and 100% of cases, respectively. These drugs would have no adverse effects or contraindication according to sellers. The proposed duration of treatment was imprecise. Discussion/Conclusion: This study reveals the ignorance of the rules of prescription and dispensing of drugs by sellers on the one hand and on the other hand a serious handicap about their pharmacological knowledge.
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Curcuma longa extract inhibits risperidone induced metabolic abnormalities in mice P Duriez c Universit e de Lille, EA4481 -Lille (France) Introduction: Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice. We questioned the potential capacity of curcumin, contained in curcuma longa extract (Biocurcuma TM ), to attenuate the risperidone-induced metabolic dysfunction. Material and methods: Two groups of mice were treated once a week, for 22 weeks, with intraperitoneal injection of risperidone (Risperdal) at a dose 12.5 mpk. Two other groups received intraperitoneal injection of the vehicle of Risperdal following the same schedule. Mice of one risperidone-treated groups and of one of vehicle-treated groups were fed a diet with 0.05% Biocurcuma TM (curcumin), while mice of the two other groups received the standard diet. Results: Curcumin limited the capacity of risperidone to reduce spontaneous motricity, but failed to impede risperidone-induced increase in food intake. Curcumin did not reduce the capacity of risperidone to induce weight gain, but decreased visceral adiposity and decreased the risperidone-induced hepatomegaly, but not steatosis. Furthermore, curcumin repressed the capacity of risperidone to induce the hepatic over expression of enzymes involved in lipid metabolism (LXRa, FAS, ACC1, LPL, PPARc, ACO, SREBP2) and decreased risperidoneinduced glucose intolerance and hypertriglyceridemia. Curcumin decreased risperidone-induced increases in serum markers of hepatotoxicity (ALAT, ASAT), as well as of one major hepatic pro-inflammatory transcription factor (NFjB: p105 mRNA and p65 protein). Discussion/Conclusion: These findings support that nutritional doses of curcumin contained in curcuma longa extract are able to partially counteract the risperidone-induced metabolic dysfunction in mice, suggesting that curcumin ought to be tested to reduce the capacity of risperidone to induce the metabolic syndrome in human.
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Development of a document to aid sites to report adverse events in clinical trials N Schiller, A El Hachemi, F Broussais D epartement de pharmacovigilance, LYSARC -Pierre-B enite (France) Introduction: A user friendly document for clinical research was established with two aims. On the one hand, for the sponsor, the aim is to refine the coding of adverse events (AE) to improve signal detection and to decrease the number of queries raised due to inefficient reporting. On the other hand, for investigational centers, the aim is to improve the relevance of AE reporting to reduce the number of queries. Material and methods: The document is based on real life examples. It presents the examples, the coding issue associated and a suggestion of reported term. Med-DRA hierarchy was used to present the examples by System Organ Class (SOC).
Results: The components of the document are: the SOC, the highest level of MedDRA hierarchy; appendices which give more information about a specific pathology and help to refine the diagnosis for a better notification; the initial term which is the one reported by the sites, comments to explain the coding issue, how to report the term in the form to avoid to reproduce the mistake; and the term to report in form which is the suggestion to be coded in one database. The main comments are the following: be careful with the spelling of terms, avoid "due to" and report only the diagnosis (e.g. fever due to pneumonia), report only the diagnosis (e.g. neutrophil count decreased and neutropenia), avoid general terms (e.g., cardiac disorder), avoid brackets (e.g. Hypertensive cardiomyopathy (with associated systolic souffle)), be careful with the false friends (e.g., angina = angina pectoris or pharyngitis), report only one event at a time (e.g. dyspnea and hearing loss), avoid terms which gather several diagnosis (e.g. leukoneutropenia), pay attention to translation, avoid abbreviations (e.g. DTII), specify the location of the pathology, separate pathology and treatment (e.g. atrial fibrillation treated by cardioversion). A detailed guidance was elaborated regarding the reporting of infections and auto-immune events. Discussion/Conclusion: This document may be used on a daily basis to improve the relevance of adverse events notification, especially for the Clinical Research Associates. It allows to improve the reporting, the coding of AE in databases, to reduce the number of queries generated. A correct use of this tool might be a time saver and increase performances in clinical trials. However, it is important to note that this document is a help and is not a mandatory instruction and the investigator is responsible for AE reporting and must not be influenced.
PS2 -032
Current prescription practices of antipsychotics in the treatment of psychotic disorders in the psychiatric hospital of Nancy, France c CEIP-Addictovigilance Nancy, University Medical Center; French Addictovigilance Network (FAN), Psychiatry and Clinical Psychology, Centre Psychoth erapique de Nancy, Universit e de Lorraine -Nancy (France) Introduction: The prescription of antipsychotics and in particular, second-generation antipsychotics (SGAs), has substantially increased in recent years [1] . Despite treatment guidelines usually recommending that SGAs should be used and preferentially on monotherapy, available literature revealed frequent use of first-generation antipsychotics (FGAs), polypharmacy, and use of antipsychotics at lower than recommended doses [2, 3] . Minimal data exist regarding antipsychotic use in French psychiatric hospitals. The aim of this study was to assess antipsychotic prescribing practices in the treatment of psychotic disorders and to compare them with guidelines. Material and methods: A retrospective cohort study was conducted utilizing the hospital data base of Centre Psychoth erapique de Nancy from 01/01/2015 through 12/31/2015. Only patients with diagnosis of psychotic disorders and with at least one antipsychotic prescription were included. Results: 204 patients (92 inpatients and 112 outpatients) were included. The majority of patients were men (65.2%, 45.7 AE 15.3 years). In inpatients, the FGAs (58.8%) were the most prescribed and 62.5% were treated with antipsychotics in combination with other antidepressant medications. Multiple antipsychotics were present in 66.3% of prescriptions (bitherapy, 58.7% and tritherapy, 7.6%).Although the majority of outpatients (56.3%) received at least one SGA, 26.8% received more than one antipsychotic (bitherapy, 25.0% and tritherapy, 1.8%) and 70 (62.5%) patients had antidepressant agents in addition to antipsychotics. The use of antipsychotics at lower than recommended doses was also observed in inpatients (23%) and outpatients (29%). 
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Dietary supplement consumption leading to hospitalisations: case series L Gaboriau, M Rochoy, C Niot, J B en e, S Gautier Centre r egional de pharmacovigilance, Service de pharmacologie, CHRU -Lille (France) Introduction: In France, 2 large cohort studies showed a significant dietary supplement (DS) use in adults (from 20% to 41%) [1, 2] . Main reasons for DS use were to "overcome tiredness" and to "stay healthy". They contain vitamins and minerals but also herbal DS, purchased in pharmacies. DS are wrongly considered as safe products and patients do not inquire about safety and efficacy of dietary supplements. Material and methods: We describe a retrospective case series of DS consumption leading to hospitalisation from spontaneous reports in our regional pharmacovigilance centre in a 10 years' period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) . Results: We report 17 cases of hospitalisations attributed to adverse events (AE) related to DS. Ten patients were less than 40 years old and 7 were more than 60. There was more male (12) than female (5) . Sports DS were mostly used by youngest patients (9 cases) and involved substances to increase muscle mass (proteins, amino acids) and/or reduce body fat (caffeine, L-carnitine), bought on Internet or in gyms. Main AE were: neurological (3 cases), hepatic (2 cases), and cardiovascular (2 cases). In older patients (over 60 years old), DS were used to overcome health problems (like digestive disorders). AE were more various with cutaneous AE (2 cases) and also renal, hydroelectrolytic, neurological, hepatic, cardiac AE (1 case each). In this population, DS were bought in pharmacy or health food shops. Discussion/Conclusion: Sports DS have been previously involved in AE leading to emergency department visit [3] . The French Nutrivigilance plan reported 17 adverse effects with sport DS in an 8 years' period [4] . Cardiovascular, neurological and hepatic disorders were the main AE. For young patients, physician should question about the use of DS and educate them to seek advice about DS. This case series also shows involvement of older patients, having AE related to selfmedicated DS. Moreover, DS are used in order to treat a specific health problem but should be taken into account possible interactions with medical treatment and medical history. Introduction: Metastatic colorectal cancer (mCRC) is increasingly treated by targeted therapies but little is known about real-life mCRC treatment in elderly patients. This study aimed to describe the current real-life first-line treatment modalities in elderly mCRC patients, identify factors associated with each modality and describe survival according to treatment modalities. Material and methods: A cohort of mCRC patients aged ≥65 years at diagnosis (baseline) was identified using a French national healthcare insurance system claims database (Echantillon G en eraliste de B en eficiaires, EGB), between 2009 and 2013. Treatment modalities were: (i) treatment with >1 anticancer medication vs. best supportive care (BSC) and (ii) among treated patients, treatment with targeted therapy vs. conventional chemotherapy alone. Patients were followed until death or end of 2016. Multivariate logistic regression modelling was used to identify factors associated with (i) treatment by ≥1 anticancer medication and (ii) treatment by targeted therapy. 3-year Overall Survival (OS) was estimated in all treatment groups using the Kaplan-Meier method adjusted on factors previously identified by logistic regression (corrected prognostic group method). Results: 503 patients were included: median age 78 years, 54% male. Of these, 271 (54%) were treated with ≥1 anticancer medication. Among treated patients, 131 (48%) received targeted therapy. In multivariate analysis, age ≥75 years, renal failure, denutrition, >3 concomitant non-anticancer medications, antidiabetic agents and medical home visits were associated with a lower likelihood of treatment with anticancer medications. Among treated patients, age ≥75 years, previous history of cancer, lymph node metastases and single metastatic site were associated with a lower likelihood of treatment with targeted therapy. After adjustment, the 3-year OS probability was significantly higher in treated patients in comparison to BSC patients but there was no difference among patients treated by targeted therapy in comparison to patients treated with conventional chemotherapy alone. Discussion/Conclusion: Age remained a determinant factor for the choice of treatment with anticancer medications, including the medication choice. However, if health status was a determinant factor for the choice of treatment by anticancer medications, the medication choice was guided by the seriousness of cancer disease. Finally, treatment by anticancer medications should be more proposed as they significantly increased the survival. A 37-year-old patient present a trigeminal autonomic cephalgia or a cluster headache (CH) few hours after first dose of GENVOYA (emtricitabine/ elvitegravir/cobicistat/tenofovir alafenamide). Positive rechallenge occurred twice. TAC is a type of primary headache which include CH. CH is characterized by severe, unilateral headache attacks of orbital, suborbital or temporal pain, lasting 15-180 min accompanied by autonomic symptoms. The pathophysiology remains to be elucidated. Men and cigarette smokers are more at risk [1] . Few drugs are known to be associated with CH: sildenafil, trinitrate, vasodilators but not antiretroviral. The objective is to describe cases of drug-induced TAC (term less restrictive than CH and conform to the International Classification of Headache Disorders) or CH. Material and methods: A descriptive, retrospective study was conducted in the French Pharmacovigilance Database (FPVD). The request was done with the MedDRA term LLT "cluster headache" as TAC is not referenced, with all drugs. Cases with non-evocative chronology, patient's declarations, concerning addictovigilance or inefficiency and non-informative were excluded. Results: 32 cases of cluster headache are notified in FPVD, of which 13 correspond to inclusion criteria (others cases: addictovigilance n = 6, patient's declaration n = 3, non-informative n = 4, non-evocative chronology n = 4, inefficiency n = 2). The ratio male to female is 5.5-1 with a mean age of 51 years old (minmax: 24-66). There are 18 suspected drugs for the 13 cases. Among them, there are 5 cases with positive rechallenge, including 4 patients with an HIV infection treated with antiretroviral drugs (n = 3), and anti-viral drug (n = 1). These patients have no history of CH and CH occurred at the start of the new drug. The suspected drugs are: elvitegravir (n = 2), tenofovir (n = 2), cobicistat (n = 2), emtricitabine (n = 1) and foscarnet (n = 1). Discussion/Conclusion: In the FPVD, 5 out of 13 drug-induced CH, showed positive rechallenge. Moreover all 5 have an HIV infection and 4 were treated by antiretroviral therapy. In the literature no case report of TAC induced by antiretroviral therapy are available, to our knowledge. Positive rechallenge is exceptional, and we describe 4 cases with the same class of drugs. That is a signal to evaluate. Reference Adolescence is a challenging time in the development to adulthood during which often occurs the first consumptions of psychoactive substances. Nevertheless few updated data are available in this age subgroup. We aimed to describe psychoactive substances used and misused among French teenagers. Material and methods: Data restricted to aged <18 years old were derived from two complementary tools: (i) OPPIDUM survey (patients with substance use disorders seen in specialized care centers) and (ii) and spontaneous notifications of complications and/or psychoactive medicines misused reported to our area. For each data source, several information were analysed (sociodemographic information, type of psychoactive substances used and modalities of administration). Results: In 2016, OPPIDUM survey described 174 consumptions of psychoactive substances among 150 patients aged 11-17 years old (average of 15.6 years old). Patients were more often boys (66%) and severe financial insecurity concerned 10% of all patients. Cannabis was the psychoactive substance more used (94%), 50% of cannabis users were daily users and 43% were dependent. Eight patients had snorted at least one psychoactive substance. Among 18 psychoactive medicines used, 13 were misused (at least one pattern of misuse). Between 01/01/2016 and 31/12/2017, 48 notification concerning people aged 13-17 were reported (average of 16.0 years old), 56% were boys. These complications involved a total of 68 psychoactive substances including cannabis (n = 23) and psychoactive medicines (n = 20 i.e. 5 dextromethorphan, 3 codeine and 2 promethazine), MDMA/ecstasy (n = 5), cocaine/crack (n = 5), LSD (n = 4), poppers (n = 3). Complications were mainly neurological (60%) and psychiatric (42%) and in most cases, patients were admitted to emergency department. Notably, concerning dextromethorphan abuse, a 360 mg intake (superior to the theoretical lethal dose) by a 17-year-old boy has led to loss of consciousness with fall and facial trauma. Discussion/Conclusion: This study highlights serious complications related to the consumption of psychoactive substances. Also, the relatively high proportion of medicine drugs misused, among people sometimes very young, is of public health concern. Moreover, consumption of addictive substances like cannabis, cocaine or opiates by people younger and younger could become very problematic and need awareness of Health Professionals. Material and methods: This retrospective study used records of patients hospitalized who received at least one dose of rivaroxaban or apixaban between January 1, 2016 and October 31, 2016. Among 1337 prescriptions, about forty files were randomly selected. The evaluation criteria were indication, dosage, presence of interaction /contraindication, treatment management in the event of an invasive procedure or surgery, security of treatment at the patient's discharge from hospital. The selected reference frameworks were the THERIAQUE Database, the ANSM Drug Interaction Thesaurus (September 2016), the "Groupe d'Int erêt en H emostase P eriop eratoire" proposals "Management of DOAC for surgery and programmed invasive procedures" (September 2015). Each file was audited by a doctor/pharmacist duo, using an audit grid. Results: Thirty-nine files were evaluated, including 20 men and 19 women, with an average age of 71.59 years old (min 33, max 92). Seven patients had a creatinine clearance between 30-49 mL/min (none were lower). Twenty were treated by apixaban and 19 by rivaroxaban. Indications were adequate in 100% and the main reason for hospitalization was atrial fibrillation (n = 10). Prevention of stroke and systemic embolism in atrial fibrillation accounted for 74.4% of the indications followed by 12.8% for prophylaxis of VTE in major orthopedic surgery. Thirty-one files (79.5%) were found to comply with all criteria. Nine non-compliances were identified (8 files). They concerned the dosing regimen (3 infra-therapeutics doses and 1 supra-therapeutic) and the securing of treatment at the discharge (4 cases with too long duration, including one with wrong daily dosage). Discussion/Conclusion: The respect for the rules of good use of DOAC was considered as satisfying globally. Inappropriate dosages during hospitalization confirm the need for a regular reassessment of the renal function, particularly in cases of initially impaired renal function. For orthopedics patients, we observed at discharge, prescriptions with a too long duration because hospitalization period was not taken into account in the computerized protocol. These results were presented to the DOAC prescribing physicians and the computerized protocol was modified.
PS2 -038
Drug-induced Pisa syndrome: a literature review C Lengell e, T Gagnol, L Vrignaud, AP Jonville-Bera Centre R egional de Pharmacovigilance Centre Val de Loire, CHRU -Tours (France) Introduction: Pisa syndrome is an axial dystonia characterized by tonic lateral flexion and slight rotation to the trunk. This motor phenomenon was initially described in patients with neurodegenerative disorders (i.e. Parkinson's disease) appearing several days after starting of neuroleptic treatment. Pisa syndrome is usually regarded as a rare adverse effect. The purpose of this study was to analyze all published cases of drug-induced Pisa syndrome in order to describe the drugs most frequently involved and the characteristics of patients. Material and methods: A literature search in Medline using "Pisa syndrome" "camptocormia" was performed. All the publications of case reports and series of cases were analyzed. Results: A total of 72 publications with 96 cases of Pisa syndrome were reviewed. Among them, 43 cases (44%) were reported with antipsychotic drugs of which 36 (84%) are atypical antipsychotics, 22 (23%) with antiparkinsonian drugs, 21 (22%) with antidementia drugs, 4 (4%) with antidepressant drugs and 3 (3%) with antiepileptic drug. The more frequently involved drugs were donepezil (14 cases) and risperidone (12 cases). Pisa syndrome occurred after drug initiation in 67 patients (70%) and after increasing of drug dosage in 29 patients (30%). The median time of onset was 60 days (IQR 14; 365 days). The 96 cases involved 51 men (53%) and 45 women (47%). Most of the patients (48%) were 18-65 years of age. A neurodegenerative disorder was present in 43 patients (45%) (22 Parkinson's disease and 21 Alzheimer's disease). In 66 cases, Pisa syndrome completely disappeared after withdrawal drug with median time of 14 days (IQR 7; 28 days). Discussion/Conclusion: In this literature review, we find only neurodegenerative disorders like classic risk factors of Pisa syndrome, but female gender and old age, which are also classic risk factors, are missing [1] . Pisa syndrome is a multifactorial disorder (asymmetry in neurochemical functioning associated with cerebral lesions) [2] . The pharmacologic profiles of drugs involved, most frequently neuroleptics and anticholinesterasic drugs suggest that antagonistic action for dopamine receptors and dopaminergic-cholinergic balance may be involved in the pathogenesis of Pisa syndrome. Introduction: Ethanol disrupts the balance between the excitatory glutamatergic neurotransmission system, and the inhibitory effects of the GABA neurotransmission. A better understanding of the relationship between ethanol concentration and its consequences on the GABA and glutamate systems appears crucial to account for the complex effects of acute ethanol intoxication and manage neurological and cognitive problems under repeated ethanol administration in the Central Nervous System. A limited number of previous magnetic resonance spectroscopy (MRS) have assessed the impact of an acute ethanol administration on the in vivo levels of cerebral metabolites in rats. Furthermore, none has included the GABA signal in the explored metabolites, notably within the prefrontal cortex, particularly affected by ethanol. The aim of the present study was to assess how acute ethanol intoxication affects the kinetics of cerebral metabolites changes between controls and two different doses of intraperitoneal ethanol injection in rats using in vivo high-resolution MRS. Material and methods: Three groups of ten to fifteen-week-old male Wistar rats were considered: (a) one exposed to 1 g/kg ethanol (N = 10), (b) a second exposed to 2 g/kg ethanol (N = 10), and (c) controls (N = 10). In vivo MRS spectra of the prefrontal cortex region were acquired before and across the following three hours after ethanol or saline injection. Six successive 30-min-long MRS acquisitions were obtained after injection. Ethanol brain kinetics were compared to the blood ethanol kinetic of independent groups of rats respectively receiving intraperitoneal ethanol injection at 1 g/kg (N = 6) and 2 g/kg (N = 9). Results: We evidenced that prefrontal GABA levels significantly decreased after 1 g/kg ethanol injection, and were significantly lower than in control post-injection measures. No significant difference was found for the 2 g/kg group. Choline significantly decreased after 2 g/kg ethanol injection but not after 1 g/kg ethanol injection. N-Acetyl-Aspartate did not significantly vary between groups and across time. Discussion/Conclusion: These findings suggest that acute ethanol intoxication result in specific dose-dependent changes in the GABA-glutamate balance and consecutively in neuronal dysfunctions. In-vivo MRS spectra appears to be a promising metabolic biomarker to explore the dose-dependent influence of ethanol on the prefrontal cortex. The risk of ITP with other vaccines is still not known. This study was aimed to assess the risk of vaccine-induced ITP in a nationwide population-based study. Material and methods: We conducted a population-based study in France including all children newly diagnosed for primary ITP between July 2009 and June 2015. This cohort was built using a validated algorithm in the SNIIRAM, the nationwide French health insurance database. We assessed the risk of ITP with MMR vaccines, combined vaccines containing diphtheria, tetanus and poliomyelitis (DTP), as well as pneumococcal, meningococcal and hepatitis B (HBV) vaccines. We used a case cross-over design to compare the frequency of exposure to vaccines during a 6-week interval immediately preceding the event (case period) to the frequency of exposure during prior two control time intervals (named control periods, 6 and 3 months before the case period, having the same duration as the case period). Analyses were adjusted for exposure to other drugs known as inducers of ITP. Odds ratios (OR) and their 95% confidence intervals (CI) were calculated. We also calculated the number of attributable cases, as the number of ITP cases occurring during the 6 weeks after vaccination divided by the number of vaccine doses dispensed in the French children population during the study period. Results: The cohort consisted in 2549 newly diagnosed primary ITP children. Among them, 46.3% were females and median age at ITP diagnosis was 5 years. During the study period, 43.1% had been exposed to at least one vaccine before the diagnosis of ITP. As concerns MMR vaccination, 492 patients were included in the analysis. There was an increased risk of ITP after MMR vaccination (adjusted OR: 1.62, 95% CI: 1.21-2.16). No significant excess of risk was observed with DTP, pneumococcal, meningococcal and HBV vaccines. The numbers of attributable cases per million doses dispensed were 5.3 for DTP, 5.5 for HBV, 6.2 for meningococcal, 9.0 for pneumococcal and 9.8 for MMR vaccines. Discussion/Conclusion: In this nationwide study, no significant risk was observed for vaccines against DTP, pneumococcus, meningococcus and HBV. The increased risk of MMR induced-ITP is shown in children (previously demonstrated as lower than after the natural infection with measles). Vaccine-induced ITP remains an exceptional adverse drug reaction, including for MMR vaccines. is an inhalant ointment available without prescription, composed by camphor, turpentine oil, levomenthol, eucalyptus oil, and thymol, applied to chest and throat or used for inhalation to relieve symptoms of upper respiratory tract infections. Our Regional Pharmacovigilance Centre was alerted about an original use of VVR to lose fat belly. The ointment is applied on the belly and covered by a plastic film for the night. Many "off-label" use of VVR are described on the Internet and in scientific literature. The aim of this study was to describe the use and misuse of VVR and the risks associated. Material and methods: We searched cases of VVR misused and related adverse drug reactions (ADRs) in the French pharmacovigilance database (FPVD) and in Medline.
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Results: A total of 21 ADR reports were identified in the FPVD and concerned 9 adults and 12 children (1-13 years old). Twelve were considered serious. ADRs were characterized notably by allergic reactions in 10 cases and convulsions in 3 cases. Two patients used it in nasal application, one spread the ointment all over the face, one patient drank the ointment diluted in hot water and another one ingested a spoon of ointment. In the other cases, the ointment was used according to recommendations. Few original indications of VVR are described in literature, such as onychomycosis treatment [1] . Nevertheless, on the Internet, numerous uses of VVR are described, from relieving minor aches and pain to "tingle and cleanse' vaginas". . . [2] . ADRs report in literature described exogenous lipoid pneumonia after inhalation or nasal application, seizure, contact dermatitis, or bilateral acute keratitis [3, 4] . Discussion/Conclusion: VVR expose patient to ADRs, particularly in children and/or when the ointment is misused. At a time where patients are searching for "natural" drugs, they must be vigilant when they use such a medicine, with a doubtful risk/benefit balance. References Introduction: Attention deficit hyperactivity disorder (ADHD) is a childhoodonset neurodevelopmental disorder which can persist in up to 50% of the patients in adulthood. In France, the only pharmacological therapy available is the methylphenidate (MPH), which acts by inhibiting the reuptake of the dopamine and norepinephrine. Although MPH is under strict medical prescription, it can be found online, with many other new psychoactive substances (NPS). If NPS are commonly used for a recreational purpose, some patients with ADHD may consider NPS for self-medication. Material and methods: We report the case of BA, a 33-year-old patient, referred in February 2017 to our adult ADHD unit at Lille University Hospital, France. Results: BA had a long history of cocaine dependance (CD), which he used as a psychostimulant in order to self-medicate an attentional disorder. In September 2015, as he was hospitalised for his CD, he was diagnosed with ADHD and prescribed with Concerta 54 mg, a long acting form of MPH. This medication allowed him to be abstinent from cocaine use and dramatically improved the symptoms of his attentional deficit. In November 2015, an antidepressant (Venlafaxine 225 mg) was prescribed for a mild depressive state. A few weeks later, BA began to suffer from delusional ideas, for which he was hospitalised in July and December 2016. Despite the discontinuation of the Venlafaxine and the introduction of an antipsychotic (aripiprazole), BA continued to experiment psychotic symptoms during his first appointment to our clinic. It was then decided to discontinue the prescription of MPH. In order to alleviate the burden of his ADHD, BA ordered on the Dark Web pills of 3-4 CPMT, an NPS derived from the MPH. However, BA experienced many side effects, including anxiety and agitation. His psychiatrist decided then to reintroduce MPH at lower dosage, at the condition that BA would stop all non-prescribed medication. In the following months, psychotic symptoms decreased and BA did not use any new NPS. Discussion/Conclusion: The number of NPS available online has dramatically increased for the last years. If NPS are mainly used for a recreational purpose, this clinical case report raises the question of their use for self-medication, especially in the case of ADHD. In France, the lack of practitioners specialized in diagnosing and treating adult ADHD may indeed incite some patient to use NPS as a way to relieve the burden of ADHD, and therefore, attention should be given to attentional complaint in this population.
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Adverse reactions associated with hepatitis C treatment C Ladhari, A Zaiem, I Aouinti, F Zgolli, O Charfi, N Alaya, S El Aidli, R Daghfous, S Kastalli Centre national de pharmacovigilance de Tunis -Tunis (Tunisia) Introduction: Hepatitis C is a real public health problem in Tunisia. A national program to eradicate hepatitis C (HVC) was launched in August 2016 with free dispensing treatment to all infected persons. This treatment is Ledivir â (sofosbuvir + ledipasvir) or Ebuvir â (sofosbuvir), associated or not with Riberyn â (ribavirin), according to the evolution of the disease. An active pharmacovigilance started with this program. Material and methods: Retrospective study on reports of ADR associated with HVC treatment notified to the National Tunisian Centre of Pharmacovigilance from August 2016 to February 2017. Causality assessment was evaluated by Begaud's method of imputability [1] . Results: We included 18 cases of ADR associated with HVC treatment in 17 patients. Sex ratio M/F was 0.38. Median age was 67.5 years. All our patients had chronic carriage of hepatitis C. Among them, 7 were at the stage of cirrhosis. ADR were cardiac (N = 6), cutaneous (N = 5), neurologic (N = 4), gastrointestinal (N = 1), arthralgia (N = 1) and death (N = 1). Concerning the cardiac effects, they were 2 cases of hypertension, two cases of dyspnea and chest pain and two cases of arrhythmias. Cutaneous side effects were: pruritus, rash, urticaria and macular eruption. Neurologic events were tonic-clonic convulsions, headache, worsening paraesthesia of the lower limb and encephalopathy grade 2. One case of death was noticed. In our series, nine cases were considered serious ADR. Among these 18 cases, 14 have followed their HVC treatment. Except the fatal case, 3 patients stopped the treatment. Discussion/Conclusion: Since the introduction of direct-acting antiviral treatment, significant advances in the management of chronic HVC virus have been made [2] . Considering the importance to treat HVC and reversibility of some ADR, these medications should be continued. Although nine cases among 18 presented serious events (one death), 14 patients were able to continue their treatment. Benefit/risk balance largely prevails in favor of profit. Among cardiac effects, some of them could be avoided with more attention to drug interaction (agents inducing bradycardia such as amiodarone or betablockers). The infectious complications that occur during hematological cancer lead to multiple prescriptions of anti-infectious drugs which may interact with targeted therapy. Here, we reported the case of an 80-year-old man treated with ponatinib for acute myeloid leukemia relapse, voriconazole (VCZ) and azithromycin for infectious complications who presented hepatic cytolysis with an acute hepatic failure. Material and methods: Case was analysed according to the good pharmacovigilance practices. VCZ and ponatinib were quantified using HPLC-UVDAD and LC-MS/MS, respectively. Results: The day after the prescription of ponatinib, azithromycin was added for a suspicion of respiratory infections completed by VCZ after the diagnosis of pulmonary aspergillosis. Hepatic cytolysis occurred 48 h after beginning ponatinib in the context of high ponatinib concentration. The hepatotoxicity progressed towards hepatic failure in the context of high VCZ concentration ( Table 1 ).The patient died at day 14. The pharmacological analysis identified 3 drug interactions azithromycin-ponatinib, ponatinib-VCZ, azithromycin-VCZ which can explain the 2-3 fold target concentrations in ponatinib and VCZ. Discussion/Conclusion: Two pharmacokinetic and one pharmacodynamic interactions may explain the hepatotoxicity. VCZ is an hepatotoxic drug and a substrate of CYP3A4, 2C9 and 2C19 and the P-glycoprotein efflux pump (PGP). The possible inhibition of the CYP2C9, CYP2C19 and the PGP by ponatinib and the inhibition of the PGP by azithromycin, may increase VCZ concentration. The effect is maintained after azithromycin and ponatinib discontinuation because if their long half-life, 4 days and 22 h, respectively. The possible inhibition of CYP3A5 by azithromycin may increase ponatinib concentrations which is also hepatotoxic. These results highlight: (i) the increased risk of polypharmacy and ponatinib, (ii) the need to optimize the collaboration between clinicians and pharmacologists, (iii) new drug interactions not described in monographs. Reference (Tunisia); d Biochemistry Department, LR12SP11, Sahloul University Hospital -Sousse (Tunisia) Introduction: Tacrolimus (Tac) is an immunosuppressive drug used to prevent solid-organ transplant rejection. However, its narrow therapeutic index and wide inter-individual pharmacokinetic variability require a close monitoring to avoid graft rejection or excessive immunosuppression [1] . Tac is metabolized by cytochrome P450A (CYP3A5 and CYP3A4) and is a substrate of P-glycoprotein (P-gp), also known as ABCB1. Our aim was to evaluate the potential influence of the CYP3A5, CYP3A4 and ABCB1 polymorphisms on dose-adjusted concentrations. Material and methods: Tacrolimus-treated kidney transplant recipients were recruited from the nephrology department of Sahloul University hospital. The trough concentration of C0 was carried out by MEIA (Microparticular Enzymatic Immuno Assay) method. Genotyping of CYP3A5*3, CYP3A5*6, CYP3A4*1b, CYP3A4*22, ABCB1 C3435T and ABCB1 G2677T was performed by PCR-RFLP. The dose-adjusted concentration (C0/D) of Tac was calculated. Statistical analysis was performed using SPSS v20. Results: Eighty patients were followed over 60 months with a sex ratio 1.5 and an average age 28.06 years. Hardy-Weinberg equilibrium was observed for all studied polymorphisms (P > 0.05). After adjustment to (sex, tobacco, alcohol, concomitant intake of AVK, anti-antihypertensive, anti-retroviral drugs), the carriers of CYP3A5 *3/*3 and CYP3A4 *1b/*1b genotypes have higher C0/D than wild-type or heterozygous ones (P < 0.05). Considering age, gender, smoking, mismatch-HLA, hemodialysis mode as potential confounding factors CYP3A5*3/*3 (OR = 0.6; P = 0.036/OR = 0.71; P = 0.024) and 2677TT (OR = 0.82; P = 0.042/ OR = 0.86; P = 0.03), were observed to be significantly associated with less acute and chronic rejection respectively and CYP3A4 *22/*22 only with less chronic rejection (OR = 0.82; P = 0.043). Moreover after adjustment to confounders factors (age, sex, smoking, mismatch-HLA), genotypes that appeared to be significantly associated with more frequent nephrotoxicity and graft dysfunction or loss were CYP3A5*3/*3 (OR = 1.65; P = 0.027), 3435TT (OR = 9.58; P = 0.021) and CYP3A5*6/*6 (OR = 1.08; P = 0.022). Discussion/Conclusion: The CYP3A5*3 and CYP3A4*1b were associated with the Tac pharmacokinetic. The graft rejection seemed to be less frequent and toxicity more frequent in mutated genotypes of the studied polymorphisms mainly CYP3A5*3. Recommended dose is 340 mg/m 2 more often given once daily, based on adult regimen. The aim of our topic is to discuss this strategy in paediatric patients Material and methods: A very young (2.4 years old) girl was diagnosed from CML. The physician called the laboratory of pharmacology to know the best strategy for monitoring and to adapt dose of imatinib. We all decided to plan sampling for the determination of pharmacokinetics (PK) at J1, regularly or after dose adaptation. Results and PK parameters were discussed with physicians to adapt dose according to these and to clinical outcomes. Afterwards, we also retrospectively investigated imatinib trough concentration for every patient aged under 18 years at diagnosis. Results: The treatment started with a dose of 150 mg QID. The 1st PK analysis showed a first high Cmax and a low extrapolated (*) Cmin. At M1, observed Cmin was very low (supported by a short half-life) and Cmax was always high. Although AUC seemed to be good, we decided to split dose into BID. This strategy was strengthened by the difficulty of the child to get all the dose at the same time, by appearance of diarrhea and by a warning with only minor cytogenetic response at M3. The dose of 50 mg BID gave too low results but 100 mg BID was satisfying in terms of AUC, Cmin and Cmax. Moreover, a molecular response started only 2 months later and the posology was kept and is the same at the present time with a good response.
J1
M1 M3 M5 M8 M11 M17 Dosage (mg) 150 9 1 150 9 1 50 9 2 100 9 2 100 9 2 100 9 2 100 9 2 Regarding other young CML, we had data for 7 patients with a once-daily (QID) strategy and one patient with a BID strategy, aged from 12 to 16 years at diagnosis. At the recommended dose, the median Cmin was below 1000 ng/mL (664-971) for 6/7 QID patients vs. 1834 ng/mL for the BID patient Discussion/Conclusion: The PK sampling of our young patient showed a very short half-life (mean = 5.9 h) that led to low Cmin as for older patient once daily. It is of note that imatinib has a time-dependent efficacy. To maximize the time above efficient concentration (if only to obtain C min > 1000 ng/mL) and avoid high Cmax (related to concentration-dependent side-effect), the BID strategy seemed to be solid for imatinib treatment in paediatrics.
PS2 -052
Adverse drug reactions related to drug-drug interactions: lower severity level of drug-drug interactions and pharmacodynamic interactions are oversighted Material and methods: ADR reports recorded as due to a DDI were extracted from the French Pharmacovigilance Database. Demographic characteristics, medicines involved, ADRs and their seriousness level were analyzed. The type of DDI (pharmacodynamic or pharmacokinetic) and their level of severity were determined using a DDI checker tool (Theriaque â ). Results: A total of 767 reports of ADR involving DDIs were analyzed (M: 432, F: 335, median age: 76). About 93% of the ADRs were serious ADRs that lead to hospitalization or prolonged hospitalization (50%), a significant medical condition (16%) or significant disability (2%). ADRs were life threatening in 18% of the cases and fatal in 7% of the cases. The main concerned SOC were gastrointestinal disorders (18%), blood and lymphatic tissue disorders (16%) and nervous system disorders (16%). The most frequent reported ADR were conditions related to bleeding events (50%), renal failure (3%) and hyperkalemia (1%). The most represented ATC class were the blood and blood forming organs class (50%), nervous system class (14%), anti-infectives for systemic use (13%) and cardiovascular system class (12%). Antithrombotic agents (ATC B01) represented 50% of the medicines involved in DDIs followed by Antibacterials (11%), analgesics (4%), antipsychotics (3%) and antidepressants (2%). More than 75% of DDIs were pharmacodynamic DDIs and the average number of drugs involved in a DDI was 2. Minor DDIs and moderate DDIs were respectively involved in 33% and 28% of the cases while severe DDIs represented 31% of the cases. In 114 cases, the DDI was not clearly identified in the summary of product characteristics of the medicine. Discussion/Conclusion: A substantial number of ADR arises from minor or moderate DDIs that seem to be neglected due to their lower level of severity. Most of these ADR are related to a pharmacodynamic mechanism. A particular attention should be paid on these DDIs both during the process of prescription and pharmaceutical validation, especially in populations such as the elderly who are the most likely to be polymedicated. The classical antidote used in anticholinergic poisoning is the anticholinesterase, physostigmine. Another anticholinesterase, neostigmine, has been less described for this indication [1] . Tropatepine (Lepticur â ) can be used to correct Parkinson syndromes induced by neuroleptic drugs [2] . The authors describe a case of acute anticholinergic poisoning with tropatepine which responded well to antidote treatment using neostigmine. Material and methods: This poisoning has been managed by the poison centre control of Marseilles. Results: A suicidal patient of 17 yrs old usually treated with loxapine and tropatepine took 30 tablets of Lepticur â 10 mg, i.e. 300 mg of tropatepine. Two hours post ingestion at the emergency department she was still asymptomatic and was given activated charcoal on the advice of the poison control centre. Four hours post ingestion she showed severe signs of atropinism: tachycardia, agitation and muscular hypertonia of the limbs, hyperthermia at 38.2°C, mydriasis with confusion, and without seizures. An antidote treatment of 0.5 mg neostigmine was injected. This antidotal treatment was repeated 20 min later. During this 20 min second infusion, a marked clinical improvement of all symptoms was noticed. A relapse into these neurological signs was noted 21 h post ingestion. Therefore a third dose of 0.5 mg of neostigmine was prescribed. A clinical improvement with a decrease in neurological signs allowed the patient to be discharged 4 days after taking the tablets. Discussion/Conclusion: Central nervous system symptoms were preponderant in this anticholinergic poisoning, in accordance with pharmacological data which suggests a greater affinity of tropatepine for the central nervous system [3] . To our knowledge, only a single case of fatal tropatepine poisoning has been published [4] . It is important to be familiar with treatment indications for neostigmine which is an efficient antidote for cases of severe anticholinergic poisoning, with rapid pharmacokinetics.
PS2 -065
PS2 -073
Captopril induced acute pancreatitis associated to angioedema F Ben Salem, A Zaiem, I Hamza, F Zgolli, I Aouinti, S El Aidli, R Daghfous, S Kastalli Centre National de Pharmacovigilance -Tunis (Tunisia) Introduction: Drug-induced acute pancreatitis is relatively rare (0.1%-2%). The association between ACE inhibitors and acute pancreatitis has been reported in many clinical cases with patients treated by enalapril, captopril, lisinopril, ramipril and perindopril. Results: A 36-year-old woman, following for acute renal failure and high blood pressure, was treated by corticosteroid since August 2016 in the course of decreasing of doses, furosemide 40 mg a day, moxonidine 0.4 mg a day, nebivolol 5 mg a day and nicardipine 50 mg a day. Captopril 25 mg was introduced on 27/09/2016. Few hours later, the patient presented an intense epigastralgia with vomiting and apyrexia. The assay of lipasemia was about 20 N. The abdominal CT scan showed diffuse swelling of the pancreas grade B of Balthazar score. Her white blood cell count, calcemia and triglyceridemia were normal. The patient had no history of alcohol consumption. The radiologic investigations showed no evidence of gallstone, dilatation of the bile duct or pancreatic malformation. The next day, the patient presented an edema of the neck-down extended to the face. Captopril was withdrawn with continuation of the rest of treatment. The evolution was favorable in two days. Discussion/Conclusion: In this case, acute pancreatitis was diagnosed based on abdominal pain with elevated level of lipasemia and CT scan findings and it was with a mild severity. The responsibility of captopril in the genesis of acute pancreatitis was retained in front of a compatible delay of few hours and a suggestive evolution. Despite this delay is too short by comparing data from the literature, some drugs (analgesics, immunosuppressive drugs and insulin-secreting agents) have been responsible acute pancreatitis with a delay less than one day. In the semiological plan, the association with angioedema is in favor of the role of ACE inhibitors even more so the negativity of etiologic investigations (biliary, alcoholic, metabolic, infectious or malformatted causes). Moreover, the angioedema can point towards the theory that bradykinin-mediated edema causes pancreatic duct obstruction. In fact, ACE inhibitors decrease the degradation of bradykinins which leads to increasing vascular permeability in the pancreas. It is important to be aware of the possibility of pancreatitis linked to ACE inhibitors and the withdrawn of treatment in case of severe unexplained abdominal pain.
PS2 -074
Cutaneous reactions due to allopurinol: a report of 25 cases I Jebrane, M Ouhakki, I Rahmoune, H Filali, F Hakkou Laboratoire de pharmacologie et toxicologie cliniques, CHU Ibn Rochd -Casablanca (Morocco) Introduction: Allopurinol is an inhibitor of xanthine oxidase indicated for the treatment of gout. Despite the various recommendations developed by the international authorities to restrict the modalities of its prescription, allopurinol remains at the top of the list of drug suppliers of toxiderma mainly in the context of prescriptions not adapted to this urico-brake medication [1] . Material and methods: Our work consists of a multicenter retrospective analytical study, through which we collected 25 cases of toxidermy developed in patients treated with allopurinol and spontaneously reported to the pharmacovigilance unit by the different departments of Ibn Rochd Hospital of Casablanca. The aim of this series is to study the imputability of this drug in the occurrence of these undesirable effects as well as to analyze the modalities of its prescription. Results: The average age of the patients was 64 years with a minimum of 2 years and a maximum of 83 years, and a sex ratio of 0.64 with a female predominance. The cutaneous side effects collected include Stevens-Johnson syndrome (60%), dress syndrome (24%), Lyell syndrome (4%), erythematous pustular lesions (4%), erythroderma (4%) and maculopapular rash in 4% of cases. All patients in the series were on allopurinol (100%) treatment with a prescribed average dose of 200 mg/day. However, the indication was documented in only 10 cases (40%), of which 6 was for asymptomatic hyperuricemia. Through this work, we found that allopurinol was inappropriately associated with a thiazide diuretic in 64% of cases and in a manner contraindicated with penicillin A in 4% of cases. Discussion/Conclusion: Allopurinol is an effective and inexpensive drug, however, it is considered a potential provider of serious toxidermias. Like any treatment, its indication must be considered and based on good practice recommendations [2, 3] . References 
PS2 -075
Skin tests in hypersensitivity reactions associated with iodinated contrast media F Zgolli, A Zaiem, G Lakhoua, BH Syrine, A Imen, C Ons, EA Sihem, K Sarrah Tunisian National Centre of Pharmacovigilance -Tunis (Tunisia) Introduction: Iodinated contrast media (ICM) are widely used in radiology. They are generally considered as safe drugs, but hypersensitivity reactions may occur. A previous reaction to an ICM, either immediate or delayed, is a risk factor for developing further reaction. Some authors proposed investigations by skin tests to avoid the risk of recurrence. Material and methods: We performed a retrospective observational study, which included the cases of hypersensitivity reactions associated with ICM reported to the Pharmacovigilance from 2014 to 2017. The causality assessment was evaluated according to the French method of imputation. These patients had all investigations by skin tests. We then contacted them by phone to ask whether they had subsequently been exposed to ICM. Results: The study included 11 cases: 7 women and 4 men. The median age was 61 years. The suspected drug was iopromide in 3 cases, iohexol in 1 case, and iopamidol in 1 case. The IMC product was not specified in 6 cases. The hypersensitivity reaction was immediate in 5 cases, delayed in 2 cases and not specified in 4 cases. Positive skin tests were observed in only one case of the eleven patients. It had a positive intradermal test to iopamidol (which was first the culprit drug). Nine among these eleven cases could be contacted by phone. Only one patient had reported the recurrence of an identical delayed reaction (compared with the first reaction which was notified to pharmacovigilance), within the same lapse of time and to the same ICM (iohexol). The skin tests were negative in this patient. Discussion/Conclusion: Despite the small size of our series and the lack of immediate biological tests (Plasma determination of tryptase and histamine), skin tests seem to be interesting in the investigation of hypersensitivity reactions, especially immediate ones. In case of negative tests, the immunoallergic type of the reaction is almost discarded. Moreover, many authors, including those of the American College of radiology, agree that the majority of the reactions presented with contrast media are of toxic mechanism, and not immunoallergic. This could explain the elevated rate of negative skin tests to ICM. Further studies are needed with larger series of patients to confirm these results.
PS2 -076
DRESS syndrome in an 8-year-old child associated with amoxicillin S Ben-Hammamia, A Zaiem, S Zerei, F Zgolli, I Aouinti, G Lakhoua, O Charfi, H Zayani, N Alaya, S El-Aidli, R Daghfous, S Kastalli Tunisian National Center of Pharmacovigilance, Tunis El Manar University -Tunis (Tunisia) Introduction: Drug Rash with Eosinophilia and Systemic Symptoms syndrome (DRESS Sd) is a severe drug-induced hypersensitivity. It is commonly associated with the aromatic antiepileptic drugs, sulfonamides and allopurinol. Amoxicillin seems to be more implicated in neosensitizations, occurring after DRESS Sd. Material and methods: We report a case of DRESS Sd in an 8-year-old child probably associated with amoxicillin. Results: An 8-year-old girl with no medical history was prescribed amoxicillin then relayed by the association amoxicillin-clavulanic acid. Nine days after the beginning of the treatment, she developed a pruriginous maculopapular eruption with fever. The laboratory findings showed hypereosinophilia and elevated liver enzymes. Renal tests were at normal range. At histology, the dermis has a superficial and deep perivascular inflammatory infiltrate, with neutrophils. Amoxicillin-clavulanic acid was stopped. Skin condition improved within 5 days following the drug withdrawal. Laboratory parameters returned to normal level in a month. The REGISCAR score was 3: possible diagnosis of DRESS. Discussion/Conclusion: Amoxicillin was suspected in this case for causing the DRESS Sd. However, the delay of the onset of the syndrome was shortened compared to the suggestive delay of a usual DRESS Sd. This shortened delay has been reported in the literature, in a study including 11 children with a DRESS Sd. The authors supposed that the shorter latent interval in the antibiotic-induced cases compared to the anticonvulsant-induced ones, could be due to past exposure to related drugs [1] . Other authors stipulated that this shorter delay queries the diagnosis of DRESS in itself. In fact, amoxicillin is rather a triggering factor of rash in a viral infection, which could constitute a differential diagnosis of DRESS Sd. Only viral serologies can guide the diagnosis [2] . In our case, a viral cause cannot be ruled out, since viral serologies were not performed. DRESS syndrome, although rare in pediatric ages and with antibiotics such amoxicillin, should not be overlooked. The discontinuation of the culprit drug in association with the virologic tests should be considered.
